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Abstract / Summary 
Plasma cell myeloma (PCM), also known as multiple myeloma (MM) or myeloma, is a cancer 
of the bone marrow. It is a neoplastic disorder characterised by an abnormal clonal 
proliferation of plasma cells in the bone marrow (BM) and the consequent overproduction of 
circulating monoclonal immunoglobulin (paraprotein). Myeloma is defined by the presence of 
≥10% clonal plasma cells in the bone marrow, a paraprotein and the presence of end organ 
damage, including hypercalcaemia, renal insufficiency, anaemia and bone lesions. 
Over the past two decades the treatment of myeloma has seen huge advances leading to 
significantly improved outcomes, specifically as a result of the introduction of new classes of 
therapeutic agents including immunomodulatory agents (IMiDs), proteasome inhibitors, 
monoclonal antibodies and improved stem cell transplantation techniques. It is usually 
possible to reduce disease load substantially and induce a remission phase in the patient’s 
myeloma. However, complete elimination of residual disease is not possible, and the disease 
almost invariably begins to recrudesce resulting in relapse, and so, in the majority of cases, 
myeloma remains an incurable disease.  
Bone disease is seen in approximately 70% of patients at diagnosis, but with a range of 
severity. It is estimated that over 90% of patients exhibit evidence of bone disease at some 
stage throughout the course of their disease. 
Myeloma genetics is intrinsically complex and highly heterogeneous; there is no single, 
discrete genetic aberration that causes the typical phenotype seen in myeloma, rather a range 
of characteristic aberrations in key regions of the genome. Clonal evolution drives a tendency 
for myeloma to accumulate genetic aberrations over time. Despite this complexity, genetic 
analysis offers an opportunity to categorise the disease, offer prognosis based on these 
categorisations and potentially apply a personalised medicine approach to therapy. Access to 
diagnostic genetic testing in myeloma is ad hoc and highly dependent upon whether patients 
are entered into national trials and local commissioning arrangements, even then the 
techniques employed and the exact nature of the testing vary dramatically.  
This project assessed the role of five different genetic techniques used in the diagnosis of 
myeloma; cytogenetic analysis, fluorescence in situ hybridisation (FISH), multiplex ligation-
dependant probe amplification (MLPA), DNA array and targeted next generation sequencing 
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(NGS). These data, alongside current recommendations, were used to design and propose 
appropriate diagnostic testing strategies in myeloma, and to inform national best practice.  
Alongside this work, and through collaboration with UKNEQAS (GenQA), a quality assessment 
and assurance programme was introduced for the genetic testing of myeloma patients, with 
the aim of not only providing quality assurance in this area, but in order to create a more 
consistent and equitable service through provision of an educational component to the 
scheme. 
The final aim related to myeloma bone disease was to explore, using targeted NGS, a possible 
association between high risk variants in bone related genes and bone phenotype, which if 
proven, would allow a more personalised and targeted approach to the treatment of bone 
manifestations associated with myeloma.  
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Chapter 1: Introduction 
Plasma Cell Myeloma 
Plasma cell myeloma is a neoplastic disorder characterised by an abnormal 
monoclonal proliferation of plasma cells in the bone marrow and overproduction of 
circulating monoclonal immunoglobulin product (paraprotein). Neoplastic plasma 
cells secrete osteoclast activating factors and osteoblast deactivating factors leading 
to destructive, osteolytic bone disease. Malignant plasma cells accumulate within 
the bone marrow effectively crowding out normal haemopoietic tissue leading to 
bone marrow failure manifesting as anaemia, thrombocytopaenia and leucopenia as 
well as impaired cellular and antibody-mediated immunity. 
Plasma cell myeloma is defined by the presence of ≥10% clonal plasma cells in the 
bone marrow, increased paraprotein levels and the presence of end organ 
damage1,2, which can be summarised by the acronym, CRAB. 
• HyperCalcaemia 
• Renal insufficiency 
• Anaemia 
• Bone lesions 
Hypercalcaemia results from bone destruction and is seen in 20% of patients at 
diagnosis3. Renal insufficiency, and ultimate failure, is due to tubular damage 
resulting from proteinuria. Anaemia is observed in approximately 67% of patients, 
and results from effacement of BM by plasma cells and renal damage resulting in 
loss of erythropoietin. Osteolytic disease is seen in 70% of patients with MM1,4. 
Plasma cell neoplasms progress through distinct clinical phases: monoclonal 
gammopathy of undetermined significance (MGUS), asymptomatic myeloma (AS) or 
smouldering myeloma (SM), plasma cell myeloma (MM), progressing to plasma cell 
leukaemia (PCL). Other clinical phases following treatment can include myeloma in 
remission (termed ‘plateau phase’), relapsed myeloma and refractory myeloma 
(where disease is non-responsive to treatment). 
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Myeloma is the 19th most common cancer in the UK accounting for 2% of all new 
cases reported5. This equates to approximately 6,000 new patients being diagnosed 
with myeloma in the UK per year5. MM is a cancer of older adults: the majority of 
cases occur in patients over the age of 65. 26% of patients are aged between 65-74 
years at diagnosis, and 44% are over 75. MM is diagnosed in younger people, but 
only 2% of cases are in patients below 40 years of age5. MM is not a disease that is 
seen in children1. Myeloma is likely to increase in incidence in the UK in line with the 
aging population, and over the last decade (2007-2017), myeloma incidence rates 
have increased by 15%, and future projections suggest a further rise of 11% by 
20355. Data suggests that myeloma is more common in men than in women (ratio 
1.33:1), and more common in black people than in people of Asian or Caucasian 
descent (ratio ~2:1)1,5. There is a 2.3 fold increased risk to first degree family 
members of patients with MM, suggesting some inherited component1,6. 
Approximately 14% of myeloma cases in the UK are considered to be preventable 
and are linked with obesity5. 
Approximately 15% of MM patients have no symptoms at presentation, and a high 
paraprotein level may be discovered following routine screening. Approximately 40% 
present with more substantial morbidity including anaemia, renal failure and skeletal 
disease including pathological fractures, hypercalcaemia, spinal cord compression or 
generalised bone loss (osteoporosis). Less critical symptoms can include backache, 
bone pain, anaemia and tiredness. Diagnosis is dependent on results from a number 
of clinical tests, including full blood count and chemical analysis, serum and urine 
electrophoresis, bone marrow morphology, radiography and genetic analysis1. 
Treatment strategies are conventionally divided into intensive and non-intensive 
regimens. The former feature chemotherapy using a combination of steroids (e.g. 
dexamethasone), alkylating agents (e.g. cyclophosphamide) and immunomodulatory 
agents (e.g. thalidomide or lenalidamide) and /or a proteasome inhibitor (e.g. 
bortezomib (Velcade) or carfilzomib) for younger (<60 years), fitter patients, 
followed by autologous stem cell transplantation. High dose melphalan (i.e. 
200mg/m2) is used as a consolidation therapy prior to autologous stem-cell 
transplantation, further reducing plasma cell load within the bone marrow. Non-
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intensive regimens comprise similar combinations used at attenuated doses and 
without autologous stem cell transplantation4,7.  
Immunomodulatory drugs, such as lenalidomide (and other thalidomide analogues) 
have been shown to have clinical efficacy in the treatment of myeloma. These 
immunomodulatory drugs have been shown to bind to and inhibit the cereblon 
ubiquitin ligase. It has been demonstrated that lenalidomide-bound cereblon, 
acquires the ability to target two specific lymphoid transcription factors, IKZF1 and 
IZKF3, both known to play a central role in B and T cell biology, for selective 
ubiquitination and degradation8,9.  
Proteasome inhibitors are also extremely effective in myeloma treatment. The 
proteasome is an intracellular enzyme complex that breaks down damaged proteins. 
The exquisite sensitivity of myeloma to proteasome inhibitors remains largely 
unexplained, although the drugs are thought to act in a multi-faceted and extensive 
mechanistic fashion. They have been thought to stimulate apoptotic pathways, 
inhibit the NF-ĸB pathway, down regulate expression of genes associated with DNA 
repair and induce an endoplasmic reticulum stress response10-12. 
Anti-CD38 monoclonal antibodies, such as daratumumab (Darzalex) and isatuximab 
(Sarclisa), are now in routine use for the treatment of myeloma. Daratumumab has 
been NICE approved for use in second line therapy alongside Velcade and 
dexamethasone, and for fourth line therapy as a monotherapy. The Cassiopeia trial 
which is currently on going is likely to suggest that Daratumumab in combination 
with Velcade, thalidomide and dexamethasone (VTD) is more effective that VTD 
alone13. Isatuximab, an alternative anti-CD38 monoclonal antibody, has recently 
been approved by NICE in combination with pomalidomide and dexamethasone as a 
fourth line treatment for patients with myeloma not yet treated with an anti CD38 
monoclonal antibody14. 
Shorter survival times correlate with higher clinical stage at diagnosis, renal 
insufficiency, degree of marrow replacement, increased proliferative activity and 
certain karyotypic abnormalities15. Although significant advances have been made in 
MM treatment over the past two decades, and it is now regarded as highly treatable, 
myeloma remains almost always incurable. The only potentially curative option 
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available for the treatment of myeloma is allogeneic stem cell transplantation. 
However, although this intensive procedure can achieve long term remission, it is 
associated with high treatment related mortality and risk of relapse, and tends to be 
considered only in a small minority of patients16.  
Of patients diagnosed with myeloma (between 2013-2017), 82.7% of patients 
survived for one year or more, 52.3% of patients survived their disease for five years 
or more, and it is predicted that 29.1% will survive ten years or more5. These figures 
demonstrate a dramatic improvement in survival rates; in the 1970’s, only 5% of 
patients were expected to survive their disease beyond ten years, and now 
approaching one third of patients will5. Importantly, there remain a subset of 
patients for whom current treatment modalities are not effective, with 
approximately 20% of clinical responses considered sub-optimal and 5% non-
responsive. 
 
Plasma Cell Biology 
The human immune system has evolved in order to confer resistance to infection. 
Plasma cells are part of the ‘adaptive’ component and are required to produce 
antibodies in response to antigenic insult17-19. The immunoglobulin (Ig) antibody 
molecule is composed of two heavy chain and two light chain proteins. These are 
encoded by the IGH gene for the heavy chain, located on chromosome 14, and the 
IGK and IGL genes for the light chain, kappa and lambda, located on chromosomes 2 
and 22 respectively18. Variable gene segments at these loci undergo irreversible 
rearrangement, at the DNA level, and this creates individual B cells with specificity 
for a single antigen. In summary, the several stages of B cell development each 
represent a change to the genomic DNA involving the variable (V), diversity (D) and 
junctional (J) gene segments of the immunoglobulin genes. These stages can be 
divided into three processes, all of which generate double stranded DNA breaks: VDJ 
recombination, somatic hypermutation and IgH-switch recombination20,21. 
Following maturation, plasma cells which have undergone the final stages of 
development home to the bone marrow20. These cells are long-lived, terminally 
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differentiated and non-dividing. They are highly dependent on the BM 
microenvironment where their longevity is favoured by survival factors found in 
permissive niches22,23. Plasma cells interact with the BM microenvironment via a 
number of complex interactions, which are crucial to tumour survival and disease 
progression22.  
Whilst key to the creation of a diverse adaptive immune repertoire these complex 
developmental processes imply inherent genome instability, and it is this required 
instability that may facilitate oncogenic transformation, resulting in neoplastic 
disease such as myeloma. 
 
Genetic Complexity of Plasma Cell Neoplasms 
Myeloma is a genetically complex disorder characterised by multiple genetic 
changes, affecting different pathways, that have the ability to deregulate plasma cell 
biology leading to a broadly similar phenotypic manifestation of disease: genetic 
heterogeneity22,24. Myeloma genetic abnormalities include hyperdiploidy, the non-
random gain of a specific subset of chromosomes, rearrangements of the IGH gene 
resulting in aberrant expression of a number of different oncogenes, loss and gain of 
specific chromosomal regions, gene mutation thought to target specific pathways, 
specific gene variants thought to predispose a subset of patients to myeloma and 
epigenetic modification of the DNA. As well as this complex range of genetic change, 
there is evidence of clonal heterogeneity. This genetic complexity and heterogeneity, 
in part, is likely to have hindered the development of effective treatments. A deeper 
and clearer understanding of genetic abnormalities associated with myeloma, and 
their role in specific pathways, may offer new routes for drug development and the 
possibility of a more personalised medicine approach. 
 
Hyperdiploidy vs Hypodiploidy 
From a genetic perspective, myeloma can be divided into those with and without a 
hyperdiploid karyotype25,26. Hyperdiploidy is seen in approximately 30-40% of 
patients. Chromosome number ranges from 48-75, median 53, and the chromosome 
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gains are non-random, often involving the odd numbered chromosomes4,25. 
Chromosome 9 is the most common gain (seen in 48% of hyperdiploid cases), 
followed by chromosome 15 (47%), 19 (46%), 5 (38%), 3 (36%), 11 (33%), 7 (26%), 21 
(23%), 18 (11%) and 17 (5%)27,28. These changes are not seen as serial gains, but 
rather as the result of a single catastrophic mitotic event22. It is thought that 
compensatory mechanisms exist in cancer cells allowing the stress of aneuploidy to 
be tolerated29 and, indeed, are considered relatively stable. Hyperdiploidy in 
myeloma has been associated with a better overall survival when compared to the 
non-hyperdiploid group30. Within the hyperdiploid group, trisomy 3 and/or 5 have 
been associated with an improved survival, and indeed are thought to overcome the 
poor prognosis associated with t(4;14), whereas trisomy 21 has a significantly worse 
prognosis28. This associated good prognosis is likely to be related to the chromosome 
excess and the aneuploidy stress in the cells, which has been demonstrated to be 
uniquely chemosensitive. This phenomenon is also seen in ALL patients with 
hyperdiploidy (of a different set of chromosomes), where the prognosis and 
response to therapy is also good29. 
The non-hyperdiploid group include karyotypes with hypodiploid, pseudodiploid or 
near tetraploid chromosome number30. The near tetraploid groups appear to be a 
doubling (i.e. 4n) of the hypodiploid and pseudodiploid cell lines. The non-
hyperdiploid group are typically associated with IGH translocations, although IGH 
rearrangements are also present in approximately 10% of the hyperdiploid group25. 
 
Translocations 
Non-hyperdiploid patients are frequently (55-70%) associated with rearrangements 
of IGH on chromosome 1422,31,32. IGH rearrangements are considered promiscuous 
due to their many partner genes. They are usually simple reciprocal translocations 
juxtaposing the IGH enhancers to an oncogene25. This gives rise to abnormal 
expression of the oncogene and contributes to the myelomagenic effect. Detailed in 
table 1.1, the five main translocation partners are: t(4;14), t(11;14), t(6;14), t(14;16) 
and t(14;20). Together these are seen in approximately 40% of patients. These 
rearrangements are thought to be associated with upregulation of one of the cyclin 
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D genes. t(11;14) and t(6;14) directly deregulate CCND1 and CCND3 respectively, 
t(14;16) upregulates CCND2 as MAF directly binds to the CCND2 promoter and 
t(4;14) also upregulates CCND2 via FGFR3 and MMSET, although the exact 
mechanism is unknown22. Such translocations are mediated by errors in DNA 
modification associated with B cell maturation, following plasma cell-antigen 
interactions. IGH switching is considered the most common, whilst somatic 
hypermutation and VDJ recombination are likely to be less frequent events17,18. 
 
 





Bone development & 
maintenance 
 
Oncogene, over expression 
results in proliferation and 
anti-apoptotic effects 
t(11;14)(q13;q32) CCND1 15% Good Cell cycle G1/S transition 
t(14;16)(q32;q23) MAF 5% Poor 
Oncogene, enhances 
tumour stroma interactions 
t(6;14)(p21;q32) CCND3 3% Good Cell cycle G1/S transition 
t(14;20)(q32;q11) MAFB 2% Poor 
Regulation of lineage-
specific haematopoiesis 
Table 1.1: The five main translocations associated with IGH in myeloma 
 
The t(4;14)(p16.3;q32) translocation is cytogenetically cryptic25, and therefore FISH 
(or another non-karyotypic technique) is required in order to determine the 
presence of this rearrangement. The t(4;14) rearrangement involves the IGH gene 
and two protein coding genes located at 4p16.3, multiple myeloma SET domain, 
MMSET (also known as the Wolf Hirschhorn candidate 1, WHSC1 or NSD2) and the 
fibroblast growth factor receptor 3 (FGFR3), an oncogenic receptor tyrosine 
kinase25,33,34. In the balanced translocation, both FGFR3 and MMSET are juxtaposed 
to IGH enhancers. FGFR3 is over expressed from the derivative chromosome 14 and 
MMSET is overexpressed from the derivative chromosome 4. 25% of cases are seen 
in an unbalanced form, with loss of the derivative chromosome 14, which is 
associated with loss of the aberrant FGFR3 expression25,26. This translocation is 
universally associated with a poor prognosis34-37 38. The upregulation of FGFR3 
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associated with t(4;14) induces CCL3 expression, which has receptors expressed on 
osteoblasts, osteoclasts and plasma cells, and may be the pathway through which 
the adverse effect is mediated, resulting in differential effects on osteolytic disease 
and cell migration39. It is seen in MGUS (approximately 3% of cases), but more highly 
associated with SM and MM40-42. Data suggests that these patients benefit from 
bortezomib therapy and in addition TKI-258 (Dovitinib), an FGFR3 inhibitor, is also 
undergoing clinical evaluation26,43. 
t(11;14)(q13;q32) involves translocation of the CCND1 gene located at 11q13, where 
it comes under the regulatory influence of IGH at 14q3244. This translocation is 
balanced in the majority of cases and associated with a favourable prognosis38. 
Additional copies of the derivative chromosome 14 have been seen and are thought 
to be associated with progressive disease44.  
The t(6;14)(q21;q32) involves the gene CCND3 at 6q21, resulting in its upregulation. 
It is often seen on a backdrop of a complex karyotype, and the derivative 
chromosome 14 can be present in multiple copies. This is a rare event and has only 
been associated with approximately 3% of MM patients 22. 
t(14;16)(q32;q23) and t(14;20)(q32;q11) both show juxtaposition of the IGH gene to 
a MAF family gene, MAF and MAFB respectively 45,46. They have been described in 5-
7% of MM. MAF rearrangements are considered to be mediated by a fragile site in 
the WWOX gene on the long arm of chromosome 1620,26. This results in MAF coming 
under the regulatory influence of IGH, which in turn has the effect of upregulating 
CCND2 22. MAF rearrangements have been associated with a more aggressive clinical 
course and a poor prognosis26,38. Data on MAFB rearrangements associated with 
t(14;20) (see figure 1a & 1b) are not robust due to their rarity; although a similar 
clinical course would be predicted 26. 
Translocations not involving IGH do occur, but are considered unusual and usually 
associated with progressive disease. CCND3-MAF, MAF-FGFR3/MMSET, CCND3-




Figure 1.1: Partial karyotypes and FISH images of genetic abnormalities associated with MM. 
 
MYC translocations are seen in approximately 15-20% of patients with myeloma at 
presentation25,47,48 and up to 45% of patients with advanced disease25,26. These 
translocations are not thought to be initiating events, but late events associated with 
increased proliferation and stromal independent plasma cells, and in turn associated 
with a poor prognosis25,38. These are frequently seen as non-reciprocal translocation 
events involving more than one chromosome and associated regions of amplification 
and duplication25 (figure 1c). The t(8;14)(q24;q32) accounts for only 25% of MYC 
 
1a & b) The partial karyotype shows the normal chromosome 14 and the normal chromosome 20 on 
the left of each pair. Additional material can be seen on the long arm of the derivative chromosome 
14, from the derivative chromosome 20 depicting the t(14;20)(q32;q11). The FISH image using the 
Cytocell probe set for IGH and MAFB, confirms that the rearrangement involves the juxtaposition of 
IGH and MAFB.  
1c) FISH image depicting the Vysis MYC breakapart probe. There is an intact copy of the probe on 
one chromosome 8. The second fusion has broken apart, but also demonstrates associated 
complexity with duplication of the centromeric part of the probe and involvement of three 
chromosomes.  
1d & e) The partial karyotype shows a normal chromosome 1 on the left with an isochromosome 1q 
on the right. The isochromosome shows two copies of the long arm mirror imaged around the 
centromere with effective loss of the short arm of chromosome 1. The FISH image shows the Cytocell 
CDKN2C/CKS1B probe which highlights a gene of interest on the long arm in red and a gene of 
interest on the short arm of chromosome 1. A three red and one green signal pattern confirms the 
gain of 1q and the loss of 1p. 
Coloured arrows demonstrate the probe positions, green and red arrows show green and red signals 






rearrangement 20,48, and recent studies have demonstrated that MYC is able to 
recruit active super-enhancers from highly expressed genes associated with B cell, 
plasma cell or myeloma development49. Examples of this include enhancers 
associated with CCND1, XBP1, KRAS, FAM46C and CHST15 49. 
 
Deletions and Duplications 
Myeloma genetics includes copy number variation as a common and recurrent 
finding22,26. Theoretically, and simplistically, deletions are likely to involve loss of 
tumour suppressor genes at those sites, and duplications are likely to be associated 
with overexpression of oncogenes within the region. Regions of recurrent deletion 
and/or duplication include 1p, 1q, 9q, 11q, 12p, 13q, 15q, 16q, 17p, 19q and 
22q20,22,26,50, and a number of these are described further. 
Deletion of chromosome 13 was the first chromosome abnormality to be associated 
with a poor prognosis in myeloma51. Chromosome 13 abnormalities are seen in 50% 
of myeloma patients26, of these 85% are associated with monosomy for 
chromosome 13, and the remaining 15% associated with an interstitial deletion, 
involving the 13q14 region known to be associated with the RB1 gene48,52. More 
recently the poor prognosis associated with deletion/monosomy of chromosome 13 
has been contested in the literature. Its close association with the presence of 
t(4;14), suggest that the statistically poor prognosis may be a result of association 
alone26,53. 
Deletion of the short arm of chromosome 17, the site of the TP53 tumour suppressor 
gene remains the most important prognostic factor in myeloma genetics22,26 
conferring an extremely poor prognosis54. Deletion of 17p is seen in 7-10%22,25,37 and 
has been associated with shorter survival, aggressive disease and increased 
hypercalcaemia and extramedullary disease26. 
Chromosome 1 rearrangements are the most common aberrations in myeloma25. 
These usually result in deletions of the short arm of chromosome 1 and duplications 
of the long arm of chromosome 125,26. Short arm deletions have been shown to span 
a region from 1p13~1p31 and have been associated with a poor prognosis25,55,56. 
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Genes that have been associated with this deletion include CDKN2C, FAF1 and 
FAM46C22,56. Rearrangements of the long arm of chromosome 1 are often 
complex25,57 and have been associated with pericentromeric instability. They are 
seen in 40% of myeloma patients at diagnosis and 70% of cases at relapse25. 
‘Jumping’ translocations can be associated with chromosome 1q duplication25; this 
term describes rare chromosomal events in which the same donor chromosome 
segment is translocated onto two or more recipient chromosome sites, such that it 
can be present in different guises in different cells. Implicated genes include CKS1B 
and ANP32E25. Duplication of 1q is also associated with a poor prognosis, although 
the intrinsic relationship with the presence of deletion 1p, creates difficulties in 
assessing these abnormalities separately25. A common manifestation of del1p/dup1q 
is the isochromosome 1q (Figure 1.1d), in which the short arm is lost and the long 
arm is duplicated and mirrored around the centromere. 
Uniparental disomy (UPD) represents a further mechanism by which alleles can be 
lost. UPD is term used to describe loss of a chromosome, or chromosome part, which 
is then duplicated from the second allele. This results in loss of heterozygosity (LOH) 
without the associated loss of copy number. UPD can be seen associated with cancer 
genotypes and is termed ‘acquired UPD’ (aUPD) in this scenario. Walker et al (2006) 
have demonstrated that aUPD / LOH is prevalent in MM with a median number of 
three aUPD regions per sample. The size ranges from 677kb to whole chromosomes, 
but tends to implicate relatively small regions at 1p, 1q, 6q, 8p, 13q and 16q58. These 
areas of aUPD have the potential to highlight areas containing genes important in 
myeloma pathology. 
 
Mutations and Implicated Pathways 
Whole exome sequencing (WES) studies have suggested that an average of 35 gene 
mutations are present per MM patient sample. This figure sits part way between the 
suggested mutation level of eight in the more genetically simple haematological 
malignancies and approximately 540 mutations detected in the genetically complex 
epithelial tumours59. Determination of these multiple mutations, and general genetic 
heterogeneity seen in myeloma, support the hypothesis that a pathological 
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requirement of myeloma development is pathway deregulation, rather than specific 
gene rearrangement or modification. It is likely that multiple genetic abnormalities 
seen converge to result in a more simplified effect, of targeting a smaller number of 
specific functional pathways. 
Although the presence of copy number abnormalities and recurrent translocations in 
myeloma have been known for some time, the presence and pattern of gene 
mutations associated with myeloma has only developed with the more novel 
technologies such as massively parallel sequencing. The first genome sequencing of 
myeloma was described by Chapman et al in 201159, and since then a number of 
publications have described a group of significantly mutated genes38,60-62. 
Fifteen significantly mutated genes were described by Walker et al, with similar sets 
described by both Lohr et al and Bolli et al38,61,62. The dominant mutations include 
those from the RAS/MAPK pathway including NRAS (G12, G13, Q61 & Y64 variant 
hotspots), KRAS (G12, G13, Q61 & Y64 variant hotspots), BRAF (most commonly 
V600), NF1 and RASA2 genes making up 43% of patients38,60,62,63 The NF-ĸB pathway 
is next most commonly affected which includes the genes TRAF3, CYLD 
and LTB, affecting 17% of patients38. These mutations are considered prognostically 
neutral but could still be therapeutic targets. Mutations in CCND1 and DNA 
repair pathway genes such as TP53, ATM, ATR and ZNFHX4 are considered poor 
prognostic markers, whereas IRF4 and EGR1 are considered favourable38. 
Keats et al, and Annunziata et al, have also demonstrated constitutive activation of 
the NF-ĸB pathway in 50% of MM cases using gene expression profiling64,65. This is 
not caused by a single mutation, but rather a collection of gene mutations and 
deletions. Genes implicated include BIRC2 and BIRC3 at 11q, CYLD at 16q and TRAF3 
at 14q32. Increased NF-ĸB nuclear activity is thought to have an anti-apoptotic 
effect22. In addition, data suggests that low-level TRAF3 expression is associated with 
a better response to bortezomib26.  
Other affected pathways include the WNT signalling pathway, RANK/RANKL/OPG, 
PI3K, Notch and JAK pathways, some of which are discussed further as part of the 
section on bone involvement. 
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Involvement of IKZF1 and IKZF3 has become important. Recent work has shown that 
cereblon ubiquitin ligase is inhibited by the immunomodulatory drugs and 
lenalidamide-bound cereblon targets IKZF1 and IZKF3 for degradation disrupting 
their central roles in the lymphoid transcription pathway8,9.  
A number of mutational groups have been associated with previously described 
genetic sub-groups, and these have been described as oncogenic dependencies. 
Mutations in FGFR3, DIS3 and PRKD2 have been associated with t(4;14), mutations in 
CCND1 and IRF4 with t(11;14) and mutations in MAF, BRAF, DIS3 and ATM with 
t(14;16), and then finally FAM46C mutations with hyperdiploidy66-68. Of interest, 
increased age has also been associated with hyperdiploidy in myeloma68. 
It is highly likely that these clinically relevant mutations will become incorporated 
into the diagnostic testing and risk stratification of myeloma patients. 
 
Epigenetic Changes 
Epigenetic factors are also involved in the aetiology of MM, with changes to both 
DNA glycosylation/acetylation and histone modification playing a part in modulating 
gene expression. Global DNA hypomethylation and specific gene hypermethylation 
have been reported in association with the transformation of MGUS to MM22. 15% 
of t(4;14) patients show a gene-specific hypermethylation pattern. Overexpression 
of MMSET leads to histone modification which in turn promotes cell survival and cell 
cycle progression22. Dysregulation of miRNA has been associated with a particular 
gene cluster on chromosome 13 implicated in the MGUS to MM transition69.  
 
Genetic Predisposition 
Relatives of myeloma patients have a 2-4 fold increase in their risk of developing 
myeloma providing good evidence for an inherited component of the genetic 
aetiology of myeloma. 
An inherited genetic variation at 2p23.3, 3p22.1 and 7p15.3 has been associated 
with a genetic predisposition to MGUS70,71, with genome wide association studies 
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(GWAS) demonstrating further regions of common variation at 3q26.2, 6p21.33, 
17p11.2 and 22q13.172. Chubb et al (2013) suggested that these seven loci were 
likely to account for only 13% of the familial risk of myeloma suggesting that many 
further regions would be involved72. Since 2013, a further 16 regions have been 
proposed73. A more recent GWAS published in 2019 by Went et al, assessed data on 
7319 myeloma cases against 244,385 controls across different tissue types. 108 
genes were identified at 13 regions, all of which were within 1Mb of known 
myeloma risk variants. Of the 108 genes, 94 located at eight regions had not 
previously been considered candidate genes74. Of particular interest were a number 
of genes from the APOBEC family and RNF40 with known roles in myelomagenesis, 
and QPRT which has been implicated in other malignancies74.    
 
Intra-tumour Clonal Heterogeneity  
Whole exome sequencing, cytogenetics and copy number analysis have been used to 
show that myeloma cases can have a complex subclonal structure with a high level 
of clonal genetic heterogeneity suggesting that myeloma populations are not 
homogeneous, but made up of different populations with different clonally related 
and unrelated changes. Intraclonal heterogeneity is present at all disease stages, and 
clonal progression is a key feature of transformation75. Bolli et al have 
demonstrated, using serial sampling, that clonal evolution is diverse and includes 
both linear and branching evolution62. Further to that, Keats et al describe the 
existence of three temporal myeloma types; genetically stable, linearly evolving or 
heterogeneous clonal mixtures with clones shifting in dominance over time76. They 
also suggested that few changes were seen in standard risk patients, with 
significantly more changes being associated with high risk patients76. The t(4;14) is 
usually considered a primary change, but this has also been shown to be present in 
low level silent sub-clones both at diagnosis and relapse, suggestive of the 
movement of the dominant nature of specific clones throughout the disease course, 
a phenomenon described as clonal tides77. 
Although myeloma is a disease of the bone marrow where a rapid movement and 
dissemination of more dominant clones may be expected, the distribution of disease 
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is not homogeneous either. Multi-region sequencing has also shown that spatial 
heterogeneity is present in approximately 75% of patients, with dissemination of 
new clones happening more freely in the early stages, but regional evolution 
commonly seen in advanced disease78. 
There are important implications to therapy as these clones can demonstrate a 
differential response to therapy; reducing the level of one clone, may result in 
expansion of a more prognostically detrimental refractory clone. The process of 
branched evolution, intra-tumour and spatial heterogeneity provide further 
ambiguity, since a single genetic picture obtained at a single timepoint and single site 
is likely to under-represent the complexity of the underlying disease79. It remains 
likely that combination therapies targeting a number of coexisting disease subclones 
will be particularly important in myeloma as a whole, and specifically high risk 
myeloma75,76,78. 
It is recognised that the prognostic associations of specific genomic changes may be 
treatment dependant, and where these have been specified in the text, they have 
been referenced appropriately demonstrating the context of the association. 
Recent review articles from Anwar et al (2019) and Pawlyn et al (2019) describe the 
current potential of personalised medicine in myeloma based on determining 
genomic aberrations contributing to disease progression and drug resistance. The 
t(11:14) has been shown to respond specifically to treatment with venetoclax and an 
FGFR3 inhibitor (AZD4547) has been shown to be effective in myeloma associated 
with t(4;14). BRAF mutations can be targeted by vemurafenib (alone or in 
combination), JAK2 pathway activation can be targeted by ruxolitinib, and the NF-kB 
pathway activation has been shown to respond to danfin combined with 
bortezomib. Other potential targets include IDH1/2 mutations and IDH inhibitors, 
ATM/ATR mutations and PARP inhibitor treatment, and MDM2 overexpression, 
CCND1 and MYC rearrangement80,81. 
Pawlyn et al also describe targeting a high-risk markers patient cohort using 
intensified therapeutic approaches agnostic to molecular lesions; combinations of 
quadruplet or even quintuplet regimens and/or novel immunotherapy approaches 
such as bispecific antibodies, antibody–drug conjugates, and CAR T cells80,81. 
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Microenvironment and Bone Involvement in Myeloma 
There are complex interactions between the plasma cells and their supporting 
microenvironment, these interactions are crucial to the tumour survival and 
progression of disease 22. The marrow microenvironment is made up of extracellullar 
matrix and five types of bone marrow stromal cells; fibroblastic stromal cells, 
osteoblasts, osteoclasts, vascular endothelial cells and lymphocytes25,82. The cross-
talk between myeloma cells and the microenvironment can either be directly or 
indirectly by secretion of adhesion molecules, cytokines and growth factors. The 
interaction between myeloma cells and the bone microenvironment results in the 
uncoupling of the normal bone remodelling process leading to osteoclast activation 
and osteoblast suppression. It is this decoupling process that is thought to be pivotal 
in the pathogenesis of the osteolytic lesions and bone damage associated with 
myeloma20,83.  
A number of intra- and intercellular signalling pathways have been implicated in this 
complex process, and over recent years osteocytes have emerged as key regulators 
associated with the bone lesions seen in myeloma39. These signalling pathways 
include RANK/RANKL/OPG, WNT, TNF and Notch, and a number of specific signalling 
molecules have also been implicated such as DKK1, sclerostin, periostin, 
osteopontin, TGFβ84,85 and activin A86 amongst others. It is thought that a better 
understanding of these biological interactions will offer promising future therapeutic 
strategies39,83. 
The RANK/RANKL/OPG signalling pathway is a crucial regulatory system of bone 
remodelling. Deregulation of this pathway has been well described in myeloma, and 
the resulting increase in RANKL and decreased OPG expression, ultimately increases 
bone resorption4,39,87. A promising agent targeting this pathway is denosumab, which 
is able to prevent RANK activation, and subsequent osteoclast activation39. 
The WNT signalling pathway drives osteoblast differentiation. WNT pathway 
inhibitors associated with myeloma, such as sclerostin and Dickkopf-1, therefore 
result in the inhibition of osteoblast differentiation, and hence reduced numbers of 
mature osteoblasts leading to reduced bone formation. Antibodies to these WNT 
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inhibitors such as Romosozumab, an anti-sclerostin antibody39, and anti-DKK1 
antibodies39,87 are demonstrating some encouraging results. 
Similarly, the Notch pathway is actively implicated in MM-induced 
osteoclastogenesis, and offers a further treatment targetable area for future 
development39. 
Bisphosphonates are an important class of drugs used to treat bone manifestations 
in MM. They are potent inducers of osteoclast apoptosis, thereby reducing elevated 
bone resorption (anti-resorptive therapy) associated with MM88-90. Long-term or 
high-dose use of bisphosphonates is associated with some adverse effects. Whilst 
anti-resorptive therapies are widely used in the treatment of myeloma, anabolic 
therapies, those that promote bone formation by enhancing osteoblast activity are 
less widely used. In osteoporosis, the most common bone disease worldwide, a 
number of anabolic therapies are available; parathyroid hormone (PTH) and its 
analogues, teriparatide and abaloparatide, and romosozumab (a sclerostin 
neutralising antibody). A number of more experimental agents91,92 are also being 
considered as suitable anabolic therapies88,90. It is likely that these anabolic therapies 
used in osteoporosis will impact on myeloma treatment also. 
In early MGUS and myeloma, the plasma cells are highly stromal dependent. As the 
disease progresses and becomes more aggressive, the plasma cells are able to 
develop stromal independence. Many of these cellular interactions are also 
governed by genetic changes affecting the normal regulation of these interactions 
and relationships22,89.  
These relationships between myeloma plasma cells, the microenvironments and 
osteoclast/osteoblast related pathways where disruption can result in the imbalance 
between osteoblast and osteoclast function become important in this study in 
informing the ‘osteome’ work described in chapter 4. 
 
Genetic Screening Methodologies 
Genetic analysis of BM samples in myeloma patients has proven to be useful, 
offering both diagnostic and prognostic information to the clinician and patient4. 
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Since myeloma is a genetically heterogeneous disease, it is likely that genetic 
abnormalities seen in myeloma patients will increasingly be used to inform 
treatment decisions. Patients exhibiting a t(4;14) are more likely to be offered more 
aggressive therapy, including transplantation, and BRAF inhibitors are being 
considered in those patients shown to have BRAF mutations. 
A range of genetic methodologies, conventional and novel, have been used in the 
genetic analysis of myeloma patients. Each technology offers pros and cons, and the 
different data capture from each methodology is complex and varied. Currently 
there is not a single technique able to assess the full range of genetic change seen 
within the myeloma genome. This introduction covers the five genetic technologies 
chosen for evaluation as part of this study, two well established techniques in 
myeloma analysis (cytogenetics and FISH) and three more novel and less used 
techniques in the analysis of myeloma (MLPA, DNA microarray and NGS).  
 
Cytogenetic Analysis 
Cytogenetic analysis was the first methodology to be widely adopted in the analysis 
of myeloma, and relies of the ability to capture cells, specifically plasma cells, at 
metaphase of the cell division process. Robust techniques are employed in many 
laboratories to manipulate the cell cycle, often utilising colchicine, or one of its 
analogues, to disrupt formation of the spindle apparatus during cell division. At 
metaphase the chromosomes have condensed and are preparing to arrange 
themselves on the equator of the spindle apparatus, before anaphase proceeds to 
split the two chromatids into separate daughter cells. Disruption of the spindle 
apparatus arrests the cell cycle at metaphase. Harvesting samples at this stage and 
treating chromosomes with trypsin and stain, to produce the characteristic banding 
pattern, allows chromosomes to be karyotyped and analysed.  
Plasma cells are mature cells and have been shown to cycle slowly, often adaptations 
to the culturing process, allowing for longer term culturing (4-6days), are introduced 
for the assessment of myeloma to increase the chances of capturing these cells in 
division24,42.  Cytogenetic analysis offers a full genome screen, but at low resolution. 
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The rate of plasma cell capture is poor, even with enhanced culturing, and therefore 
the abnormality rate is low. 
 
Fluorescence in situ Hybridisation (FISH) 
FISH, currently the most widely adopted technique in the genetic analysis of 
myeloma, is the process of hybridising a fluorescently labelled target DNA (probe) 
from a known region of interest, to metaphase or interphase cells to allow 
enumeration or rearrangement detection, see figure 1.2. Probes can be created in-
house, but more usually, in diagnostic laboratories, are bought in from commercial 
companies. 
Probes come in a variety of sizes, designs and formats and it is important to have a 
good understanding of these before analysis is undertaken. The ability to utilise 
interphase cells, eliminates the problems associated with metaphase capture for 
cytogenetic analysis. The abnormality rate is much improved, but is dependent upon 
the probe set used. Each probe ‘asks a question’, with a yes or no answer. The more 
probes used, the more questions asked and answered. Small probe panels are 
inexpensive and efficient, but extended FISH panels, whilst providing more 
information, quickly become expensive and extremely time-consuming. 
Probe design depends on the question being asked, when looking for loss and gain of 
a probe, it is extremely useful to have a control probe region in order to determine 
whether loss is true deletion or lack of hybridisation. Rearrangement detection 
probes are usually designed as breakapart probes or dual colour dual fusion probes. 
Breakapart probes usually have a red and a green probe flanking either side of the 
breakpoints of the gene in question. They appear as a fusion (i.e. yellow) signal in a 
normal scenario and a single red and green when a rearrangement is present. Dual 
colour, dual fusion probes usually have a single colour probe (red) spanning one 
gene and a single colour probe (green) spanning the second gene. A normal pattern 
would be 2R2G, and a rearrangement results in the probes across the genes splitting 
and rejoining with the opposite coloured probe resulting in a 2F1R1G signal pattern. 
More complex patterns can be seen when rearrangements are unbalanced or when 
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additional genes not covered by the probed regions are involved. The specific 





Figure 1.2: Schematic diagram to demonstrate the process of FISH. 
 
  
Multiplex Ligation-dependant Probe Amplification (MLPA) 
MLPA is a multiplex polymerase chain reaction (PCR) methodology, which allows 
simultaneous detection of deletions or duplications of up to 50 targeted gene 
regions. This is an attractive technique in myeloma as a large number of copy 
number changes including hyperdiploidy have prognostic implications in myeloma. 
As shown in the schematic in figure 1.3, MLPA probes are designed in pairs with the 
same two primer sequences present in each of the pairs. These primers are attached 
Probe DNA of interest, usually relating to a specific gene rearrangement or deletion, is labelled with a 
fluorescent dye and co-denatured alongside the target DNA to create single stranded DNA. The single 
stranded DNA is hybridised together allowing competitive reannealing to occur. A series of post-
hybridisation washes remove any excess probe and the target and probe can be visualised using a 
fluorescence microscope 
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to the region of interest. One of the MLPA probe pair incorporates a stuffer 
sequence, creating a known total probe length.  
The DNA is denatured and hybridised with the MLPA probes. When the DNA target is 
present, with no alterations, the probe pairs lie immediately adjacent to each other 
and can ligate. When there is a deletion, or in some cases a mutation, the probes 
cannot hybridise to the DNA correctly and probe ligation does not occur. PCR is used 
to directly amplify the ligated probe pairs and not the target sequence. 
As only ligated probes will be exponentially amplified, the number of products is a 
direct measure of the number of target sequences, when compared to a control. 
Separation of the products is carried out using electrophoresis and the known probe 
length allows identification of the specific target region. 
MLPA offers a cost effective, multiplex technique, but the information output only 
relates to the loss or gain of the specific regions targeted. When mutation is present, 





Figure 1.3: Schematic diagram to demonstrate the process of MLPA  
 
DNA Microarray / Comparative Genome Hybridisation (CGH) 
DNA microarrays employ the same technology as comparative genome hybridisation 
(CGH), and offer a genome wide copy number analysis (and with the use of single 
nucleotide polymorphisms (SNPs) allow assessment of Loss of heterozygosity (LOH)) 
at an excellent resolution level. Both DNA of interest and control DNA are prepared 
and fluorescently labelled; control DNA in red and DNA of interest in green. The two 
DNA samples competitively hybridise to an array chip containing thousands of 
complementary DNA oligonucleotides. In the case of equal copy numbers in the two 
DNA samples the competitive hybridisation will be equal. Increased copy number in 
the DNA of interest will show an excess of green fluorescence and conversely when 
deletions are present in the DNA of interest the competition will be less effective 
 
 
Paired probes around an area of interest are labelled with primer sequence. A stuffer sequence of known 
length is also included to allow for probe identification. The probes are annealed to the DNA of interest. 
When no DNA alteration is present the probes lie adjacent to each other allowing probe ligation to occur. 
Ligation is not possible where deletions or mutation are present.Ligated probes are amplified and 
represent a measure of the number of copies. The products are separated by electrophoresis based on 
their size. 
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and the region will demonstrate an excess of red fluorescence. The level of 
fluorescence is measured across the chip for each oligonucleotide and collated to 
demonstrate regions of loss and gain across the genome. 
DNA microarrays are designed to provide a genome screen with a backbone level of 
resolution across the genome. Areas of interest (for example oncology related 
probes) can be designed to have enhanced resolution. Many types of array exist, but 
we propose the use of the Affymetrix CytoScan HD Array. These arrays utilise slightly 
different chemistries, in which the DNA of interest is compared to an internal normal 
reference set.  This array allows interrogation of the entire genome using more than 
2.6 million markers for copy-number analysis and approximately 750,000 SNPs. The 
higher probe density areas include 533 cancer genes, 100% of which are covered 
with 25 markers per 100kb region. The array would allow DNA copy number to be 
determined at a high sensitivity and has the ability to detect LOH and regions of 
aUPD.  
SNP array and CGH are both high resolution, whole genome techniques, but can only 
assess loss and gain of genetic material; balanced rearrangements resulting in no 
loss or gain of genetic material and mutations will not be detected. 
 
Next Generation Sequencing (NGS) 
NGS has evolved dramatically over the last few years. It offers the power of 
simultaneous sequencing of multiple DNA templates, without the requirement of the 
same number of target-specific DNA primers93. NGS has the ability to detect small 
nucleotide variants, and small insertion and deletion (indels) events across the whole 
genome or sets of targeted genes as required. The commercial platforms have 
evolved to provide confidence in the robustness of this approach to provide an 
accurate and comprehensive means of mutational analysis. There are a range of NGS 
platforms currently available, each of which employs different sequencing 
chemistries, but with similar resultant output94. 
Current methodologies start with the production of short DNA fragments with the 
addition of non-specific adaptor DNA sequences, this can be either by chemical 
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binding or ligation95. Adaptor sequences allow DNA fragments to be captured and 
tethered to a solid surface (microchip). Subsequent PCR is then carried out by 
implementing a bridging PCR reaction with Illumina technology. This allows single 
DNA fragments to be amplified non-specifically from the same clone, making the 
signals in the later stages to be more easily readable. See figure 1.4 for a schematic 
representation of the NGS process. 
The Illumina chemistry utilises sequencing primers that are complementary to the 
ligated adapter sequences. The PCR reaction mix is made up of chain terminating 
deoxyribonucleotides, labelled with a specific fluorescent tag corresponding to the 
base type. During the extension phase, termed sequencing by synthesis (SBS), each 
individual base is recorded by its fluorescence. These fluorescent tags are then 
cleaved, removing the chain terminating effect and allowing further extension to 
occur. The sequence builds up sequentially over multiple cycles (of flowing each of 
the four bases). 
Once the sequence fragments are created, they are aligned to the known reference 
sequence using complex bioinformatic techniques. Longer reads make this process 
more robust. The computational technology is able to measure the number of 
fragments over a given region (read depth or coverage) and highlight (call) sites of 
discordance to the reference sequence (variance)93.  
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Figure 1.4: Schematic representation of Illumina based Next Generation Sequencing (NGS) Process. 
 
In 2011, Chapman et al applied both whole genome sequencing (WGS) and WES 
technologies to a cohort of 38 myeloma patients. This was the first use of this 
technology in myeloma and a number of novel mutations in genes were reported, as 
well as providing additional evidence of the importance of the NF-ĸB pathway59. The 
involvement of BRAF in 4% of myeloma patients was also determined in these 
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disease course. The patient was shown to have t(4;14), and 10 other single 
nucleotide variants, seen at all timepoints. Other changes were shown to appear and 
disappear with time. Five new events were seen at the final timepoint of PCL and 
these changes have been postulated as leukaemic transformation events97. Since 
then many studies using this technology have been reported, and although this is not 
currently being utilised in the diagnostic and clinical setting for myeloma patients as 





Project Aims and Objectives: 
Plasma cell myeloma is a neoplastic disorder characterised by an abnormal 
monoclonal proliferation of plasma cells in the bone marrow and overproduction of 
circulating monoclonal immunoglobulin (paraprotein). Despite huge advances in the 
treatment of myeloma over the past two decades, and although myeloma is 
considered highly treatable, it remains an incurable disease in most patients.  
Myeloma genetics is intrinsically complex and highly heterogeneous, but offers an 
opportunity to categorise the disease, offer prognosis based on these 
categorisations and potentially apply a personalised medicine approach. Relating 
genetics to potential treatment pathways, and a deeper understanding of myeloma 
genomics will become crucial for improved myeloma outcomes. 
Access to diagnostic genetic testing is currently ad hoc and highly dependent upon 
local commissioning arrangements and whether patients are entered into national 
trials, even then the techniques employed and the exact nature of the testing vary 
dramatically. At the outset of this project there were no best practice guidelines for 
the genetic testing of myeloma and no quality assessment schemes associated with 
this testing. 
My roles within Sheffield Diagnostic Genetics Service (SDGS), and more recently the 
Haematological Malignancy Diagnostic Service (HMDS), drive a strong interest in 
translational research. I am keen to ensure that the results obtained as part of this 
project are used directly to influence, not only the diagnostic services in both SDGS 
and HMDS, but best practice and the quality of genetic testing in myeloma across 
the UK. 
Myeloma patients exhibit osteolytic disease in 70% of cases, and treatment with 
bisphosphonates can slow the progression of this bone disease. In early stages of the 
disease it is not always possible to determine who will go on to have severe bone 
disease. We would like to explore DNA changes in the osteome in relation to patient 
bone phenotypes to determine if an association might exist. Assessment of the 
'osteome' related to the myeloma bone phenotypes would contribute to the 
research interests of the SMaRT (Sheffield Myeloma Research Team). 
 38 
The aims of the project are to explore a number of different objectives: 
Objective 1: To compare five different genetic technologies, readily available in a 
diagnostic genetic laboratory and their ability to identify genetic abnormalities and 
signatures associated with plasma cell neoplasms. 
Patient bone marrow samples will be collected across all disease stages. We will 
perform karyotyping, FISH, MLPA, DNA array analysis & targeted NGS in order to 
establish genetic signatures and to assess their ability to do this in an effective and 
efficient manner, within the financial and time constraints required of a diagnostic 
testing scenario. A number of genetic changes have been shown to provide valuable 
information about disease prognosis and are beginning to guide treatment decisions.  
 
Objective 2: To explore and assess possible or potential relationships between the 
genetic signatures associated with bone related genes, the ‘osteome’, and the 
likelihood or extent of bone damage associated with the patient’s myeloma disease. 
Within the targeted NGS panel, we aim to include genes associated with the 
‘osteome’; genes involved in the development, influence, maintenance and 
destruction of bone. Assessing these genetic findings against the clinical bone 
manifestations may allow correlations to be made. Treating the bone manifestations 
of myeloma is challenging; current treatments are able to offer protection and 
slowing of bone degradation, but can rarely reverse the process. Highlighting a 
cohort of patients who may be considered at risk of a severe bone phenotype 
associated with their myeloma may offer the opportunity to treat more proactively 
and slow the advancement of the bone manifestations. The use of bone anabolics is 
a specific interest of the research group, and this work may inform and link into that 
interest. 
 
Objective 3: To generate recommendations for an all-encompassing diagnostic 
genetic panel for use in a diagnostic genetic laboratory, to introduce a quality 
assessment scheme for myeloma genetic testing and consider the requirement for 
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best practice recommendations to create a more consistent, equitable 
harmonisation of diagnostic genetic testing for myeloma within the UK. 
Translation of myeloma research into diagnostic genetic testing for NHS patients is 
lagging far behind the work reported from the research and trial groups. Comparing 
the different genetic technologies associated with objective 1, will allow us to make 
informed decisions in proposing diagnostic genetic testing strategies for myeloma, 
that provide the clinical requirements of this service. Through links with UK NEQAS 
(GenQA), we aim to create a quality assessment programme for myeloma genetic 
testing including an educational component to the scheme. Understanding myeloma 
diagnostic genetic testing at the outset and towards the end of the project will allow 
the effects of the scheme to be assessed. Again, through links within the profession 
(ACGS, the new genomic laboratory hub (GLH) structure and GenQA), we would aim 
to influence best practice in this area.  
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Chapter 2: Material and Methods  
This part-time PhD project forms part of a three year specialist programme grant, 
and a further two year extension funded by Bloodwise; Novel Targets and 
Therapeutic Combinations in Myeloma. Principle Investigator: Dr Andrew Chantry 
(LLR ref: Chantry 12053). Funding has been made available through this specialist 
programme grant, and through a further application made to the Sheffield Blood 
Cancer Charity. 
 
Patient Cohort and Recruitment 
Patients were recruited and consented to the study by Dr Chantry via patient clinics 
held at the Royal Hallamshire Hospital, Sheffield. Appropriate ethical approval 
governing collection of primary human material (serum, urine and bone marrow) 
from patients with myeloma was applied for as part of the Specialist Programme 
Grant. The ethics statement and letter are included as appendix 1 (REC reference: 
05/Q2305/96) demonstrating approval from the South Sheffield Research Ethics 
Committee in August 2005 and subsequent ratification by the NHS Health Research 
Authority, National Research Ethics Committee Yorkshire and the Humber - Sheffield 
in November 2012 & 2016. 
From January 2014, patient bone marrow (BM) samples were sent to Sheffield 
Diagnostic Genetic Service (SDGS) as part of the study. The CD138 positive 
separation process was introduced into SDGS at the end of March 2014, and it was 
samples from this point that were included as part of this PhD project. 
A total of 101 bone marrow samples from patients with MGUS, plasma cell myeloma 
or plasma cell leukaemia were collected and anonymised for genetic analysis as part 
of this study. All samples except one (a case of plasma cell leukaemia) had a 
CD138+ve cell separation. Karyotyping was performed on 91 patient samples. All 
patients were processed for FISH and DNA extraction of the CD138+ve cell 
separation. MLPA was performed on 45 patient samples, 36 samples were processed 
for Affymetrix DNA array, and 24 samples were assessed using the bespoke NGS 
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gene panel. The numbers of samples processed was limited by the quantity and 
quality of the sample and by the funding available. 
 
MACS CD138 Positive Cell Separation 
The CD138 separation methodology utilises the Miltenyi Magnetic Activated Cell 
Separation (MACS) methodology and was undertaken according to the protocol 
supplied by the manufacturer www.miltenyibiotec.com/protocols.  The CD138 
antigen (aka syndecan-1) is primarily expressed on normal or malignant plasma cells 
in the bone marrow. It is not expressed on naïve B cells, germinal centre B cells, 
memory cells, T cells or monocytes.  
Cell filtering: 1ml whole bone marrow sample was initially diluted in equal volume of 
running buffer (PBS, 2mM EDTA, 0.5% fetal calf serum) and filtered using the MACS 
pre-separation filter supplied by Miltenyi Biotec. A further 1ml of running buffer was 
used to wash the filter. This excludes large clumps and debris within the sample prior 
to separation and ensures that as much of the sample is utilised as possible.  
Cell labelling: CD138 positive plasma cells were labelled using 50ul of CD138 
microbeads per 1ml of sample. The beads and the sample were mixed well before 
incubating for 15 minutes on ice. The cells were washed by adding 5-10ml of running 
buffer and centrifuged at 1360 rpm for 10 minutes. The supernatant was removed 
before re-suspending in 3mls of running buffer. 
Cell separation: 3ml of running buffer was applied to the column by way of 
preparation before the cell suspension was then loaded into a MACS column secured 
in the magnetic field of the MACS separator. The magnetically labelled CD138 
positive cells were retained within the column whilst a series of washes 3x 3ml 
running buffer encourages the unlabelled cells to pass through the column.  
CD138 positive cell capture: Following removal of the column from the magnetic 
field, the beads and the CD138 positive cell fraction were eluted using 5ml of 
Miltenyi elution buffer. The sample was centrifuged at 1300rpm, the supernatant 
removed and resuspended into 500ul of buffer. The sample was labelled and stored. 
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The CD138 positive cell selection was assessed for purity using flow cytometric 
methods, to obtain a percentage of plasma cells within the sample, and then the 
sample was split equally, for both DNA extraction and FISH analysis. 
 
DNA Extraction 
The Chemagen Magnetic Separation Module is employed at SDGS. This is an 
automated methodology to extract DNA from whole BM or CD138 positive cell 
populations. Chemagen separation kits are bought in and contain a lysis buffer, 
magnetic beads and binding buffer, a series of wash buffers and an elution buffer. 
The automated extraction occurred in two stages; the first stage involves mixing and 
lysing of cells in order to release the DNA and the second stage involves binding DNA 
to magnetic beads, in order to undergo a series of washes before subsequent elution 
from the beads into 300μl 1xTE buffer.  
The protocol was followed according to the manufacturer’s instructions 
www.chemagen.com/chemagic-kits. 
Following extraction, a 260/280 ratio qualitative measurement was undertaken to 
determine the DNA yield and check for protein contamination, with 1.7-2.1 
considered an acceptable range and the quantity measured and recorded using 
NanoDrop (model no: 8000, ThermoFisher). 
Further DNA quantitation was undertaken for the array studies and the NGS studies 
using the Qubit 2.0 fluorometer. This system uses target-specific fluorescence which 
only emits light when specifically bound to double stranded DNA (dsDNA), this 
results in an increased accuracy in measurement of DNA concentration as the 
nanodrop measures both dsDNA and single stranded DNA (ssDNA), and RNA and free 
nucleotides. 
   
Conventional Culturing and Karyotyping 
The first method of the five methods to be assessed and compared as part of this 
project is conventional karyotyping. In order to prepare chromosomes for 
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karyotyping, the patient BM aspirate sample was treated according to the following 
methodology. 
Culture set up: The patient BM sample was assessed for white cell count in order to 
determine the amount of sample to be added to 10mls of bone marrow culture 
medium (McCoys medium with added fetal calf serum, L glutamine, penicillin and 
streptomycin), resulting in a final concentration of 106 cells/ml. Two cultures were 
set up and cultured at 37oC for 4 and 6 days respectively. This is much longer in 
duration than culturing for other leukaemic samples and is based on protocols 
described by Ross et al42. Plasma cells have a slow cell cycling time and this 
additional time in culture and the use of two culture times aims to capture as many 
plasma cells as possible.  
Culture harvest: Colcemid was added to the cultures 20 hours prior to the 
harvesting. Colcemid is a colchicine analogue which prevents microtubule formation 
of the spindle apparatus, this in turn has the effect of arresting cells at the 
metaphase stage of cell division. Cultures were centrifuged at 1200rpm for 10 
minutes, the supernatant was removed, and the cells re-suspended in hypotonic 
solution (0.075M KCl). The cells were incubated at 37oC for 10mins before a further 
centrifugation step. Fixation using approximately 2-5mls 3:1 methanol:acetic acid 
was performed dropwise to avoid clumping of the cells, and centrifuged once again. 
The fixation step was repeated 3 times, or until the sample was clear, before being 
stored in the freezer.  
Slide preparation and banding: Chromosomes were prepared and G-banded using 
standard laboratory techniques100. Two drops of fixed bone marrow suspension 
were dropped onto pre-washed, wet glass slides, and allowed to air dry. The slides 
were baked on a 60oC hotplate for 10 minutes. The slide was flooded with trypsin 
working solution (10x trypsin stock solution dissolved into 49.5mls of a 0.9% Sodium 
Chloride solution) for 10-15 seconds before rinsing using Gurrs solution and then 
staining using 0.4% Giemsa stain for 90 seconds. Trypsin treatment produces the 
characteristic banding pattern on the chromosomes. 
Karyotype analysis: The slides were scanned using the CytoVysion metaphase finder 
and analysed using CytoVysion software. Twenty cells were fully analysed where 
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possible (10 cells minimum) unless an abnormal clone was detected where two cells 
with the same abnormalities would be considered clonal. Where only normal cells 
were detected all cells captured (in the region of 200 cells dependant on the 
culturing success) were viewed to assess for gross abnormality. 
See appendix 2 for reagent list associated with culturing bone marrow. 
 
Fluorescence in situ Hybridisation (FISH) 
A minimum probe set of IGH/FGFR3, IGH/MAF and TP53 has been suggested for the 
analysis of myeloma samples42. The FISH strategy employed at SDGS is considered a 
two-step process. Step 1 involves the IGH, TP53 and CDKN2C/CKS1B probes, and step 
2 is initiated if an IGH rearrangement is detected at step 1. The aim of step 2 is to 
elucidate the IGH partner and includes IGH/CCND1, IGH/FGFR3 and IGH/MAF probes 
(the most common low risk, and the two most common high risk rearrangements). 
The IGH breakapart probe was obtained from Vysis (Abbott Molecular, Des Plaines, 
IL) and TP53, CDKN2C/CKS1B, IGH/FGFR3, IGH/MAF and IGH/CCND1 were obtained 
from Cytocell (Cambridge, UK). Figure 2.1 shows the probe set employed in step 1. 
FISH was performed by using standard methods on interphase cells and in 
accordance with the manufacturer’s instructions for co-denaturation using 
ULTRAhyb (Life technologies) probe buffer: 
https://www.abbottmolecular.com/products/oncology/fish/hematology-
probes.html, &   
http://www.cytocell.co.uk/products/aquarius/haematology-probes/ 
Slide preparation: Slides for FISH processing were prepared as described in the 
chromosome karyotyping section above up until the baking step. 
Slide pretreatment: The slides were incubated in 2xSCC at 75oC for 15 minutes, and 
then transferred to a pepsin solution (4mg/ml in 0.9% NaCl, pH 1.5) for digestion for 
15mins at 37oC. The slides were then washed in 2xSSC for 5mins at room 
temperature, before an ethanol series (70%, 95% and 100%) for 2mins each was 
used to dehydrate the cell preparations. 
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Figure 2.1: Representation of the FISH probes used in Step 1 of the described myeloma FISH strategy. This 
includes the Vysis (Abbott) IGH breakapart probe (a) and the Cytocell TP53/17cen (c) and CDKN2C/CKS1B 
(1p/1q) (e) probes. FISH images (b, d & f) demonstrate the normal expected pattern for each of these probes. 
 
Probe preparation: Probes were prepared according to the manufacturer’s 
instructions, using hybridisation buffer containing dextran sulphate, formamide and 
SCC (pH 7.0), added to a coverslip which was overlayed onto the slide and sealed 
using rubber cement. 
Denaturation and hybridisation: Co-denaturation of both the target DNA and the 
probes was performed on a PCR thermocycler adapted for slides, at 72oC for 2mins 
and then hybridised at 37oC for 16 hours (overnight). 
Post hybridisation washes: The following morning a series of washes were 
performed to remove excess probe. The rubber cement seal and the coverslip were 








the detergent tween) at 75oC. The slides were then transferred to 2xSSC for 2mins at 
room temperature, before using the same ethanol series to dehydrate the slides 
before airdrying. The slides were mounted using DAPI (4´,6-diamidino-2-
phenylindole) counterstain in vectashield antifade. 
See appendix 2 for reagent list associated with FISH. 
FISH analysis: The slides were then analysed using a fluorescence microscope set up 
with the appropriate triple, dual, and single band pass filters to allow visualisation of 
the individual fluorophores associated with each probe. At least 200 interphase 
nuclei were scored for each probe set per sample. It is important at this stage to 
understand the probe set being employed, and what both expected normal and 
abnormal populations would demonstrate in terms of signal patterns.  
 
Multiplex Ligation-dependant Probe Amplification (MLPA) 
The MRC Holland MLPA probe mix for myeloma (SALSA MLPA probemix P425-B1 
Multiple Myeloma) contains 46 probes for the following chromosomal regions, 1p32-
p12, 1q21-q23, 5q31, chr 9, 12p13, 13q14, 14q32, chr 15, 16q12-q23 and 17p13, all 
thought to have diagnostic / prognostic relevance for myeloma patients, and 11 
reference probes for regions thought to be relatively stable in myeloma genomes. 
The SDGS in-house protocol is based on the one-tube protocol supplied by the 
manufacturer http://www.mrc-holland.com but has been validated in house to use 
half the volumes. DNA is required at 50ng/μl diluted in 1xTE buffer. The protocol was 
undertaken as follows: 
DNA denaturation: 2.5μl of DNA was incubated on a thermocycler for 5 minutes at 
98°C 
Hybridisation of probes to sample DNA: The sample was cooled to room 
temperature, and 1.5μl of the 1:1 probemix:MLPA buffer was added and mixed. This 
was incubated for 1 minute at 95°C and then hybridised for 16 hours at 60°C 
overnight. 
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Ligation of hybridised probes: The thermocycler temperature was reduced to 54°C, 
and 16μl of ligase master mix was added and incubated for 15mins at 54°C. The 
ligase enzyme was then thermally inactivated by heating to 98°C for 5 minutes. 
PCR amplification of ligated probes: The samples were cooled to room temperature, 
and 5μl of the polymerase master mix was added and gently mixed. The PCR 
thermocycler program was set to 35 cycles of 95°C for 30 seconds, 60°C for 30 
seconds and 72°C for 60 seconds. At the end of 35 cycles the reaction was held at 
72°C for 20 minutes and then cooled to 15°C for 10 minutes. 
Capillary electrophoresis of PCR products: The PCR product was then processed 
using the 3730 GeneMapper. 
Analysis: Results were transferred from GeneMapper to the Coffalyser analytical 
software supplied by MRC Holland, to assess the control quality and determine the 
relative size of the fluorescent peaks within each sample, which were compared to 
the reference samples. The results were expressed as ratios for the likelihood of a 
probe being either deleted or duplicated.  
 
Affymetrix DNA Array – CytoScan HD 
The Affymetrix arrays were run using the equipment and hardware available at 
Sheffield Institute of Translational Neuroscience (SITraN). Dr Paul Heath and his team 
were available for help and guidance throughout this process. 
The Affymetrix CytoScan High Density (HD) Array was chosen as the array of choice 
for the analysis of the myeloma patient samples in this PhD project. The CytoScan 
HD array offers a method to detect high resolution copy number changes across the 
human genome and utilises single nucleotide polymorphisms (SNPs) to determine 
loss of heterozygosity (LOH). This high density array has >2.4 million markers; 1.7 
million unique non-polymorphic probes designed to offer coverage of RefSeq and 
OMIM genes relevant to both constitutional and cancer, and 750,000 SNPs taken 
from dbSNP and designed to offer maximum genomic coverage, genotyping accuracy 
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and optimised for LOH detection. CytoScan HD Array can reliably detect copy 
number changes of 25-50kb across the genome with high specificity. 
The CytoScan processing protocol was run over four days and can be divided into the 
following stages: 
Genomic DNA requirements: 5μl of DNA was required at a concentration of 50ng/μl 
(250ng in total) 
Restriction enzyme digestion: A digestion master mix, made up with Nsp1 enzyme 
was prepared, added to the samples and incubated at 37°C for 2 hours before 
thermally arresting the reaction at 65°C for 20 minutes, and holding at 4°C. 
Ligation: A ligation master mix was made up including the supplied ligase buffer, the 
Nsp1 adaptor and DNA ligase. 5.25μl was added to the samples and incubated for 3 
hours at 16°C. The reaction was thermally arrested at 70°C for 20 minutes, and then 
held at 4°C. 
PCR step: The samples were diluted (1:3) in nuclease-free water. A PCR master mix 
was made up with PCR primers, DNA polymerase, dNTP mixture, GC melt reagent 
and a supplied PCR buffer. 10μl of the sample dilution was then added to 90μl of PCR 
master mix in quadruplicate. The thermal cycler lid was preheated and following 3 
minutes incubation at 94°C, was then run for 30 cycles of 94°C for 30 seconds, 60°C 
for 45 seconds and 68°C for 15 seconds. At the end of 35 cycles the reaction was 
completed at 68°C for 7 minutes and was then held at 4°C. 
PCR product purification: 3μl of the PCR product was run on a 2% agarose gel at 
5V/cm for 45 minutes to ensure that the product was between 150-2000bp. A 
purification step was performed in which magnetic purification beads were used to 
attract the DNA whilst a series of washes were performed. A final elution step 
removed the DNA from the magnetic beads. 
Product quantitation: The sample concentration was determined using nanodrop 
and a 260/280 ratio qualification measurement was undertaken. This quality control 
step required the 260/280 ratio to be between 1.8 and 2.0 and the concentration to 
be >2.5μg/ƞl in order to proceed. 
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Product fragmentation: A fragmentation master mix, using the fragmentation 
reagent supplied with the kit, was made up. 10μl of the master mix was added to 
45μl of the purified PCR product and incubated for 35 minutes at 37°C. The reaction 
was thermally arrested at 95°C for 15 minutes, and then held at 4°C. The fragmented 
PCR product was run on a 4% TBE gel at 5V/cm for 45 minutes to ensure fragment 
distribution was between 25-125bp. 
Product labelling: A labelling master mix was made up using the DNA labelling 
reagent supplied with the kit. 19.5μl of the master mix was added to 51μl of the 
fragmented product and incubated for 4 hours at 37°C. The reaction was thermally 
arrested at 95°C for 15 minutes, and then held at 4°C. 
Target array hybridisation: A hybridisation master mix was made according to the 
manufacturer’s instructions and 190μl was added to each sample. This was heated to 
95°C for 10 minutes in order to create single stranded DNA and then held at 49°C. 
200μl of the sample and hybridisation master mix was loaded into the DNA array 
cassettes ensuring even flooding of the array and sealed. The cassettes were loaded 
into the hybridisation oven and incubated for 16-18 hours at 50°C, turning at 60rpm. 
Washing, staining and scanning the arrays: The array cassettes were loaded into the 
fluidics stations and automatically processed to wash and stain the arrays according 
to the preloaded software. Once the wash and stain process was complete the 
arrays were scanned using the CytoScan software. 
Analysis: The scanner records a high-resolution image. This is converted to a .CEL 
file, which is a text (ASCII) file containing the intensity of each probe, the standard 
deviation, the number of pixels used in the calculation, and a flag marking any 
results as an outlier. Analysis of the files produced by the scanner was carried out 
using the Chromosome Analysis Suite (ChAS) software supplied by Affymetrix. The 
.CEL file was read by the ChAS analysis workflow and converted to produce a 
cyhd.cychp file, and this cyhd.cychp file was further processed to provide data for 
interpretation. Three array QC metrics are provided for the CytoScan arrays, 
however only the MAPD (Median of the Absolute values of all Pairwise Differences) 
should be considered for non-constitutional samples and was therefore used as the 
quality metric for this analysis. The log2ratio, smooth signal, and LOH tracks were 
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used for analysis. Table 2.1 details the cut-off levels set for each of the abnormality 
types in order to be called by the software. 
 
Abnormality type Marker count Size (kbp) 
Gain 10 100 
Mosaic Gain 10 100 
Loss 10 100 
Mosaic Loss 10 100 
Loss of Heterozygosity (LOH) - 10,000 
Table 2.1: Details the cut off levels set for each of the different abnormality types in order for the Affymetrix 
Chas array software to call an abnormality. 
 
Targeted Next Generation Sequencing (NGS) Gene Panel 
The wet work for the NGS was completed through the research group at SDGS, 
funded by the PhD project. Whilst the panel design was entirely my work, and much 
discussion was had with the NGS team, the wet work and the initial bioinformatic 
pipeline was completed by Dr Elsie Place and Dr Matt Parker. Analysis of the pipeline 
output was again my work. 
 
NGS Panel Design 
NGS panels are often utilised as a way of applying NGS technology in a more 
manageable way, from both a technological, analytical and financial point of view. 
WGS and WES are often excluded based on the current costs. NGS panels involve 
targeting smaller regions of interest, and targeting the NGS to the exonic (or even 
mutation hotspot) regions of genes.  
For this PhD project, a custom Agilent SureSelect hybridisation probe set was 
designed. The hybridisation probes are biotinylated RNA sequences complementary 
to the regions of interest. When the probes are incubated with the fragmented 
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sample DNA, the probes have the effect of ‘pulling down’ and enriching the regions 
of interest. The probe design was completed as a single panel of 139 genes, but was 
essentially made up of two panels; the SMaRT NGS Myeloma Gene Mutation Panel 
which included 79 genes known to be involved in myelomagenesis, and the SMaRT 
NGS Osteome Probe Panel which had 60 bone related genes. The ‘osteome’ NGS 
panel was required to address a further objective of the PhD project, and playing to 
the strength of the SMaRT. The genes included in the panels are laid out in tables 2.2 
and 2.3. 
 
SMaRT NGS Myeloma Gene Mutation Panel 
ANP32E ATM ATR ATRIP B2M BCL2 BCL6 BCL7A BIRC2 BIRC3 
BRAF CCND1 CCND2 CCND3 CDKN2A CDKN2C CHD4 CKS1B CRBN CUL4A 
CUL4B CYLD DDB1 DIS3 DNAH5 EGR1 ERBB4 FAF1 FAM46C FAT1 
FAT3 FAT4 FGFR3 FLT3 HIST1H1E HOXA9 IKZF1 IKZF2 IKZF3 IRF4 
KDM6A KDM6B KMT2A KRAS LRRK2 LTB LTBR MAF MAFB MAPK1 
MAX MRE11A MYC NCKAP5 NF1 NFKB1 NFKB2 NR3C1 NRAS NRM 
PARP1 PIK3CA PRDM1 PRKD2 PSMB5 PSMG2 RASA2 RB1 RET ROBO1 
ROS1 SF3B1 SP140 TP53 TRAF3 WHSC1 WWOX XBP1 ZFHX4  




















SMaRT NGS Osteome Probe Panel  
ACVR1 AKT1 CCL3 CCL4 CCR1 CCR3 CDH2 CER1 CSF2 CTNNB1 
DCN DKK1 DKK2 FRZB FZD1 FZD2 FZD3 FZD4 HGF ICAM1 
JAG1 KREMEN1 KREMEN2 LRP5 LRP6 MET MMP9 NOG NOTCH1 POSTN 
RUNX2 SDC1 SFRP1 SFRP2 SFRP4 SMAD2 SMAD3 SMAD4 SMAD7 SOST 
TAZ TGFB1 TGFB2 TGFB3 TNF TNFRSF11A TNFRSF11B TNFRSF13B TNFSF11 TNFSF12 
TNFSF13 TNFSF13B VCAM1 VEGFA WIF1 WNT10A WNT10B WNT3 WNT3A WNT5A 
Table 2.3: Detailing the genes included in the bespoke NGS panel covering the ‘osteome’, - bone related genes. 
 
The genes selected for inclusion in these panels were based on a number of papers, 
and also from experience of the SMaRT. The composition of the osteome NGS panel 
will be discussed further in the materials and methods section of Chapter 4. The 
myeloma gene NGS panel was initially based on three papers which had been 
published at the time of NGS panel design detailing abnormalities which were 
considered to be of importance in the diagnosis of myeloma: 
• Walker et al (2015). Mutational spectrum, copy number changes, and 
outcome: Results of a sequencing study of patients with newly diagnosed 
myeloma. J Clin Oncol 33:3911-2038. 
• Lohr et al (2014). Widespread heterogeneity in multiple myeloma: 
Implications for targeted therapy. Cancer Cell 25:91-10161 
• Bolli et al (2014). Heterogeneity of genomic evolution and mutational profiles 
in multiple myeloma. Nature Communications 5:299762 
These papers covered mutations that were recurrently seen in myeloma, those 
considered to be associated with prognostic impact and those considered to be 
predictive for response to current or potential future therapies. Gene names were 
used according to the HUGO gene nomenclature committee101. 
Walker et al, described 13 significantly mutated genes which included, KRAS, NRAS, 
TRAF3, TP53, FAM46C, DIS3, BRAF, LTB, CYLD, RB1, HIST1H1E, IRF4 and MAX38. Lohr 
et al described a similar set of 11 significantly mutated genes which did not include 
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LTB, HIST1H1E, IRF4 or MAX, but did include PRDM1 and ACTG161, and Bolli et al 
described seven highly recurrent genes KRAS, NRAS, BRAF, TP53, FAM46C, SP140 
and LTB62.  
Genes associated with the RAS/MAPK pathway are the most frequently mutated in 
all series, seen in approximately 43.2% of patients, these genes as well as MAPK1 
were included in the SMaRT myeloma NGS panel62. The NF-κB pathway is the next 
most frequently affected, seen in 17% of patients, the NFKB1, NFKB2 and LTBR genes 
were included. TP53 variants were seen in 11% of myeloma cases, other genes 
associated with delivering an apoptotic pathway, ATM, ATR, LRRK2, MRE11A and 
FAF1 were also included. 
IRF4 is a key plasma cell survival gene and downstream of cereblon (CRBN), the 
target of the IMiD group of drugs used for myeloma patients. EGR1 is another IMiD 
target gene, and the Ikaros group of genes (IKZF1, IKZF2 and IKZF3) have also shown 
association with cereblon and these were also included in the panel. A further paper 
from Kortüm et al published in 2015102 also described an NGS panel which included 
additional genes associated with specific treatment types. As well as the genes 
already described, they included CUL4A, CUL4B and DDB1 known to be associated 
with IMiD resistance, PSMG2 and PSMB5 associated with proteosome inhibitors and 
NR3C1 associated with glucocorticoid therapies, as well as DNAH5 and XBP1 which 
were added to our panel. 
Walker at al also described a number of significantly mutated genes associated with 
specific cytogenetic sub-groups, for example FGFR3 was only mutated in t(4;14) 
cases, and a further five genes were associated with this group; PRDM1, BCL7A, 
ATRIP, NRM and PRKD2. CCND1 mutation was highly associated with the t(11;14) 
group and EGR1 was associated with the hyperdiploid group38.  The other common 
IGH gene partners were also added in at this stage; MAF, MAFB, CCND3, WHSC1 as 
well as CCND2, although less common, and then finally MYC. 
CHD4 is known to interact with ZFHX4 to modulate TP53 function and mutations 
were seen in both genes. These were also shown to be associated with a negative 
survival impact as were CCND1, NCKAP5, ATM and ATR. IRF4 and EGR1 were shown 
to have a positive prognostic effect38. 
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Bolli et al go on to describe a further set of genes that may be associated with 
myeloma using less stringent cut-offs. These included: ROBO1, EGR1, FAT3 a 
transmembrane protein which is part of the cadherin family of genes, NFKB1, 
NFKBIA, CYLD, TRAF3, and some rarer mutations associated with other known cancer 
genes such as RAG2, SF3B1, PIK3CA, PTEN, KDM6A, CDKN2C and SETD262. Finally, a 
set of known genes associated with other lymphoid diseases and cancer have been 
implicated such as BCL2, BCL6, ERBB4, FLT3, HOXA9, KMT2A, PARP1, RET and ROS1, 
some of which were included in our panel along with closely related genes e.g. FAT1, 
FAT4, CDKN2A, KDM6B. 
B2M, beta2 microglobulin is known to be increased in patients with myeloma and 
this gene was also added to the NGS panel. A number of genes known to be 
associated with copy number change in myeloma were also included in the panel, 
some previously associated with mutations using NGS, and these included: CDKN2C, 
CKS1B, BIRC2, BIRC3, CYLD and WWOX 22. 
 
The probe set covers all exonic coding regions, from all transcripts (if multiple 
transcripts were present) and including +/-25bp into the intron/exon boundaries. 
The National Centre for Biotechnology (NCBI) website was used to obtain the 
reference sequence accession numbers for the genes involved: 
www.ncbi.nlm.nih.gov 
A BED file was downloaded based on these accession numbers containing the 
genomic coordinates for the start and finish +/-25bp for all exons, of all known 
transcripts of the genes involved. These co-ordinates were then uploaded to the 
panel design module of the Agilent web-based SureDesign software: 
https://earray.chem.agilent.com/suredesign/ 
Selection parameters were applied; Density was set to 5x, meaning that the 
overlapping, staggered probes covered the region five deep in a tiled manner, 
Masking was set at moderately stringent, this hides repetitive regions so that probes 
are not designed to these regions, and finally Boosting was set to Max performance, 
which ensures that probes with a higher GC content are replicated by a higher factor. 
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The software provides tiled probes that can be downloaded again as a BED file, 
which gives information on regions that have been missed on the first probe 
selection. These missed regions were then resubmitted at lower stringency selection 
parameters to ensure all regions were adequately covered. These additional probes 
were added to the original probe set and assessed using the UCSC (University of 
California Santa Cruz) genome browser alignment tool (BLAT): 
https://genome.ucsc.edu/ 
This gives a quality score, based on how many other regions of the genome the 
probes map to, and any probes that had a score of >40 were removed. 
Once the design of the probe panel was complete, it was ordered through the 
website for production. 
 
NGS Processing and Sequencing  
Twenty four samples were processed and these included both DNA from the 
CD138+ve cell selection, i.e. DNA from the myeloma tumour cells, and matched 
blood samples, representing the germline patient DNA.  
Library preparation: The blood sample libraries were prepared with the Agilent 
SureSelect QXT kit according to the manufacturer’s protocol using 50ƞg input 
genomic DNA (gDNA). Briefly, the gDNA is enzymatically fragmented and adapter 
tagged in a single 10 minute reaction. The samples were purified using AMPure XP 
beads, before amplifying through 8 cycles of PCR. The PCR primers overlap with the 
ligated adapter sequences and, at this stage, are unindexed.  
The CD138 positive cell selection DNAs from the patient BM samples were prepared 
with the Agilent SureSelect XT HS according to the manufacturer’s protocol using 32-
200ƞg input DNA. The starting DNA was fragmented to ~200bp using the Covaris 
E220 instrument. Adapters were ligated to the fragments using a 30min incubation 
step at 20°C, followed by an A-tailing step by way of end repair. Again, the samples 
were purified using AMPure XP beads, before amplifying the adapter-ligated library. 
Amplification of the samples uses the adaptor sequences ligated to the DNA 
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fragments and involves the use of one universal primer and one indexed primer, 
which is unique to each sample. The number of PCR cycles required is dependent 
upon the starting amount of DNA, in this case 8-12 cycles were used, based on the 
variable (but around 50ƞg) DNA input.  
For both sets of libraries, a further purification step is required post amplification, 
and before assessment of the quality and quantity. 
Pre-hybridisation quality assessment: The resulting DNA libraries were assessed for 
quality and quantity using the D1000 ScreenTape and reagents on an Agilent 
TapeStation 2200, and concentrations measured using Qubit high sensitivity ds DNA 
assay. The samples should ideally demonstrate a peak fragment size of 200-400bp in 
size. 
Hybridisation and capture: The libraries from both the blood sample DNA, and the 
bone marrow CD138+ve cell selection DNA, were hybridised to the target-specific 
probes designed as part of the bespoke NGS panel. Hybridisation occurred on a 
thermocycler using the manufacturer’s suggested run cycle. Capture of the regions 
of interest was carried out using streptavidin-coated magnetic beads. The samples 
were incubated with the magnetic beads for 30mins at room temperature, and a 
magnetic separator device designed for 96 well plates, effectively ‘pulls down’ the 
beads. A series of washes were performed, before the bead-bound, target enriched 
DNA was further amplified using a PCR step. At this stage, for the germline samples 
(blood samples), this PCR step also served to introduce sample indexes in a similar 
way to that described for the CD138+ve libraries. A further purification step was 
completed. 
Post hybridisation quality assessment: As described for the pre-hybridisation quality 
assessment the resulting post capture DNA libraries were analysed on the Agilent 
TapeStation 2200 using the high sensitivity ScreenTape. A peak fragment size of 200-
400bp was expected following this step also. 
Sample pooling and sequencing: The DNA libraries are denatured and passed 
through an Illumina eight lane flow cell; these flow cells are lined with millions of 
oligonucleotides, which are complementary to the adapters added to the DNA 
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libraries, allowing binding to occur. Amplification occurs to generate amplicon 
clusters in a process named parallel bridge amplification. Further denaturation 
leaves only the amplicon strands as extensions to the oligonucleotides adhered to 
the flow cell. These strands are then ‘sequenced by synthesis’ (SBS); SBS involves the 
addition of a complementary terminating fluorescent nucleotide in each cycle of 
sequencing, at which stage the fluorescence of each cluster is read. The termination 
molecule and the fluorescence is cleaved before moving on to the next cycle. This 
was repeated for 108 cycles in forward and reverse directions, resulting in 216 total 
cycles, with each cluster generating one forward and one reverse sequence read. 
The pooling was performed such that blood sample DNA libraries were allocated 
approximately 1/100th of a lane each, and the bone marrow sample CD138+ve cell 
selection DNA libraries were allocated approximately 1/14th of a lane each. This was 
calculated based on the approximate read depth required for each sample type, 30x 
read depth for the germline samples and 500x read depth for the myeloma disease 
samples. 
A paired end 2x 100bp sequencing run was performed on a HiSeq 2500 using TruSeq 
(v3) reagents, with an 8bp index 1 read and a 10bp index 2 read. Index Sequences, 
pooling data and final library sizes are provided in appendix 3. 
Bioinformatics: Raw FASTQ DNA sequence files obtained from the Illumina HiSeq 
platform are analysed through a bioinformatics pipeline developed at SDGS. This 
pipeline conforms to the Broad Institute best practice guidance with some additional 
customised data filtering and QC check steps. The pipeline aligns reads to the hg19 
(GRCh37) build human genome using Burrows-Wheeler Alignment (BWA)103. 
Variants were called using the Genome Analysis Toolkit (GATK) software104, and were 
then analysed using a variety of bioinformatics tools; mutect2, vardict and strelka104-
106 to assess the likelihood of associated pathogenicity. A consensus set based on 
calls from all three tools was created. This list of variants with further annotation 
including ClinVar and ExAC allele frequencies as well as links to the Myeloma or 
Osteome gene panel, was provided from the SDGS service for further analysis, and 
interpretation. ClinVar is a freely accessible, public archive of the relationships of 
human variants and phenotypes with supporting evidence. ExAC (the Exome 
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Aggregation Consortium) database covers a number of large-scale sequencing 
projects with the aim of aggregating and harmonising exome sequencing data. 
A full list of the bioinformatics reference files, and software tools applied to the NGS 
data are detailed in appendix 4. 
 
Genetic Data Analysis 
The output from the five genetic methodologies described is broad, and direct 
comparison can be difficult, as the data are not presented in the same way. It can 
relate to individual pieces of genomic information about specific genes or regions to 
whole genome wide analyses, and can represent analysis on many different levels of 
resolution from base pair level to megabase level.  
Cytogenetics provides a karyotype image and an International System for 
Cytogenetic Nomenclature (ISCN) description. ISCN is the coded written description 
of the karyotype. FISH provides information on the specific regions assessed; this can 
be rearrangement in the case of IGH and its partner genes, loss/deletion or 
gain/duplication in the case of 1p/1q and TP53 FISH. FISH results can be represented 
in ISCN, but this is often considered complex and difficult to interpret and therefore 
summary statements are often used. MLPA will also offer information on loss or gain 
of the regions included in the panel, these results can be written using ISCN, but 
again is not considered as user friendly as written summary statements. Array 
analysis again, highlights areas of loss and gain but on a whole genome wide level as 
well as providing evidence of loss of heterozygosity (LOH). Once again, ISCN 
nomenclature is available for array results, but is not always the method of choice to 
display these results. Finally, NGS results in lists of variants for analysis and 
interpretation of pathogenicity, usually variants are written according to Human 
Genome Variation Society (HGVS)107. HGVS nomenclature, is equivalent to ISCN, 
when reporting and exchanging information about variants in DNA, RNA and protein 
sequence and serves as an international standard.  
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Chapter 3: Genetic Results from the Patient Cohort 
Patient Cohort 
The rationale for this part of the project was to assess five different genetic 
technologies on a set of patient samples received as part of the research project. The 
five technologies included cytogenetic analysis (karyotyping), FISH, MLPA, DNA 
arrays and NGS, all technologies available within an NHS diagnostic laboratory. This 
covers Objective 1, which aims to establish genetic signatures for a set of patients in 
order to assess the ability of each technology to do this in an effective and efficient 
manner, within the requirements of a diagnostic testing scenario. The results from 
this part of the project will also contribute towards Objective 3, in which a best 
practice testing strategy will be proposed, alongside setting up a quality assessment 
scheme for the genetic testing of myeloma. 
Since January 2014, just over 100 patient bone marrow samples were received in 
SDGS, following consent taken by Dr Andrew Chantry, for diagnostic analysis and use 
in this research project. Twelve patients were shown to have, either an unrelated 
neoplastic condition or a normal bone marrow, and these patients were excluded 
from the research project analysis cohort. 
All patient BM samples received in medium were set up for long term cell culture for 
karyotypic analysis on the whole bone marrow sample. 
MACS separation was introduced as a validated technique in March 2014 in SDGS, 
and only samples that had been through this process were used as part of the 
patient cohort for this project. One exception to this was patient #113, who was 
diagnosed with plasma cell leukaemia and showed an extremely high level of plasma 
cells (80%), and therefore did not require the plasma cell selection process in order 
to target and analyse the plasma cells.  
CD138 positive cells were processed for both FISH and DNA extraction, where 
enough material was available. FISH processing and analysis were prioritised where 
there was not sufficient material, as this makes up the standard of care (SOC) 
analysis for diagnostic workup of myeloma patients at diagnosis. FISH for IGH, TP53 
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and CDKN2C/CKS1B (including further follow up, using IGH/CCND1, IGH/FGFR3 and 
IGH/MAF probes, if IGH is rearranged) was performed. 
MLPA was performed on 45 patients who were selected based on those who had 
enough DNA at sufficient quality to perform the analysis. 
The Affymetrix array analysis demands good quality DNA, at a quantity of 250ng at a 
concentration of 50ng/μl. Patients, again, were selected based on the quality and 
quantity of DNA available, and was completed on a cohort of 36 patients. 
Finally, the NGS sequencing was performed on 24 patients, and the cohort was 
chosen not only by the availability of sufficient DNA from the CD138+ve cell 
selection, but by the availability of a germline sample. In the case of myeloma, the 
patient’s blood is not involved in the disease and therefore this is a suitable sample 
type for germline analysis. Although blood samples were taken alongside the bone 
marrow for most patients, following consent for the project, this sample was not 
available for all patients. The NGS arm of the project not only assessed the feasibility 
of using NGS technology in the diagnosis of myeloma, but also explored a possible 
correlation or predisposition to an associated bone phenotype in myeloma through 
abnormalities that may or may not be found in the ‘osteome’; bone related genes. It 
was important therefore, that this cohort represented myeloma/MGUS with and 
without bone involvement, and ideally split 50:50. This arm of the project is further 
explained and discussed in Chapter 4. The NGS processing and analysis has a 
substantial cost associated with it, and the number of patients processed for NGS 
were, in part, limited by funds available for the project. 
The quality and quantity of patient samples varied dramatically across the full 
patient cohort. Although the ideal would have been to carry out the full genomic 
analysis on a single set of patients, very few patients were likely to have had enough 
genetic material, and the funds and the time for the project did not allow for all 100 
patients to have all five technologies applied. However, over the whole cohort, we 
have data on a subset of patients for each technology described here.  
The patient cohort included samples from 101 patients in total, 91 were karyotyped, 
101 were FISHed, 45 had MLPA analysis, 36 were processed for the Affymetrix DNA 
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array and 24 had the NGS bespoke gene panel analysis. Table 3.1 shows the number 
of cases that had which tests applied. Four cases had only FISH analysis, and a single 
case had all five genetic technologies. The majority of patient cases, 68/101 (67.3%) 
had either three or four of the genetic technologies applied. 
 
 
Test(s) applied Number of Cases 
FISH 4 
Cytogenetics & FISH 23 
FISH & MLPA 5 
Cytogenetics, FISH & MLPA 21 
Cytogenetics, FISH & Array 13 
Cytogenetics, FISH & NGS 5 
FISH, MLPA & NGS 1 
Cytogenetics, FISH, MLPA & Array 11 
Cytogenetics, FISH, MLPA & NGS 6 
Cytogenetics, FISH, Array & NGS 11 
Cytogenetics, FISH, MLPA, Array & NGS 1 
Table 3.1 Demonstrating the number of cases that had the described tests applied. Four cases had a single FISH 
test and only case had all five technologies applied, however the vast majority, 68/101 patient samples had 
either three or four technologies applied. 
 
 
Table 3.2 shows all 101 patients in the sample cohort used as part of this research 
project demonstrating the genomic analysis applied to each patient, the diagnosis at 
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the study timepoint and the percentage of plasma cells seen. This table also includes 
a basic result of the test, although these results will be discussed in further detail 
within each specific technique results section. Failed tests are coloured purple, NAD 
(no abnormality detected) tests are coloured green, and all abnormal tests are 
coloured blue. 
Of the 101 patient samples, 89 (88.1%) showed abnormality (or a failed / unknown 
result) in at least one of the techniques applied. Twelve of the total 101 cases 
showed normal results across the full range of tests applied, however, it should be 
noted that nine of those 12 patients only had 1 or 2 test types, and therefore 
abnormality may have been detected using the alternative testing technologies. 
Sample 
No: Cytogenetics  FISH  MLPA  
Array 
  NGS  Diagnosis  
Plasma 
cells (%) 
#113 Complex Abnormal Abnormal Complex  Plasma cell myeloma 63 
#119 NAD NAD  Hyperdiploid  Plasma cell myeloma 36 
#134 Complex Abnormal Abnormal Complex  Plasma cell myeloma 70 
#136 Complex Abnormal Failed  Abnormal Plasma cell myeloma 70 
#138 NAD Abnormal Failed   Plasma cell myeloma 60 
#139 NAD Abnormal    Plasma cell myeloma 70 
#141 NAD Abnormal Abnormal   Plasma cell myeloma  
#140 NAD Abnormal NAD  Abnormal Plasma cell myeloma 15 
#142 NAD NAD Abnormal   MGUS 8 
#144 Missing Y NAD Abnormal Complex Abnormal Plasma cell myeloma 70 
#146 NAD Abnormal Abnormal Complex  Plasma cell myeloma 18 
#147 NAD NAD Abnormal Hyperdiploid  Plasma cell myeloma 60 
#106 Hyperdiploid NAD Hyperdiploid   Plasma cell myeloma 54 
#51 NAD NAD Hyperdiploid Hyperdiploid  Plasma cell myeloma 55 
#149 Failed Abnormal    Plasma cell myeloma 90 
#138 NAD NAD  Hyperdiploid  Plasma cell myeloma 75 
#150 Hyperdiploid NAD    Plasma cell myeloma 60 
#88 NAD NAD   Abnormal Plasma cell myeloma 50 
#151 NAD NAD Failed Hyperdiploid  MGUS 7 
#152 NAD Abnormal    Asymptomatic Myeloma 10 
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#156 NAD Abnormal    Plasma cell myeloma 30 
#157 NAD Abnormal  Abnormal  Plasma cell myeloma 70 
#158 NAD NAD  Complex  Plasma cell myeloma 25 
#159 NAD Abnormal Failed NAD  Plasma cell myeloma 20 
#160 Missing Y NAD    MGUS 7 
#161  Abnormal Failed  NAD Plasma cell myeloma 40 
#162 NAD NAD   NAD Plasma cell myeloma 35 
#165 Complex Abnormal Abnormal   Plasma cell myeloma 70 
#166 Failed NAD    Plasma cell myeloma 60 
#168 Hyperdiploid Abnormal Hyperdiploid   Plasma cell myeloma 70 
#170 Failed Abnormal Abnormal   Plasma cell myeloma 80 
#44 Complex NAD Failed  Abnormal Plasma cell myeloma 56 
#171 Failed Abnormal  Hyperdiploid  Plasma cell myeloma 25 
#175 Hyperdiploid Abnormal Hyperdiploid   Plasma cell myeloma 70 
#176 NAD NAD    Plasma cell myeloma 20 
#178 Complex Abnormal Abnormal   Plasma Cell Leukaemia  95 
#179 Failed NAD  Hyperdiploid NAD Plasma cell myeloma 30 
#180 Failed NAD Failed  NAD Plasma cell myeloma 20 
#184 Failed NAD  Complex NAD Plasma cell myeloma 21 
#187 NAD Abnormal Failed   Plasma cell myeloma 15 
#188 NAD Abnormal Abnormal   MGUS 4 
#186 NAD NAD    Plasma cell myeloma 20 
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#190 NAD Abnormal  NAD  Plasma cell myeloma 24 
#189 Hyperdiploid NAD Failed Failed  Plasma cell myeloma 59 
#84 Complex Abnormal    Relapsed myeloma 95 
#192 Failed NAD    Plasma cell myeloma 11 
#191 NAD Abnormal Failed  Abnormal Plasma cell myeloma 25 
#196 NAD Abnormal Abnormal   Plasma cell myeloma 16 
#197 NAD Abnormal Abnormal   Plasma cell myeloma 7 
#198 NAD Abnormal   Abnormal Plasma cell myeloma 62 
#200 Missing X Abnormal   Abnormal Plasma cell myeloma 50 
#199 Failed NAD  Failed Abnormal Plasma cell myeloma 60 
#201 NAD Abnormal  Complex  Plasma cell myeloma 60 
#202 NAD Abnormal  NAD NAD Plasma cell myeloma 20 
#203 NAD Abnormal Hyperdiploid Hyperdiploid  Plasma cell myeloma 70 
#204 NAD Abnormal  Hyperdiploid  Plasma cell myeloma 59 
#205 NAD NAD Abnormal   Plasma cell myeloma 18 
#207 NAD NAD  Hyperdiploid  Plasma cell myeloma 73 
#209 Failed Abnormal  Hyperdiploid NAD Plasma cell myeloma 14 
#208 NAD Abnormal  Abnormal Abnormal Plasma cell myeloma 12 
#210 Complex Abnormal Failed Failed  Plasma cell myeloma 40 
#213 Missing X Abnormal    MGUS 8 
#146 (2) NAD Abnormal    Plasma cell myeloma 12 
#215 NAD NAD  Failed NAD Plasma cell myeloma 36 
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#216 NAD NAD  NAD  Plasma cell myeloma 50 
#218 NAD NAD Failed   Relapsed myeloma 16 
#219 NAD NAD    Plasma cell myeloma  
#220 Failed NAD    Plasma cell myeloma 15 
#217 NAD Abnormal Failed  NAD Plasma cell myeloma 24 
#222 Failed NAD Hyperdiploid Hyperdiploid  Plasma cell myeloma 52 
#226 NAD Abnormal  Hyperdiploid  Plasma cell myeloma 80 
#225 NAD Abnormal  Failed  Plasma cell myeloma 21 
#224 Failed NAD  Hyperdiploid  Plasma cell myeloma 80 
#227 NAD NAD    MGUS 8 
#229 NAD NAD    Asymptomatic Myeloma 15 
#230 Failed Abnormal  Hyperdiploid Abnormal Plasma cell myeloma 85 
#231 NAD NAD    MGUS 7 
#232 NAD Abnormal  NAD NAD Plasma cell myeloma 17 
#233 NAD Abnormal  Hyperdiploid Abnormal Plasma cell myeloma 45 
#235 NAD NAD   Abnormal Plasma cell myeloma 42 
#234 NAD NAD  Hyperdiploid Failed Plasma cell myeloma 80 
#236 NAD Abnormal    MGUS 7 
#237 Complex NAD    Plasma cell myeloma 50 
#238 NAD NAD NAD   Plasma cell myeloma 35 
#239 Triploid Abnormal    
Plasma cell myeloma post 
treatment 6 
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#240 NAD NAD    MGUS 5 
#241 NAD NAD    Plasma cell myeloma 55 
#243 NAD NAD Hyperdiploid   Plasma cell myeloma 65 
#244 NAD Abnormal Abnormal   MGUS 7 
#61  Abnormal Abnormal   Plasma cell myeloma 39 
#245 NAD Abnormal Abnormal   Plasma cell myeloma 60 
#247 NAD NAD Hyperdiploid   Plasma cell myeloma 28 
#248 NAD Abnormal Abnormal   Plasma cell myeloma 20 
#251  Abnormal Abnormal   Plasma cell myeloma 65 
#250  Abnormal Failed   Plasma cell myeloma 26 
#253  Abnormal    Plasma cell myeloma 45 
#252  NAD    Plasma cell myeloma 30 
#256  Abnormal Failed   Plasma cell myeloma 90 
#260  Abnormal    Plasma cell myeloma 37 
#263  NAD Failed   Plasma cell myeloma 30 
#268  NAD    Plasma cell myeloma 18 
TOTALS 91 101 45 36 24   
 
Table 3.2: Total number of samples processed as part of the research project cohort. This indicates the number of samples processed for each technology and the technologies applied to 
each patient in the cohort. Each test has a basic result recorded, NAD (no abnormality detected) is coloured green, failed tests are coloured purple, and any test with an abnormal result is 
coloured blue. The table also details the working diagnosis of the patient along with the percentage of plasma cells associated with the sample (where this figure is known). 
Conventional Culturing and Karyotyping 
Whole bone marrow samples from 91 patients were processed for long term 
culturing for cytogenetic analysis, and of these 91 patients, 78 yielded sufficient 
metaphases for a cytogenetic result (85.7% success rate). Cytogenetic analysis of 
plasma cell myeloma is notoriously difficult and relies of the ability to capture cells, 
specifically plasma cells, at metaphase of cell division. Plasma cells are mature cells 
and cycle slowly. Although robust processes are used routinely to analyse 
chromosomes in leukaemia samples, myeloma bone marrow samples do not yield 
good preparations for karyotyping using standard techniques. Adaptations to the 
culturing process were employed, allowing for longer term culturing (4-6 days), 
which are recommended for myeloma chromosome analysis42. The success rate was 
based on the presence of at least 10 metaphase cells for karyotype analysis. This 
compares to a success rate of 97.4% for standard karyotyping for leukaemia samples, 
using the 2018 figures from the SDGS routine service. This figure is known to be low 
for myeloma, and success rates of only 30-40% are reported25,108. 
Of the 78 bone marrow samples successfully cultured, 59/78 (75.6%) showed a 
normal karyotype, and 19/78 (24.4%) demonstrated an abnormal karyotype. These 
figures are presented in table 3.3.  
 










91 78 (85.7%) 59 (75.6%) 19 (24.4%) 
Table 3.3: Details the total number of samples cultured, those with successful karyotypes further divided into 
those with abnormal and normal karyotypes. 
 
The rate of plasma cell capture is poor, even with enhanced culturing, and therefore 
the abnormality rate is low. Cytogenetic abnormalities are reported in the literature 
in approximately 30% of myeloma patients42, using long term culturing. The low 
abnormality rate in our cohort (24.4% compared to the reported 30%) is likely to 
reflect the composition of our cohort, which is known to include a proportion of 
patients classified as MGUS, rather than myeloma. MGUS patients show a lower 
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level of abnormality, but also, by definition have <10% plasma cells, increasing the 
difficulty in capturing these cells in metaphase.  The abnormality rate seen 
karyotypically in myeloma both in the literature and in our cohort is very much lower 
than those rates reported by FISH or MLPA technologies which do not rely on the 
ability to capture abnormal plasma cells in division.  
Cytogenetic analysis requires the individual karyotyping of a number of cells, this 
time-consuming step contributes to the slow and expensive nature of karyotyping. 
Cytogenetic analysis is also highly dependent upon the skill and experience of the 
analyser. A standard diagnostic analysis for the majority of leukaemia types involves 
the analysis of 20 cells, but screening of 100 cells is recommended in order to use 
karyotyping as a diagnostic tool for myeloma42.  
The 19 abnormal karyotypes are listed in table 3.4 using the International System for 
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Table 3.4: Details the 19 abnormal karyotypes detected in the 91 patients whose bone marrow samples were 
cultured and processed for karyotyping. 
 
Two of the 19 abnormal cases have a missing chromosome Y karyotype, and 2/19 
show a missing chromosome X cell line. Loss of a sex chromosome, specifically loss of 
chromosome Y is a known age related effect110. Although this abnormality has been 
associated with haematological disease, it is also seen in older patients with no 
known disorder, and therefore when seen as sole change is not considered 
consistent with neoplastic change. In essence, these should be considered normal 
with regard to the patient’s myeloma. 
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The remaining 15 cases can be sub-divided into hyperdiploid cases 7/15 (46.6%) & 
non-hyperdiploid cases 8/15 (53.3%). This reflects the reported incidence of 
hyperdiploid vs non-hyperdiploid cases in the literature25,26. 
The hyperdiploid cases include #106, #150, #168, #44, #175, #189 and #84. Of the 
eight non-hyperdiploid cases, three showed a cytogenetically detectable 
rearrangement of chromosome 14 at the site of IGH (#113, #168 and #210). Only one 
of those three demonstrated a known and detectable partner chromosome, #113 in 
which a t(14;20) was detected. It should be noted that t(4;14) rearrangements are 
not detectable cytogenetically as the regions are small, approximately the same size 
and with similar banding patterns. The t(4;14) is one of the two most common IGH 
rearrangements, along with t(11;14), and the cytogenetically cryptic nature of this 
abnormality demonstrates the need to employ a different technology in order to 
detect the t(4;14). 
Four cytogenetically abnormal cases have been selected to demonstrate the range of 
karyotypes seen. Figure 3.1 shows a representative karyotype from patient #113 
demonstrating complex abnormalities including a t(14;20) IGH-MAFB 
rearrangement. Figure 3.2 shows a second complex karyotype from patient #134 
who was shown to have a cytogenetically cryptic t(4;14), but also has abnormalities 
of chromosome 1q and loss of TP53 on chromosome 17. Figure 3.3 shows a 
karyotype from patient #106 demonstrating a hyperdiploid karyotype with classic 
chromosome gains. Finally figure 3.4 shows a karyotype from patient #175, again 
with a hyperdiploid karyotype, but with a further abnormality of chromosomes 1 and 
17 resulting in loss of TP53 on the short arm of chromosome 17 and gain of the long 
arm of chromosome 1. Patients #113 and #175 will be discussed in further detail as 








Figure 3.2: Demonstrating a representative karyotype from patient #134 with a complex karyotype including rearrangements of chromosomes 1, 2, 5, 6, 7, 11, 17, 21 and a marker 





Figure 3.3: Demonstrating a representative karyotype from patient #106 with a hyperdiploid karyotype. This shows classic gains of chromosomes associated with myeloma, in this case, 




Figure 3.4: Demonstrating a representative karyotype from patient #175 with a hyperdiploid karyotype, but with an additional abnormality of chromosomes 1 and 17 resulting in loss of 
TP53 on the short arm of chromosome 17 and gain of the long arm of chromosome 1. This case is discussed further as a case report. 
56,XY,+3,+5,+5,+7,+9,+9,+11,+15,der(17)t(1;17)(q11;p13),+19,+21 
Cytogenetic analysis offers a full genome screen and can detect hyperdiploidy and 
abnormalities involving the IGH locus on chromosome 14, however, the resolution of 
cytogenetic analysis is low. The example karyotypes demonstrate the resolution level 
that can be obtained using cytogenetic analysis. A fine chromosome band is 
considered to be around 5Mb, and the quality of chromosomes and banding seen in 
leukaemia preparations make these fine bands difficult to assess. Therefore, changes 
involving approximately 10Mb are likely to be the best level of detection for 
chromosome analysis in myeloma.  
 
Fluorescence in situ Hybridisation (FISH) 
FISH was performed on 101 patients with a CD138 positive separated fraction. As 
described in the methods, FISH was undertaken as a two-step process as part of this 
project.  
Step 1 involves the Abbott Vysis IGH breakapart probe, Cytocell TP53 (including a 
control region at the centromere of chromosome 17) and Cytocell CDKN2C/CKS1B 
probes. Probe maps for each of these three probes are shown in the materials and 
methods chapter, figure 2.1. The IGH breakapart probe is designed with a red and a 
green probe flanking the IGH region. In a normal cell with no IGH rearrangement this 
would be seen as two fusion (2F) signals, fusion signals describe visualisation of red 
and green at the same region which is often seen as yellow. When a rearrangement 
of IGH is seen, there is a break between the red and the green probes and these are 
then visualised as separate signals, a standard rearrangement pattern would be one 
fusion signal, one red signal and one green signal (1F1R1G). The TP53/17cen probe is 
designed to have a red probe covering the critical region of TP53 and a green probe 
at the centromere of chromosome 17. The control probe provides reassurance that 
the probe is working correctly, but also allows the number of chromosome 17s to be 
enumerated. A normal cell would show two red signals and two green signals 
(2R2G). Deletion of TP53 would usually be seen as loss of one of the red signals 
(1R2G), but relative deletions can also be seen with three copies of chromosome 17, 
demonstrated by the green centromere probe, and loss of one of the TP53 signals 
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leaving two (2R3G). Occasionally, trisomy for chromosome 17 is seen, showing three 
red signals and three green signals (3R3G). The CDKN2C/CKS1B probe is designed to 
have a green probe covering the critical region of CDKN2C at 1p21.3 and a red probe 
covering the critical region of CKS1B at 1q21.3. A normal cell would show two red 
signals and two green signals (2R2G). The expected abnormal pattern would be 
either loss of 1p (2R1G) or gain of 1q (3R2G), or these can be seen together (3R1G). 
Sometimes further additional copies of 1q are gained (e.g. 4R1G), and amplification 
of CKS1B is also seen with five or more copies of the probe (e.g. 5R2G). 
Step 2 is initiated if an IGH rearrangement is detected at step 1 using the IGH 
breakapart probe. The aim of step 2 is to elucidate the IGH partner gene and the 
FISH panel used here includes IGH/CCND1, IGH/FGFR3 and IGH/MAF probes. This 
covers the two most common rearrangements IGH-CCND1 and IGH-FGRF3 each seen 
in approximately 15% of patients, and IGH-MAF which is the next most common 
poor prognostic translocation seen in approximately 5% of patients. NICE guidelines 
recommend, as a minimum, the exclusion of IGH-FGFR3 and IGH-MAF as the two 
most common poor risk rearrangements, along with TP53 deletion status111. These 
three probe sets used in step 2 are described as ‘dual colour, dual fusion’. Each 
probe set has a green probe covering the IGH gene and a red probe covering the 
potential IGH partner gene; FGFR3, CCND1 or MAF. In a normal cell, the probes 
would demonstrate two green signals on each of the normal IGH genes, and two red 
signals on each of the normal IGH partner genes (2R2G). In a cell with an IGH 
rearrangement, for example IGH-CCND1, both the abnormal IGH and CCND1 split to 
give three signals, and two of each fuse giving a 2F1R1G pattern. The fusion signals 
represent the derivative chromosomes 11 and 14 in this case, and the single red 
signal marks the normal CCND1 gene and the single green probe marks the normal 
IGH gene. Myeloma genetics can be extremely complex and non-standard 
rearrangements can be seen along with loss and gain, FISH probes can show non-
standard signal patterns reflecting these complex rearrangements.  
Chapter 5 describes the introduction of a quality control assessment scheme for 
myeloma genetic analysis, and demonstrates a number of alternative FISH panels 
utilised by different laboratories. We have described a two-step FISH process here, 
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which covered the NICE guideline requirements at the time as well as the 1p/1q 
assessment. IGH-CCND1 is seen in approximately 15% of myeloma patients. IGH-
MAFB is a marker of poor prognosis, but seen at a very low frequency, 1-2% of 
myeloma patients. IGH-CCND1 was included in this panel based on the frequency of 
occurrence, but currently IGH-MAFB is not included although there is a strong 
argument for inclusion based on the prognosis attached to this rearrangement. 
At this stage it should be noted that initially in this project, FISH was performed on 
whole BM samples whilst the CD138+ve selection process was undergoing 
validation. Of the first 10 patient samples that had FISH processed on whole BM 
samples an abnormality rate of 0% was seen. This compares to a 54.4% abnormality 
rate in cases with a preceding plasma cell separation. Plasma cells can be present at 
levels as low as 10% in myeloma patients and less in MGUS patients, if the 
abnormality is only present in a proportion of those plasma cells, for example 10%, 
then only one cell in a standard analysis of 100 cells would show abnormality. This 
demonstrates the importance of ensuring that a separation step is completed and 
offers good evidence for why this step is considered best practice in the analysis of 
myeloma bone marrow samples. FISH results from the whole bone marrow samples 
were excluded from this study and the FISH results presented here are solely from 
the patients FISHed following plasma cell separation.  
FISH is generally a robust technique and no cases failed using all FISH probes. Two 
cases failed to give a result for the IGH breakapart probe, but all cases gave a result 
with the TP53 and CDKN2C/CKS1B probes. Considering numbers of FISH 
hybridisation performed in this project, 301/303 (99.3%) achieved a result, 
demonstrating an excellent success rate.  
Table 3.5 details the FISH results for all probes used across the 101 patients. Boyd et 
al112, describe a worsening prognosis based on the presence of three poor risk 
abnormalities; poor risk IGH rearrangements (IGH-FGFR3, IGH-MAF and IGH-MAFB), 
TP53 deletion and gain of chromosome 1q. Patients in our cohort have been scored 
based on the number of these adverse risk abnormalities described in Boyd’s 
prognostic schema, and also scored for the number of abnormalities detected using 
the FISH panel presented here (see table 3.5). Where these numbers are shown in 
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blue, the IGH partner gene is not known, and definitive proof of a poor risk IGH 
rearrangement is unknown. Table 3.6 presents the abnormalities seen for each of 









No. of adverse 
abnormalities 
Total no. of 
abnormalities 
#113 Normal Loss of 1p & gain of 1q Rearranged IGH-MAFB rearrangement MYC rearrangement 2 4 
#119 Normal 
Not enough material to 
complete Normal     0 0 
#134 Deleted Normal 1p, gain of 1q Rearranged IGH-FGFR3 rearrangement   3 3 
#136 Normal Normal 1p, gain of 1q Rearranged IGH-MAF rearrangement   2 2 
#138 Normal Normal 1p, gain of 1q Normal     1 1 
#139 Normal Normal 1p, gain of 1q Normal     1 1 
#141 Normal Normal Rearranged IGH-CCND1 rearrangement   0 1 
#140 Normal Normal Rearranged IGH-CCND1 rearrangement   0 1 
#142 Normal 
Not enough material to 
complete Normal     0 0 
#144 Normal 
Not enough material to 
complete Normal     0 0 
#146 Normal Normal 1p, gain of 1q Rearranged IGH-CCND1 rearrangement   1 2 
#147 Normal Normal Normal     0 0 
#106 Normal Normal Normal     0 0 
#51 Normal 
Not enough material to 
complete Normal     0 0 
#149 Deleted Normal Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF    1 2 
#138 Normal Normal Normal     0 0 
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#150 Normal Normal Normal     0 0 
#88 Normal Normal Normal     0 0 
#151 Gain Gain of 1p & 1q Normal   
Extra copies of 
chromosome 1 & 17 0 0 
#152 Normal Normal Rearranged IGH-CCND1 rearrangement   0 1 
#156 Normal Loss of 1p & normal 1q Normal     0 1 
#157 Normal Normal Rearranged IGH-CCND1 rearrangement   0 1 
#158 Normal Normal Failed     0 0 
#159 Deleted Normal Normal     1 1 
#160 Normal Normal Normal     0 0 
#161 Abnormal Normal Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF  
 Loss of 17 
centromere 1 2 
#162 Normal Normal Normal     0 0 
#165 Normal Normal 1p, gain of 1q Normal   MYC rearrangement 1 2 
#166 Normal Normal Normal     0 0 
#168 Gain Normal 1p, gain of 1q Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF  
Extra copies of 
chromosome 17 1 3 
#170 Normal Normal 1p, gain of 1q Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF    1 2 
#44 Normal Normal Normal     0 0 
#171 Deleted Normal 1p, gain of 1q Normal     2 2 
#175 Deleted Normal 1p, gain of 1q Normal     2 2 
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#176 Normal Normal Normal     0 0 
#178 Deleted Loss of 1p & gain of 1q Rearranged 
IGH-FGFR3 rearrangement, with 
loss of FGFR3   3 4 
#179 Normal Normal Normal     0 0 
#180 Normal Normal Normal     0 0 
#184 Normal Normal Normal     0 0 
#187 Normal Normal Rearranged IGH-FGFR3 rearrangement   1 1 
#188 Normal Normal 1p, gain of 1q Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF on whole BM only   1 2 
#186 Normal Normal Normal     0 0 
#190 Normal Normal Rearranged IGH-CCND1 rearrangement   0 1 
#189 Normal Normal Normal     0 0 
#84 
Relative 
deletion  Loss of 1p & gain of 1q Normal   MYC rearrangement 1 4 
#192 Normal Normal Normal     0 0 
#191 Normal Normal Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF on whole BM only   0 1 
#196 Normal Normal 1p, gain of 1q Normal   
Loss of one IGH 
signal 1 2 
#197 Normal Normal Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF on whole BM only   0 1 
#198 Normal Normal 1p, gain of 1q Normal   
Loss of one IGH 
signal 1 2 
#200 Normal Normal 1p, gain of 1q Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF    1 2 
#199 Normal Normal Normal     0 0 
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#201 Normal Normal Normal   
Loss of one IGH 
signal 0 1 
#202 Normal Loss of 1p & normal 1q Failed     0 1 
#203 
Relative 
deletion  Normal Normal     0 1 
#204 Normal Loss of 1p & gain of 1q Normal     1 2 
#205 Normal Normal Normal     0 0 
#207 Normal Normal Normal     0 0 
#209 Gain Normal Normal   
Extra copies of 
chromosome 17 0 1 
#208 Gain Normal 1p, gain of 1q Rearranged IGH-MAF rearrangement 
Extra copies of 
chromosome 17 2 3 
#210 Deleted Normal Normal     1 1 
#213 Normal Normal Rearranged 
No further material available to 
assess IGH partner genes   0 1 
#146 (2) Normal Normal 1p, gain of 1q Rearranged 
No further material available to 
assess IGH partner genes   1 2 
#215 Normal Normal Normal     0 0 
#216 Normal Normal Normal     0 0 
#218 Normal Normal Normal     0 0 
#219 Normal Normal Normal     0 0 
#220 Normal Normal Normal     0 0 
#217 Normal Loss of 1p & normal 1q Normal     0 1 
#222 Normal Normal Normal     0 0 
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#226 Normal Normal Rearranged IGH-CCND1 rearrangement   0 1 
#225 Normal Normal 1p, gain of 1q Normal     1 1 
#224 Normal Normal Normal     0 0 
#227 Normal Normal Normal     0 0 
#229 Normal Normal Normal     0 0 
#230 Normal Normal Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF    0 1 
#231 Normal Normal Normal     0 0 
#232 Normal Normal 1p, gain of 1q Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF on whole BM only   1 2 
#233 Normal Normal 1p, gain of 1q Normal     1 1 
#235 Normal Normal Normal     0 0 
#234 Normal Normal Normal     0 0 
#236 Normal Normal Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF on whole BM only   0 1 
#237 Normal Normal Normal     0 0 
#238 Normal Normal Normal     0 0 
#239 Normal Normal 1p, gain of 1q Normal     1 1 
#240 Normal Normal Normal     0 0 
#241 Normal Normal Normal     0 0 
#243 Normal Normal Normal     0 0 
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#244 Normal Normal 1p, gain of 1q Normal   
Additional copies of 
1, 14 & 17 1 3 
#61 Normal Normal Rearranged IGH-FGFR3 rearranged   1 1 
#245 Normal Normal Rearranged IGH-FGFR3 rearrangement   1 1 
#247 Normal Normal Normal     0 0 
#248 Normal Normal 1p, gain of 1q Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF on whole BM only   1 2 
#251 Normal Normal Rearranged IGH-CCND1 rearrangement   0 1 
#250 Normal Normal 1p, gain of 1q Rearranged 
No partner detected using FGFR3, 
CCND1 or MAF on whole BM only   1 2 
#253 Normal Normal Rearranged 
No further material available to 
assess IGH partner genes   0 1 
#252 Normal Normal Normal     0 0 
#256 Normal Normal 1p, gain of 1q Normal     1 1 
#260 Normal Normal 1p, gain of 1q Rearranged IGH-FGFR3 rearranged   2 2 
#263 Normal Normal Normal     0 0 
#268 Normal Normal Normal     0 0 
Table 3.5: Details the results seen from the FISH performed on the project cohort. The first three results columns shows the results from FISH step 1; IGH, CDKN2C/CKS1B (1p/1q) and 
TP53.  Column four and five details the results of FISH step 2 if completed, ie information on the IGH partner gene and any other comments on the FISH performed. The final two 
columns record the total number of abnormalities seen, and the number of adverse abnormalities seen based on Boyd et als model. Blue font shows those where the full results aren’t 
available, usually the partner gene information for IGH, and therefore the lowest number of abnormalities are scored. 
TP53 Normal Failed Deleted Gain Relative 
deletion 
Abnormal     Notes 
No. 87 0 7 4 2 1    ‘Abnormal’ case showed loss of the 17 
centromere 
 
IGH Normal Failed Rearranged FGFR3 CCND1 MAF MAFB Other Loss  
No. 66 2 33 6 8 2 1 16 3 ‘Other’ includes those where IGH 
partner not found using standard 3 
probes (3 had no more material, 7 were 
completed on whole BM). Cases of loss 
were not associated with 
rearrangement. 
1p/1q Normal Failed 1q gain 1p del 1q gain 
& 1p del 
Other Not enough 
material 
   
No. 64 0 25 3 4 1 4   ‘Other’ case was both 1p & 1q gain 
(trisomy 1) 
MYC Normal Failed Rearranged        
No. N/A 0 3       Rearranged in three cases, but only 
completed when cytogenetic analysis 
suggested abnormality 
Table 3.6: Demonstrating the abnormalities detected by FISH by category; TP53, IGH, CDKN2C/CKS1B (1p/1q) and MYC. 
 
Of the 101 cases FISHed, 46 patients (45.5%) of patients showed no abnormality with 
this panel of probes, and 55 patients (54.4%) demonstrated abnormality. Based on 
the literature, 60% is the approximate FISH abnormality rate expected utilising the 
probe panel described here. An abnormality rate of 90% has been reported in 
myeloma samples where extended FISH panels are employed42, particularly those 
including hyperdiploidy assessment.  
Fifty-five patients (54.4%) showed one or more abnormalities. Within our cohort, 
27/55 abnormal patients showed a single poor risk abnormality, 6/55 patients 
showed two poor risk abnormalities and 2/55 patients showed three poor risk 
abnormalities according to the Boyd et al prognostic schema112. The presence of this 
set of abnormalities confers an accumulative risk in terms of prognosis. Patients 
harbouring two or three poor risk abnormalities are referred to as ‘double’ or ‘triple 
hit’ myeloma respectively. As an overall cohort, we have the full data to complete 
this assessment on 79 patients, based on this 6.2% and 2.1% of patients could be 
considered double hit and triple hit myeloma respectively112. Currently this 
assessment of prognosis is not used in treatment decision making in the UK, 
although it may be that this becomes increasingly utilised with time and as more 
trials data corroborate these findings. 
Step 1 only was performed on 68/101 (67.3%) cases. Sixty-six cases showed no 
evidence of an IGH rearrangement, and two cases failed to give a result with the IGH 
breakapart probe. Thirty-three (32.7%) cases showed an IGH rearrangement and 
were FISHed according to step 2 to elucidate the partner gene for IGH where 
possible. IGH rearrangements are reportedly seen in approximately 60% (range 55-
70%) of myeloma patients22,33,34. IGH rearrangement is lower in our cohort than the 
expected rate, although this could be explained by our cohort including patients with 
a range of plasma cell neoplasms, not simply myeloma. Of note a similar study by 
Rack et al113, comparing cytogenetics, FISH and array reported IGH rearrangement in 
34% of their cohort very similar to abnormality rate detected here. Of the 33 
rearranged cases, a partner gene was demonstrated in 17 (51.5%) cases, eight cases 
(24.2%) with IGH-CCND1, six cases (18.2%) with IGH-FGFR3 and two cases (6%) with 
IGH-MAF. It should be noted that MAFB is not part of the standard step 2 FISH panel, 
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but was completed following detection of a t(14;20) by cytogenetics and therefore 
IGH-MAFB was detected in a single case. Sixteen cases did not demonstrate an IGH 
partner gene using the probe sets employed. Based on reported data, it would be 
expected that partner genes would be detected in more cases, however, three 
patients had no remaining material to test, and seven cases had step 2 completed on 
the whole bone marrow as insufficient CD138+ cell separated cells were available. 
FISH on whole bone marrow in myeloma has been demonstrated to be a very much 
less sensitive test, and therefore partner gene detection may have failed based on 
the test sensitivity in these cases. The relative levels of each abnormality are 
approximately in line with the expected frequencies with IGH-FGFR3 and IGH-CCND1 
being the most common rearrangements, and IGH-MAF being very much rarer. Loss 
of IGH was seen in 3/101 (3.0%) cases, and these cases were not associated with 
rearrangement of IGH. 
Figure 3.5 shows the probe map for the Abbott Vysis IGH/MAFB probe, (the IGH 
region on chromosome 14 labelled in green in figure 3.5a and the MAFB region on 
chromosome 20 labelled in red in figure 3.5c) used to detect the IGH-MAFB 
rearrangement in patient #113. Figure 3.5b shows the 2F1R1G signal pattern in an 





Figure 3.5: To demonstrate an example of an IGH rearrangement detected by FISH. The schematic 
demonstrates the Vysis IGH/MAFB dual colour dual fusion probe map covering IGH (a) and MAFB (c), and 
shows both an interphase (b) and metaphase (d) cell with the two fusion (yellow arrows), one red, one green 
(2F1R1G) pattern expected in a rearranged case. 
 
 
TP53 deletion was seen in 7/101 (6.9%) cases, fitting well with the level reported in 
the literature of approximately 7-10%22,25,37. Relative deletion of TP53 is seen as a 
2R3G signal pattern and was seen in 2/101 cases (2.0%). Relative deletion describes 
those cases where there is evidence of three copies of chromosome 17 as assessed 
by the centromere probe, with loss of TP53 relative to the baseline of three. This still 
leaves two functional copies of TP53. It is not totally clear from the literature how 
these patients should be classified, i.e. are they TP53 deleted or not? However, it 
seems likely that as two functional copies of TP53 remain, these patients are not 
likely to respond in the same way as TP53 deleted patients. Gain of TP53 was seen in 
four cases (4.0%), and a single case showed an abnormal pattern 2R1G, suggesting 
loss of the 17 centromere, but with two normal copies of TP53. 
The CDKN2C/CKS1B (1p/1q) probe was not completed on four cases where 
insufficient material was available. In this situation, IGH and TP53 FISH were 
prioritised based on the original NICE guidelines which include these two probes as a 






(34.0%) cases demonstrated an abnormality of chromosome 1. Of these 33 cases, 25 
(25.8% of total cases FISHed) showed gain of chromosome 1q, three cases (3.1%) 
showed loss of chromosome 1p, and a further four cases (4.1%) demonstrated both 
gain of 1q and loss of 1p. Gain of 1q is reported to be seen in 40% of myeloma 
patients at diagnosis25. The figures seen in our cohort are lower, again likely to be 
related to the composition of our cohort as previously discussed, however, they do 
proportionally reflect those reported in the literature22. A common manifestation of 
concurrent del1p/dup1q is the isochromosome 1q in which the short arm is lost and 
the long arm is duplicated and mirrored around the centromere. Although we do not 
have definitive evidence that this is the mechanism seen in all four cases in the 
cohort, cytogenetic analysis in one patient has confirmed the presence of an 
isochromosome 1q. A single case showed both gain of both 1p and 1q and this would 
suggest trisomy for chromosome 1. Gain of 1q and loss of 1p have both been 
associated with a poor prognosis55,57, but are not recognised by all myeloma risk 
stratifications114-116. Boyd et al include gain of 1q in their prognostic schema and 
based on this we have included CKS1B (1q) in the FISH panel. 
Figure 3.6 shows examples of CDKN2C/CKS1B and TP53 probe signals seen in the 
patient cohort. The first three images (a-c) show the CDKN2C/CKS1B 
1p(green)/1q(red) probe; image a shows gain of 1q, image b shows loss of 1p, and 
image c shows concurrent loss and gain. Images d-f show the 
TP53(red)/17centromere(green) probe; image d shows a normal pattern of two of 
each signal, image e shows loss of TP53 and image f shows loss of TP53, but on a 





Figure 3.6: To demonstrate examples of probe signals seen in the patient cohort. Images a, b & c show the 
CDKN2C (1p in green) and CKS1B (1q in red). Image a shows gain of 1q (CKS1B) 3R2G, image b shows loss of 1p 
(CDKN2C) 2R1G and image c shows concurrent loss of 1p and gain of 1q 3R1G. Images d, e & f shown the TP53 
(red) and 17 centromere (green) probe. Image d shows a normal pattern with 2R2G, e shows a deletion of TP53 
1R2G and image f shows a relative deletion of TP53, loss of a red signal against a background of three copies of 
17 centromere, 2R3G. 
 
Finally, three cases were FISHed with a MYC breakapart probe; all of these showed 
rearrangement. This FISH test was only undertaken when the karyotype analysis was 
abnormal, and where chromosome 8 demonstrated abnormality in the region of 
MYC at 8q24. MYC translocations are seen in approximately 15% of patients with 
myeloma at presentation25,47,48 and up to 45% of patients with advanced disease 
25,26. These translocations are not thought to be initiating events, but late events 
associated with increased proliferation and stromal independent plasma cells25. 
Recent studies have demonstrated that MYC is able to recruit active super-
enhancers from highly expressed genes associated with B cell, plasma cell or 
myeloma development49. The current literature suggests that MYC rearrangement is 
highly prognostic49, this may simply be related to the association with advanced 







Of the 55 cases with FISH abnormalities, 44 (80.0%) were successfully karyotyped.  
Seven patients (12.7%) were not processed for cytogenetic analysis, four patients 
(7.3%) failed their cytogenetic analysis. Of those karyotyped, 11 patients (20.0%) also 
demonstrated abnormal cytogenetics, and 33 samples (60.0%) were cytogenetically 
normal. This provides confirmation that normal non-neoplastic populations had been 
karyotyped in these cases, in turn providing further evidence that karyotyping 
myeloma patients is not a good analytical tool in the vast majority (approaching 80% 
in our cohort) of cases. 
Conversely, of the 19 patients with a karyotypic abnormality, eight patients did not 
demonstrate abnormality with this FISH panel. Three of the cases showed missing 
sex chromosomes (two with missing Y and one with missing X), and the remaining 
five cases would be considered hyperdiploid. Even though one case demonstrated 
complex abnormalities alongside the hyperdiploidy, the abnormalities would not 
have been detected on the FISH panel employed here. This highlights the limitations 
of the current FISH panel and demonstrates the need to extend this panel, either 
with additional probes or with additional techniques to increase the detection rate 
further. Hyperdiploidy can be confidently assessed using a 3-chromosome 
combination of FISH probes (chromosomes 5, 9, 15). The presence of two of the 
three chromosomes is a highly specific indicator of hyperdiploidy117. Of note 
hyperdiploidy would also be detected on an MLPA or array analysis. Within this 
particular cohort, none of these five patients had MLPA or array analysis and 
therefore we have not been able to confirm hyperdiploidy in these cases using these 
alternative technologies. 
Myeloma genetics can be extremely complex and non-standard rearrangements can 
be seen along with loss and gain. This complexity is also represented in the FISH 
probes which can generate non-standard signal patterns, and reflects a strong need 
to ensure robust training of personnel involved in this analysis to ensure that non-




Multiplex Ligation-dependant Probe Amplification (MLPA) 
Forty-five cases were processed for MLPA using the DNA extracted from the 
CD138+ve plasma cell fraction. Data were transferred from GeneMapper to the 
Coffalyser analytical software supplied by MRC Holland. Coffalyser involves a series 
of steps to assess the QC of the controls and samples to ensure robustness of data. 
For each run the control samples require assessment, and any controls showing 
deletion or gain should be removed from the comparative analysis and a minimum 
of four controls should be taken forward to the final analysis. For each sample, the 
DNA Denaturation (DD) fragments and the four quality fragments (Q-fragments) 
require assessment before the individual samples can be deemed of sufficient 
quality for analysis. The DD fragments at 88 and 96 nucleotide (nt) length, detect 
fragments in exceptionally high GC regions, these regions can be difficult to denature 
and when these fragments appear low it indicates incomplete denaturation which in 
turn can result in false positive deletions.  The Q-fragments at 64, 70, 76 and 82 nt in 
length are complete fragments which do not require ligation in order to be amplified 
during the PCR step, high level Q-fragments indicate poor quality or low quantity 
DNA. These quality parameters are assessed as part of the FMRS (Fragment MLPA 
Reaction Score) bars in the software, and only these with ≥2 bars should be 
processed. Those with 0 or 1 bar should be considered a failed sample. Other 
samples which pass this initial QC step, can still fail on the analysis, some samples 
show such wide standard deviation bars that it cannot be considered robust enough 
data to report on, so a further set of samples fail at the final processing and analysis 
point. 
The ‘comparative analysis’ step involves a complex algorithm which assesses the 
relative size of the fluorescent peaks within each sample and compares and 
normalises them against the reference samples and the other samples within the 
run. The results were expressed as ratios (also known as dosage quotients) for the 
likelihood of a probe being either deleted or duplicated. A score of 1.0 represents 
two copies of a probe and was considered normal, scores of 0.5 (0.35-0.65) and 1.5 
(1.35-1.65) represent deletion and duplication of a probe respectively, and scores of 
0 (<0.15) and 2 (>1.85) denote no copies or four or more copies respectively. The 
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Coffalyser software demonstrates the data in a number of ways; the data are 
presented as a table with each probe alongside the height, area, ratio and standard 
deviation figures. The ratios are highlighted in blue (gain) or red (loss) when an 
abnormal ratio is detected. These results are also available as electropherograms 
detailing the peak heights for each probe. The DD- and Q-fragments can also be 
assessed (left hand side of this figure). Finally, the results are also represented 
graphically with a ratio of one used as the normalised line with standard deviation 
bars, regions of gain appear as blue data points above the standard deviation line 
and regions of loss are seen as red data points below the standard deviation line. 
These ratio graphs demonstrate the losses and gains pictorially making the 
assessment relatively simple at this level. Examples of both the electropherogram 
and the ratio graphs are shown in figure 3.7 and 3.8 respectively, for patient #238 
with a normal MLPA result, but for further results the ratio graphs will be shown. 
 




Figure 3.8: To show the ratio graphs produced as part of the MLPA analysis by the Coffalyser software. 
  
Of the 45 cases processed for MLPA analysis, 16 cases (35.6%) failed to give a result. 
This is a high level of failure. In part, this may be due to poor quality DNA or lack of 
experience in using this technique, however, the MLPA process can be highly 
sensitive to contaminants in the system that can affect the PCR, more so than 
standard PCR. Following discussions with a laboratory that use this technique 
routinely for myeloma analysis, they too report similar levels of failure and indeed 
now set strict thresholds for processing lower quality samples. MLPA is still 
considered a useful and accurate test on samples with high quality DNA, but routine 
practice includes an option to FISH samples considered too poor for MLPA. 
If MLPA were to be included as part of a diagnostic testing strategy, then 
contingency testing would have to be considered for failed samples. This is likely to 
be additional FISH hybridisations for the regions considered prognostic (i.e. TP53, 
1p/1q, and possibly the three chromosomes associated with hyperdiploidy 
assessment). This adds further steps to a testing strategy and increases the expense. 
Of the remaining 29 cases, 27 cases (93.1%) showed abnormal results (see table 3.7). 
The table details those cases with successful MLPA analysis, with results described 
for each individual chromosomal region, a final comments column has been used to 
ascribe hyperdiploidy status or NAD (no abnormality detected). Of the successful 29 
cases, 27 cases (93.1%) were shown to have an abnormal result. This is a very high 
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abnormality rate. Of note, MLPA has been incorporated into the genetic analysis of 
myeloma in a number of current UK myeloma trials. 
The most common change detected by MLPA in our cohort was loss of chromosome 
13 seen in 15/27 cases (55.6%). Gain of regions of chromosome 1q were seen in 12 
cases (44.4%), and loss of regions of chromosome 1p were seen in eight cases 
(29.6%). Only two patients (7.4%) showed loss of TP53 on the short arm of 
chromosome 17. Nine of the abnormal cases (33.3%) show hyperdiploidy as 
determined by the presence of two of the three chromosomes highly associated 





No: 1p 1q 5 9 12 13 14 15 16 17 Comments 
#188 DAB1 Gain Gain          
#196  
CKS1B & 
RP11 Gain  
COL5A
1 Gain        
#197      Loss  
IGF1R 
Gain    
#205          
Low level 
loss  
#222   Gain Gain    Gain   Hyperdiploid 












FAM46C Loss     
Low 
level 




FAM46C Loss   
COL5A
1 Gain  Loss      
#247   
Low level 
gain     Gain   Hyperdiploid 
#248  Gain    Loss   
CYLD 
Loss   
#251      Loss Loss     
#113 Loss Gain    Loss      
#140           NAD 
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#144     Loss Loss   Loss   
#106   Gain Gain    Gain Loss  Hyperdiploid 
#51   Gain Gain  Loss  Gain 
WWOX 
Loss  Hyperdiploid 
#141         Loss   
#142   
PCDHB2 
Loss         
#147 FAM46C Loss   
JAK2 
Gain    Gain   Hyperdiploid 
#134  Gain    Loss      
#146  Gain Loss   Loss      
#165 
DPYD & 
FAM46C Loss Gain    Loss      
#168  Gain Gain Gain    Gain   Hyperdiploid 
#170  Gain  Gain  Loss   
WWOX 
Gain   
#175 FAM46C Gain Gain Gain Gain    Gain   Hyperdiploid 
#178 Loss Gain   Loss Loss   Loss Loss  
#203 
DPYD & 
FAM46C Loss  Gain Gain  
DIS3 
Loss  Gain   Hyperdiploid 




1 Gain  Loss      
 
Table 3.7: Detailing the results seen in the cohort of patients who had successful MLPA analysis. The results are presented by the chromosomal regions in which the 46 MLPA probes lie. 
Where gain or loss is recorded, this includes all probes within the chromosomal region, where specific probes are recorded smaller regions of loss or gain are involved. The final column 
records hyperdiploidy where two or more of the chromosomal gains associated with hyperdiploidy are present and NAD (no abnormality detected) where appropriate. 
Of the 27 abnormal cases using MLPA, 14 cases were shown to be normal using the 
described FISH panel. This demonstrates that MLPA is able to offer additional 
information in some circumstances. Six of the 14 cases were shown to be 
hyperdiploid by MLPA and the current FISH panel design would not detect this. The 
remaining eight cases demonstrated abnormalities such as loss of chromosomes 12, 
13, 14 and 16 not present on the FISH panel. Of these eight, there were four cases of 
1p loss. The FISH panel includes a probe for 1p (CDKN2C), however all four cases 
demonstrated a partial loss not covered by this specific FISH probe.  
Of the two cases shown to be normal by MLPA, one was also normal by both 
cytogenetics and FISH, and did not have array or NGS analysis. The second case was 
shown to have an IGH-CCND1 rearrangement by FISH. This highlights the potential of 
using a combinatorial testing strategy of MLPA and FISH as the testing regimes offer 
strengths in assessing different abnormality types associated with myeloma. 
In the 29 cases where copy number was assessed by both FISH and MLPA, (ie. 
deletion and duplication of chromosome 1p/1q and deletion of chromosome 17), 
data were checked for concordance. There were no cases of discordance for the 
1p/1q except in those cases described above where the FISH probes employed did 
not cover the region of loss. However, chromosome 17 demonstrated considerable 
discordance. There were five discordant cases within the cohort of 29 (17.2%). The 
first case showed what was considered a possible low-level loss of TP53 by MLPA, 
however, this was not confirmed by FISH. The remaining four cases were normal by 
MLPA, but abnormal by FISH. Two of these cases demonstrated deletion by FISH at 
8% and 15%, the level of resolution for MLPA is considered to be around 15-25%119. 
Low level abnormal populations, therefore, can be problematic for MLPA, and in the 
case of multiple myeloma, plasma cell purification to a minimum level of 50% 
purification would be a prerequisite. All samples within our cohort were completed 
on DNA extracted from CD138+ve selected cells, and showed plasma cell purification 
levels exceeding 50% in each case. Even with this quality assessment in place, a small 
number of cases demonstrated low level abnormality. Small abnormal populations 
are widely seen and reported in myeloma patients, and the issue of mosaicism will 
always be a consideration in the genomic analysis of these patients. 
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The third case showed relative deletion of TP53, two copies of TP53 against a 
background level of three copies of chromosome 17. The MLPA panel only assesses 
TP53 so would not detect a change here, two being the normal and expected copy 
number for TP53. Relative deletion of TP53 is a rare, but recurrent finding in 
myeloma. It will not be detected by all techniques and consequently has not been 
consistently assessed in trials or defined as part of the poor prognostic group. The 
final case demonstrated gain of chromosome 17 in 72% by FISH, it would be 
expected that MLPA would detect this abnormality. Considering the design and 
resolution of both FISH probes and the MLPA panel, this final case is the only true 
discordant case giving a discordance rate of 1/29 (3.4%) in our cohort.  
A technological understanding of the MLPA technique is a prerequisite for those staff 
analysing the results of MLPA, however, the analytical software (Coffalyser) supplied 
by MRC Holland is straightforward to manage and use.  
By way of example, the ratio graphs are shown for three cases in figures 3.9, 3.10 
and 3.11, these demonstrate the ease with which the results can be interpreted 
once the analytical process has been completed and the ratio graphs are 
represented pictorially. Each probe is labelled with a number on the X axis, which is 
prefixed with the chromosome number. Above the graph the probes are labelled 
with the gene name, the exon number and the nucleotide length. The ratio for each 
probe in the myeloma MLPA probe set is represented by a circle with corresponding 
standard deviation bars. The rectangles show the same for the full run result, and 
are coloured blue for the 46 myeloma probes of interest, and green for the 11 
control probes. The ratios represent loss and gain as described previously, and the 
ratio circles are coloured blue for gain and red for loss.  
Figure 3.9 shows the MLPA result for patient #140. This patient shows a normal 
result for all probes within the MLPA set with all ratios at approximately 1.0, and 
most within the range bars set as acceptable standard deviation. 
Figure 3.10 shows the MLPA result for patient #106. This patient has hyperdiploidy 
with gains of chromosomes 5, 9 and 15. The ratios for the probes on chromosomes 5 
and 15 are at approximately 1.3-1.4 and suggest one additional copy of each 
chromosome. The ratios for the probes on chromosome 9 are approximately 1.7-1.8 
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suggestive of two additional copies, i.e. four copies of chromosome 9. This was 
confirmed by the cytogenetic analysis for this patient. There is also loss of the probes 
associated with chromosome 16.  
As the final example, figure 3.11 shows the MLPA result for patient #248.  This shows 
gain of the probes associated with the long arm of chromosome 1, loss of the probes 
on chromosome 13, and loss of the CYLD markers on chromosome 16. There is also 
evidence of loss of three probes within the control set. The control probes have been 
selected from ‘quiet’ areas of the myeloma genome, however given the highly 
complex nature of myeloma genomics, it would not be possible to select areas that 
are never involved in change. Involvement of the control probes is a phenomenon 
seen in a number of our samples. Whilst the results are clear from the histogram, 
abnormalities in the control probes disturb the internal algorithms and can cause 
interpretative problems. The Coffalyser software has been designed to manage this 
scenario, but of note this probe set is much more ‘messy’ than the MLPA CLL probe 
set as an example, where the data are clean with little deviation from the expected 
ratio and this is partly attributed to the less complex nature of CLL genetics and the 







Figure 3.9: To show the MLPA results for patient #140 who has a normal MLPA profile.  
 
 




Figure 3.11 : To show the MLPA results for patient #248, the result shows gain of the probes associated with the long arm of chromosome 1, loss of probes on chromosome 13 
and loss of the CYLD markers on chromosome 16. There is also evidence of loss of three probes within the control set. 
Affymetrix CytoScan HD DNA Array 
Many types of DNA array exist, but for the purposes of this project we have 
employed the Affymetrix CytoScan HD Array. Affymetrix arrays compare the DNA of 
interest to an internal normal reference set.  This allows interrogation of the entire 
genome for copy number change, using more than 2.6 million markers for copy-
number analysis and approximately 750,000 SNPs. The higher probe density areas 
include 533 cancer genes, 100% of which are covered with 25 markers per 100kb 
region. The array has the ability to detect loss of heterozygosity (LOH) and regions of 
acquired uniparental disomy (aUPD). Although SNP incorporation allows for 
extended analysis (of LOH), DNA array technology remains predominantly a method 
for detecting copy number changes. The nature of these arrays means the quantity 
of information created is huge and the extent of analysis required is also great. 
Array analysis is not designed to detect balanced rearrangements or translocations, 
or mutations at a base pair level.  However, in the context of myeloma, a number of 
translocations are seen in an unbalanced form which would be detected. It is also 
recognised, in other leukaemia types as well as myeloma, that small regions of copy 
number change can be generated at and around rearrangement breakpoints120, 
detailed analysis of these regions can alert to the presence of rearrangements 
involving those genes. It should be noted that although array analysis may provide 
this information in a number of cases, this is not definitive evidence and should not 
be considered to exclude a rearrangement and indeed would require confirmation 
with an alternative technique in order to clinically report the finding. 
DNA from 36 myeloma patients were processed using the Affymetrix CytoScan HD 
Array, DNA from CD138+ve cell selections was used in the assessment which allows 
targeting of tumour DNA. 
Of this cohort, five samples failed to give a result. These failures were absolute and 
demonstrated large regions of the array with no image consistent with the probes 
simply not being present. The damage was integral and internal to the array 
cartridge, and therefore not considered to be damage that could have occurred 
during the processing, but more likely to be a result of damage at the time of 
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production. The company were contacted and informed, and confirmed that the 
error was in array manufacture. 
Of the remaining 31 samples in which analysis was possible, the array quality was 
measured using MAPD (Median of the Absolute values of all Pairwise Differences). 
MAPD is a per-microarray estimate of the variability. It measures the variability in 
the log2 ratios by looking at the paired difference of all of the probes and taking 
median values, this can be considered a standard deviation measure. Cases were 
required to have a MAPD value of ≤0.25 to be considered good quality. Of the 31 
cases, 23 cases (74.2%) met this QC score, whilst eight of the 31 cases (25.8%) 
samples had MAPD figures above this cut-off value. Five of these eight cases were 
marked as borderline quality (see table 3.8), and the analysis was considered 
acceptable. Three of these eight cases were considered poor quality, of these, one 
case was suggestive of hyperdiploidy, one showed no clear abnormalities, and the 
third showed some abnormalities, however, these findings should not be considered 
reliable in this context, and indeed the third case was not consistent with the FISH 
findings.  
Analysis is undertaken using Chas software supplied from Affymetrix. The software is 
excellent but requires extensive training. The data sets from the arrays are huge and 
the analysis is time consuming and therefore, expensive. Whilst options are included 
in the software for reporting the data, it remains problematical to ensure that a full 
and comprehensive analysis has been undertaken, but within the confines of 
reporting relevant information to the clinician which will inform patient 
management. Much of the data and information gained from this analysis would not 
inform clinical management. 
Of the 28 cases with an acceptable MAPD QC score, 24 (85.7%) cases showed an 
abnormal result, and four (14.3%) patients showed a no abnormality detected (NAD) 
result. This is a high abnormality rate, but not quite as high as that seen with the 
MLPA analysis. Given the MLPA analysis is panel based, (i.e. only assessing a small 
number of regions), genome-wide array analysis might have been expected to have 
the highest abnormality rate, although this technique also does not have the ability 
to detect balanced IGH rearrangements. This may be related to the specific cohort of 
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patients, but may also be related to the presence of low level disease. Array analysis 
assesses pooled DNA, and although the DNA was extracted from CD138+ve cell 
selections, it is thought that abnormalities present at 30% or less may not be 
detected using array analysis113. Myeloma is known to heterogeneous, and even with 
selected cell populations, some abnormalities may still be present at a low level and 
therefore will be missed using this type of analysis. 
The array results are presented in Table 3.8. Of the 24 abnormal results, 16 patients 
(57.1% of the total analysed) showed a pattern consistent with hyperdiploidy, 
slightly higher than the expected reported figures. 
The remaining eight cases (28.6% of the total cases analysed) showed losses, gains 
and LOH regions, but not associated with hyperdiploidy. Gain of 1q was seen in 
seven (25.0%) cases, loss of 1p was seen in five (17.9%) cases, loss of chromosome 
13 was seen in 11 (39.3%) and loss of chromosome 17 was detected in a single case 










Comment Affymetrix CytoScan HD Array Result 
#51 (2) 0.171 Good Hyperdiploid, with loss of 13, 16q & 20q 
#113 0.294 Borderline Gain of 1q, loss of 1p, 2q, 3p, 13, LOH of 16 
#119 0.219 Good Hyperdiploid, gain of 1q and 2p, loss of 13 and X 
#134 0.168 Good Gain of 1q, 8q, 3p, loss of 2q, 6q 12q & 13 
#138 (2) 0.192 Good Hyperdiploid, with loss of 6q 
#144 0.169 Good Gains of 15q, 18 and 19. Loss of 1p, 4, 8, 10p, 12, 13, 14, 15, 16, 17, 20, 21 & 22,  
#146 0.185 Good Gain of 1q, loss of 6q, 12q, 13, 
#147 0.181 Good Hyperdiploid, with loss of 1p, 8p, 2q, 6q 
#151 0.210 Good  Hyperdiploid, with loss of regions on 8p, 13, 20p & 21 
#157 0.247 Good Gain of 18 
#158 0.525 Poor 
Failed, but suggestive of loss of 1p & gain of 1q (not consistent with FISH), gain of 19q & 20q, loss of 13, 
14 & 20p. 
#159 0.647 Poor Failed, no clear abnormalities 
#171 0.259 Borderline Hyperdiploid with 1q gain 
#179 0.247 Good Hyperdiploid 
#184 0.261 Borderline Loss of chromosome 13 & 14 
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#190 0.274 Borderline NAD 
#201 0.215 Good Gain of 11p, and loss of chromosome 8, 13, 14. 
#202 0.216 Good NAD 
#203 0.199 Good Hyperdiploid 
#204 0.220 Good Hyperdiploid with 1q gain, and 8p loss 
#207 0.222 Good Hyperdiploid with some double gains, loss of 8p, and LOH for chromosome 1 
#209 0.227 Good Hyperdiploid with loss of 8p 
#208 0.251 Borderline Gain of 1q 
#216 0.242 Good NAD 
#222 0.240 Good Hyperdiploid, LOH 16q 
#226 0.239 Good Hyperdiploid, with gain of 1q & X, & loss of 1p, 6q, 13. 
#224 0.171 Good Hyperdiploid 
#230 0.200 Good Hyperdiploid, loss and gain of chromosome 6 and LOH of chromosome 12 
#232 0.242 Good NAD 
#233 0.235 Good Hyperdiploid, with gain of 1q, and loss of 1p and 16q 
#234 0.480 Poor Failed, but suggestive of hyperdiploidy 
Table 3.8: Table to show result of the array analysis excluding those five cases considered an outright fail. 
The abnormalities detected by array analysis were not entirely concordant with the 
cytogenetic, FISH and MLPA results. Of the 28 cases processed for array and 
considered to have either good or borderline quality parameters, 19 (67.9%) cases 
demonstrated total concordance with the other genomics tests performed. There 
were nine (32.1%) cases, however, that demonstrated some discordance. Of these 
nine cases, five cases showed abnormalities by FISH that were seen in <30% of cells. 
As discussed, these low-level clones will not be detected by the DNA array. The 
remaining four included a relative deletion of chromosome 17, a 1p gain seen in 40% 
of cells by FISH, gains of chromosome 1 and 17 seen in 60% of cells by FISH, and 
finally a deletion of 17p seen in 58% of cells by FISH. DNA microarrays are designed 
to offer a dramatically better resolution than karyotyping and indeed FISH, and it 
would be expected that the array would detect this level of clone size. However, 
based on experience within a diagnostic laboratory using arrays alongside other 
techniques, the concordance is not always perfect. This view is also reported by Rack 
et al 113, who state ‘we also observed some discordance relating to array sensitivity 
and to accurate assignment of ploidy group’. They reported that arrays fail to detect 
aberrations at low level, but specifically below 20% clonality113. 
The information is presented in multiple ways for array analysis but perhaps the 
simplest pictorial representation is the karyoview. This shows the chromosome 
karyogram with regions of gain marked in blue and regions of loss marked in red. 
Regions of LOH are represented in purple. More detailed analysis is possible by 
chromosome which gives further information on the B-alleles, copy number and the 
smoothed logR ratio. These images can be further enhanced to assess specific 
regions when required. 
Figure 3.12, 3.13 and 3.14 show images from three of the array cases. The first case 
(patient #202) demonstrates a normal array.  The second case (patient #138) shows 
a hyperdiploid karyotype with classic gains of whole chromosomes 3, 5, 7, 9 (two 
additional copies), 11, 15, 19 and 21 and loss of a region on the telomeric long arm 
of chromosome 6. The final example (patient #146) shows a gain of 1q, and loss of 
regions of 6q, 12q and 13, and a likely smaller region of loss on 5q. Expanded images 
of chromosome 11 have shown a 515kb region of gain at the site of CCND1. FISH 
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confirmed an IGH-CCND1 rearrangement, and this pattern of gain (and/or loss) of 
regions around the breakpoints has been previously demonstrated by array in a 
number of ‘balanced’ cancer related translocations120. 
These traces are not entirely clean which may reflect poor quality DNA in some cases 
and DNA arrays are known to be sensitive to DNA quality.  The project demonstrates 
optimistic results relating to the utility of this technique and the higher level of 
resolution, they also show that further work would be required in this area to 
optimise the quality of the output and to fully utilise the Chas software to analyse 




Figure 3.12: Demonstrates the array result for patient #202 showing a normal karyoview image with no clear 








Figure 3.13: Demonstrates the array result for patient #138. The karyoview (a) demonstrates gain of 
chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 as shown by the blue bars, and loss of the terminal region of the long 
arm of chromosome 6. Chromosome 9 has a darker blue bar suggesting an increase in copy number. The 
second two images (b & c) show a chromosome view of chromosome 3 and 9 in order to compare the B- alleles 
bars (second set of green bars); this confirms the presence of three copies of chromosome 3 and four copies of 
chromosome 9. The final image (d) in this set shows an enhanced view of chromosome 6 showing the copy 
number (top green bar) and B-allele bars (second set of green bars). This indicates the presence of two 
chromosome 6’s up to 6q22, when the pattern changes to show a single copy and a telomeric deletion 






Figure 3.14: Demonstrates the array result for patient #146. The karyoview image (a) shows a gain of 1q 
(represented by a blue bar), and loss of regions of 6q, 12q and 13, and a likely smaller region of loss on 5q 
(represented by a red bar).  The second image (b) within this group shows a chromosomal view of 
chromosome 1 depicting the gain of the long arm as shown by the copy number bar (top blue bar) and the B-
alleles (second set of blue bars). Images c & d show chromosome 11; c shows the whole chromosome with a 
tiny blue bar (at the top of the image) at the region of CCND1, and d shows an expanded version of this 
demonstrating a 515kb gain. This patient was shown to have an IGH-CCND1 rearrangement using FISH probes, 
some patients are reported to have both losses and gains around the region of the translocation break as 





Targeted Next Generation Sequencing (NGS) Gene Panel 
NGS technology has superseded Sanger sequencing for all but small target regions 
within the research arena, and indeed implementation of NGS technology into 
diagnostic laboratories is moving forward at a pace. There remain issues and 
concerns when transitioning this technology to the diagnostic arena with the 
expense, the magnitude of data, the time-consuming analysis and interpretation, the 
minimal analytical tools, and the issues of consent and ethics. 
There are number of ways of applying NGS technology in a more manageable way, 
from technological, analytical and financial points of view. Instead of working with 
whole genome sequencing (WGS) or whole exome sequencing (WES), NGS panels 
offer a chance to harness the accuracy and depth of NGS analysis in a more targeted 
fashion. They require selection of a set of genes to create a panel design. Analysis is 
clearly limited to the set of genes that are involved in the panel, and this analysis 
strategy loses the functionality of novel gene discovery.  
The targeted NGS Myeloma Gene Panel was designed as a single panel of 139 genes. 
However, this was essentially made up of two panels; the SMaRT NGS Myeloma 
Gene Mutation Panel which included 79 genes known to be involved in 
myelomagenesis, and the SMaRT NGS Osteome Probe Panel which had 60 bone 
related genes known to be involved in the development, influence, maintenance and 
destruction of bone. The results presented in this chapter will describe the 
performance of the NGS panel as a whole, but will discuss only those results 
associated with variants / mutations in the first part of the panel, those genes known 
to be involved in the pathogenesis of myeloma. The assessment of the osteome has 
been designed as an innovative aspect of the project to explore and assess possible 
or potential relationships between the genetic signatures associated with bone 
related genes, the ‘osteome’, and the likelihood or extent of bone damage 
associated with the patient’s myeloma disease. This covers objective two of this 
project and will be described and discussed in Chapter 4. 
DNA from 24 patients with myeloma or MGUS were processed using the bespoke 
targeted NGS myeloma gene panel. The samples were processed as pairs; DNA from 
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the CD138+ve plasma cell selections representing the tumour (myeloma) DNA, and 
DNA from blood samples from the same patients representing their constitutional 
(germline) DNA. Of the 24 patients processed, one sample (4.2%), patient #234, 
failed to give a result. However, 23/24 samples have given successful sequencing and 
therefore a success rate of 95.8% has been achieved for this bespoke myeloma NGS 
panel. 
Of the 24 cases processed, the raw DNA sequence data taken from the Illumina 
HiSeq were analysed using the analysis pipeline described in chapter 2 - materials 
and methods NGS section. This pipeline conforms to the Broad Institute best practice 
guidance with some additional customised data filtering and QC check steps. The 
pipeline aligns reads to the hg19 (GRCh37) build human genome using Burrows-
Wheeler Alignment (BWA). Variants were called using the Genome Analysis Toolkit 
(GATK) software and were then analysed using a variety of bioinformatics tools; 
mutect2, vardict and strelka to assess the likelihood of associated pathogenicity. A 
consensus set based on calls from all three tools was created based on the most 
popular call. This produced a list of variants with further annotation including ClinVar 
and ExAC allele frequencies, and information as to whether the gene was on either 
the Myeloma or Osteome gene panel for each patient in the cohort.   
Figure 3.15 shows the number of paired and mapped reads for each of the patient 
samples. The first graph within the figure demonstrates the blood (germline) 
samples, which show a very consistent level of mapped and paired reads across each 
patient. An exception to this is patient #234 whose sample has failed the NGS 
process and does not have any mapped or paired reads. The second graph within the 
figure covers the CD138+ve (tumour) samples, these levels are very much more 
erratic likely to be associated with the variable quality of the DNA and disease stage 
but show a general increase in the number of mapped and paired reads compared to 
those in the blood samples.  
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Figure 3.15: Demonstrates the number of paired and mapped reads for both blood (germline) and CD138+ve 
(tumour) samples for each of the 24 patients. 
 
Duplicate reads arise following PCR of the same DNA molecule and are often defined 
as reads with an identical start and stop point. However, reads with identical start 
and stop points can arise from independent DNA molecules so this rule cannot 
identify true duplicates in all cases. In order to overcome problems associated with 
duplicate reads it is possible to introduce unique molecular identifiers (UMIs) to 
essentially barcode specific reads. This allows a separation of technical duplicates 
based on PCR from the same molecule, from true biological duplicates.  
A proportion of our samples were prepared using UMIs, this included all of the bone 
marrow (tumour) samples and five of the blood (germline) samples. Samples 
prepared with UMIs allow the technical duplicates to be removed using 
bioinformatic methods leaving only the true biological duplicates. Figure 3.16 and 
3.17 shows the number of duplicates and then duplicates as a percentage of the 
total reads. These graphs were created following the bioinformatic removal of the 
technical duplicates using the UMI information, and therefore show no duplicates. 
There is a high level of duplicate reads in the blood (germline) samples, with most 
samples showing between 30-45% duplicated reads.  
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Figure 3.16: Demonstrating the number of duplicate reads per sample. A number of samples were prepared 
using UMIs and these samples show no duplication. 
 
Figure 3.17: Demonstrates the number of duplicate reads expressed as a percentage of the overall reads. The 
samples prepared using UMIs show no evidence of duplicated reads. 
 
Figure 3.18 shows a graph of the bone marrow samples and the five blood samples 
before the UMI data were utilised to remove the technical duplicates, allowing the 
original duplication rate to be seen. 
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Figure 3.18: To show the original level of duplication seen in those samples processed using UMIs. This includes 
all of the CD138+ve tumour samples and the few blood (germline) samples also processed with UMIs.  
 
Figure 3.19 shows a graph of the percentage of bases off target. This gives an 
indication of the number of bases sequenced that are not within the target regions 
described within the designed NGS panel. These values show low levels of off target 
sequencing (<1% for all cases). Although there is a level of sequencing outside of the 
targeted regions of the panels which can be considered wasted sequencing data, this 
is low and does not affect the coverage seen for the targeted regions of this panel. 
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Figure 3.19: Demonstrating the levels of ‘off target’ sequencing for both blood (germline) samples and the 
CD138+ve bone marrow (tumour) samples. 
 
The term ‘coverage’ is defined as the number of times a particular base in the 
reference genome is sequenced. The mean coverage was calculated using reads with 
a mapping quality of ≥30, bases with a quality of ≥30, and overlapping regions of the 
mate pairs were excluded. These figures relate to the Phred scores, which are a 
linear representation of the probability of a base being called incorrectly. A Phred 
score of 30 represents 99.9% accuracy (i.e. 1 in 1000 chance that a base call is 
incorrect). Figure 3.20 shows the mean coverage for each sample, both for the blood 
(germline) samples and for the CD138+ve (tumour) samples. When designing the 
experiment, coverage was considered and a higher proportion of the sequencing run 
was dedicated to the CD138+ve cell selection (tumour) DNA samples to facilitate the 
higher coverage we intended for the tumour samples aiming for a mean coverage 
level of 30x for the blood (germline) samples and 500x for the CD138+ve (tumour) 
samples. A level of 100x coverage is marked on the graph for reference.  
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Figure 3.20: Demonstrates the mean coverage for each sample for both the germline (blood) and tumour 
(CD138+). Coverage is defined as the number of times a particular base in the reference genome is sequenced. 
The red line indicates 100x coverage. 
 
The graph shows that coverage levels for the blood (germline) samples exceeded the 
100x reference and well over the 30x coverage aimed for. The mean coverage levels 
for the CD138+ve (tumour) samples were all above 350x coverage, the majority 
(16/24) were above the 500x mean coverage aimed for with a number of samples 
dramatically above this level. The germline graph confirms the failure of sample 
#234, which shows zero coverage. Although this sample has failed the NGS 
sequencing, 23 of 24 samples have shown successful sequencing, resulting in a 95.8% 
success rate for this bespoke myeloma NGS panel. 
Gaps in coverage are defined as bases which have <30x coverage, this again was 
calculated using reads with a mapping quality of ≥30 and bases with a quality of ≥30. 
Figure 3.21 demonstrates three samples with substantial gaps in coverage. Sample 
#234 is the sample that failed the NGS panel and has 100% gaps in sequencing. The 
other two samples #162 and #44 have shown 42.8% and 12.8% gaps in sequencing 
respectively, and the sequencing results from these samples require interpretation 
with caution.  
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Figure 3.21: Demonstrating the percentage of gaps in sequencing seen across both germline and tumour 
samples. Sample #245 failed sequencing and showed 100% gaps in sequence. Samples #162 and #44 have 
shown 42.8% and 12.8% gaps in sequencing respectively. 
 
The failed sample has skewed the scale in figure 3.21, therefore the following figure 
3.22 shows the same information, but with the scale zoomed to demonstrate the 
gaps in sequencing percentage for the remaining samples. All remaining samples 
show <2.5% gaps in sequencing with the vast majority of samples showing <1% gaps 
in sequencing. Overall, the gaps in coverage are lower in the tumour (CD138+ve) 
samples explained in part by the mean coverage, which is higher in the tumour 
samples.  
Gaps in Sequencing (Coverage <30x)
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Figure 3.22: Demonstrating expansion of the lower end of the previous graph to show the levels of gaps in 
sequencing seen in the remaining samples (too small to see on previous graphs scale). All remaining samples 
show <2.5% gaps in sequencing with the vast majority of samples showing <1% gaps in sequencing. 
 
 
The quality of the NGS data can be measured in a number of ways, and we have 
assessed the number of paired and mapped reads, the coverage and the gaps in 
coverage. Paired and mapped reads for each of the patient samples demonstrate a 
very consistent level across each patient in the blood (germline) samples, except for 
patient #234, which shows no evidence of paired or mapped reads. The number of 
paired and mapped reads within the CD138+ve (tumour) samples, are very much 
more erratic, and this is likely to be associated with the variable quality and quantity 
of the patient DNA and disease stage. However, in general there is an increase in the 
number of mapped and paired reads associated with the tumour samples compared 
to the germline samples. Dedicating a higher proportion of the sequencing capacity 
to the CD138+ve cell selection (tumour) DNA samples has facilitated the higher 
coverage we intended for the tumour samples, which in turn has produced an 
increase in the number of paired and mapped reads and the coverage, and a lower 
level in the gaps in coverage in the tumour samples. These quality assessments give a 
degree of confidence in the data. 
 
Gaps in Sequencing (Coverage <30x) – Zoomed in image
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Somatic variants have been derived by undertaking a further analytical step in which 
the germline variants have been subtracted from the list of variants seen in the 
tumour. This step is completed bioinformatically and effectively gives a set of 
variants only associated with the tumour sample. Figure 3.23 demonstrates the 
number of somatic variants recorded for each sample. Each of the 23 successfully 
processed samples has showed <10 variants, with the exception of patient #233 
which has a dramatically higher level of variants, approaching 150. This patient has 
been discussed in greater depth in the Case Scenarios section within this chapter. 
 
Figure 3.23: Shows the number of somatic variants for each sample sequenced, demonstrating that each 
sample has less than 10 somatic variants per sample with the exception of sample #233 that has approaching 
150 somatic variants. 
 
The somatic variant numbers demonstrated in figure 3.23, were called following 
analysis through the pipeline and included some duplicate variants where the 
bioinformatic pipeline had assessed the same variant in different transcripts. Further 
manual analysis was undertaken to remove these duplicates and then to assess the 
pathogenic status of each variant. Those variants likely to result in a protein change 
and associated with a high level of pathogenicity were considered of potential 
clinical utility. Assessing pathogenicity can be considered quite subjective and can be 
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extremely time-consuming if each variant is fully assessed individually; the 
pathogenicity in these cases was based on the bioinformatic pipeline calls using the 
consensus of three variant calling databases.  
Table 3.9 shows the somatic variants considered to potentially pathogenic for each 
patient following the removal of duplicate variants. The table details the gene in 
which the variant was seen, with both the genomic level and protein level HGVS 
(Human Genome Variation Society) variant description nomenclature107, as well as 
the likely effect of the variant and the likely pathogenic status based on the 
consensus from the pathogenicity assessment using mutect2, verdict and strelka. Of 
the 22 patients, an average of 1.32 somatic variants (range 0-4) were seen per 
patient. Those variants likely to result in a protein change and associated with a high 
level of pathogenicity are highlighted in the darker blue.  
Patient 
Variant 
Numbers Gene Effect hgvs.c hgvs.p Status 
#44 2 FAM46C missense variant c.731T>G p.Leu244Arg Strong Somatic  
  FAT1 synonymous variant c.12915G>A p.Ala4305Ala Strong Somatic  
#88 2 DNAH5 intron variant c.8010+67T>A  Strong Somatic  
  ZFHX4 missense variant c.6848A>C p.Lys2283Thr Strong Somatic  
#136 2 NFKB2 missense variant c.1405G>A p.Asp469Asn Strong Somatic  
  DIS3 missense variant c.2458C>T p.Arg820Trp Strong Somatic  
#140 2 NRAS missense variant c.182A>G p.Gln61Arg Strong Somatic  
  EGR1 missense variant c.89A>G p.Asp30Gly Strong Somatic  
#144 1 NRAS missense variant c.190T>G p.Tyr64Asp Strong Somatic  
#161 1 LTB splice donor variant & intron variant c.280+2T>C  Strong Somatic  
#162 0      
#179 0      
#180 0      
#184 0      
#191 2 CCND1 missense variant c.174G>C p.Lys58Asn Strong Somatic  
  KMT2A intron variant c.11430-12C>A  Likely Somatic 
#198 4 FAT4 splice donor variant & intron variant c.12816+1G>A  Likely Somatic 
  FAT3 missense variant c.2389T>C p.Tyr797His Likely Somatic 
  TRAF3 frameshift variant c.1142_1158delTGGAGTCCCAGCTGAGC p.Leu381fs N/A 
  NF1 frameshift variant c.2033dupC p.Ile679fs Strong Somatic  
#199 2 NRAS missense variant c.181C>A p.Gln61Lys Strong Somatic  
  FAM46C conservative inframe deletion c.1054_1056delAAC p.Asn352del Strong Somatic  
#200 3 BRAF missense variant c.1780G>A p.Asp594Asn Likely Somatic 
  CDKN2A missense variant c.35C>T p.Ser12Leu Likely Somatic 
  KMT2A missense variant c.368G>A p.Gly123Asp Likely Somatic 
#202 0      
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#208 1 ERBB4 missense variant c.1361G>T p.Ser454Ile Strong Somatic 
#215 0      
#217 0      
#230 3 KRAS missense variant c.183A>C p.Gln61His Strong Somatic 
  CUL4A sequence feature c.849-27A>G  Strong Somatic 
  PSMG2 splice region variant & intron variant c.57+3G>T  Strong Somatic 
#232 0      
#234 Sample Failed NGS Analysis    
#235 4 ATM stop gained c.5623C>T p.Arg1875* Likely Somatic 
  KRAS missense variant c.64C>A p.Gln22Lys Likely Somatic 
  KRAS missense variant c.57G>C p.Leu19Phe Strong Somatic 
  MAF synonymous variant c.168C>T p.Ser56Ser Likely Somatic 
#233 89 Complete list of variants not included here, see table 3.10.   
Table 3.9: Detailing the somatic variants seen in patients assessed using the bespoke NGS myeloma panel. 
Table 3.10 presents a simplified list of those variants considered of potential clinical 
utility. Patient #234 has been excluded as this sample failed NGS, and patient #233 
has also been excluded from this part of the analysis given the exceptionally high 





Numbers Gene Effect hgvs.p 
#44 1 FAM46C missense variant p.Leu244Arg 
#88 1 ZFHX4 missense variant 
p.Lys2283Th
r 
#136 2 NFKB2 missense variant p.Asp469Asn 
  DIS3 missense variant p.Arg820Trp 
#140 2 NRAS missense variant p.Gln61Arg 
  EGR1 missense variant p.Asp30Gly 
#144 1 NRAS missense variant p.Tyr64Asp 
#161 0    
#162 0    
#179 0    
#180 0    
#184 0    
#191 1 CCND1 missense variant p.Lys58Asn 
#198 2 FAT3 missense variant p.Tyr797His 
  NF1 frameshift variant p.Ile679fs 
#199 2 NRAS missense variant p.Gln61Lys 
  FAM46C 
conservative inframe 
deletion p.Asn352del 
#200 3 BRAF missense variant p.Asp594Asn 
  CDKN2A missense variant p.Ser12Leu 
  KMT2A missense variant p.Gly123Asp 
#202 0    
#208 1 ERBB4 missense variant p.Ser454Ile 
#209 0    
#215 0    
#217 0    
#230 1 KRAS missense variant p.Gln61His 
#232 0    
#235 3 ATM stop gained p.Arg1875* 
  KRAS missense variant p.Gln22Lys 
  KRAS missense variant p.Leu19Phe 
Table 3.10: Detailing the variants seen in patients assessed by NGS considered to be pathogenic or resulting in 
a protein change. 
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Based on the analysis of the gaps in sequencing, both patients #44 and #162 were 
shown to have poorer quality sequencing. The gaps in sequencing amount 12.8% in 
#44, but 42.8% in #162. It is possible in these cases, and particularly in patient #162, 
that variants may not have been detected.  
As detailed in table 3.10, ten cases (45.5%) showed no evidence of variants 
considered to be pathogenic. Twelve cases demonstrated the presence of 20 
pathogenic variants; two cases showed three variants, four cases showed two 
variants and six cases showed a single variant in the genes included in the NGS 
myeloma gene panel. This gives an average of 0.9 (range 0-3) variants per patient 
sample. The 20 pathogenic variants seen were within 15 different genes listed here: 
ATM, BRAF, CCND1, CDKN2C, DIS3, EGR1, ERBB4, FAM46C, FAT3, KMT2A, 
KRAS, NF1, NFKB2, NRAS and ZFHX4 
A single pathogenic variant was detected in each gene except NRAS, KRAS and 
FAM46C. NRAS and KRAS show three different variants and FAM46C demonstrated 
two variants.  
The MAPK pathway is dysregulated in approximately 55% of MM patients. Genes 
which have been associated with MAPK-signalling include KRAS, NRAS, BRAF and 
more recently NF1 and RASA262. In our cohort, eight of the 20 (40.0%) variants were 
seen in these genes, three in NRAS, three in KRAS, and one in each of BRAF and NF1, 
and these relate to seven of the 22 (31.8%) patients.  
In a diagnostic context, the variants produced as a result of NGS or WGS are 
analysed by gathering data, often using Alamut, from a number of different sources. 
This assesses the type of variant, population frequencies, COSMIC data, ClinVAR data 
and dbSNP data to more thoroughly assess the likelihood of being pathogenic or 
disease causing. For the final 20 variants, this analysis was completed. The 
information gathered through Alamut and comparison with known hotspot data 
from Lohr et al 61 are presented in appendix 3. This analysis would effectively 
downgrade a number of variants from the assessment produced by the 
bioinformatics analysis. Of the 20 variants considered pathogenic based on the 
bioinformatics assessment, 11 would be considered pathogenic following this more 
in depth analysis, five of those being previously reported hotspots in myeloma: the 
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NRAS Q61 (seen twice in our data) and Y64 hotspots, BRAF D594 and the KRAS Q61 
hotspot. The remaining nine variants would be considered variants of unknown 
significance (VUS). This would suggest that pathogenicity callers used as part of the 
bioinformatics pipeline variant assessment are overcalling the level of pathogenicity. 
Patient #233 showed dramatically more variants than the other samples. This 
number was approaching 150 overall, but with removal of duplicates numbered 89 
variants. Those variants likely to result in a protein change and associated with a high 





Number Gene Effect hgvs.c hgvs.p 
#233 45 VCAM1 splice region variant & intron variant c.662-7C>T  
  ANP32E disruptive inframe deletion c.576_581delAGAGGA p.Glu193_Glu194del 
  ANP32E missense variant c.332C>A p.Ala111Glu 
  PARP1 missense variant c.2285T>C p.Val762Ala 
  NCKAP5 missense variant c.2930T>C p.Ile977Thr 
  NCKAP5 missense variant c.2809G>A p.Val937Ile 
  FRZB missense variant c.598C>T p.Arg200Trp 
  ROBO1 splice region variant & intron variant c.4283-6C>T  
  FAT4 missense variant c.9246A>T p.Glu3082Asp 
  FAT4 missense variant c.9643C>T p.His3215Tyr 
  SFRP2 splice region variant & intron variant c.502+6C>T  
  FAT1 missense variant c.11155G>A p.Val3719Met 
  FAT1 missense variant c.10660T>G p.Ser3554Ala 
  FAT1 missense variant c.385G>C p.Val129Leu 
  DNAH5 missense variant c.12401C>T p.Ala4134Val 
  DNAH5 missense variant c.8586G>T p.Leu2862Phe 
  DNAH5 missense variant c.2296A>T p.Ile766Leu 
  CCND3 missense variant c.775T>G p.Ser259Ala 
  CCND3 missense variant c.395T>G p.Leu132Arg 
  ROS1 missense variant c.500G>A p.Arg167Gln 
  LRP5 splice region variant & intron variant c.884-4T>C  
  LRP5 splice region variant & intron variant c.2318+6T>C  
  FAT3 missense variant c.8983C>A p.Gln2995Lys 
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  FAT3 missense variant c.10552G>T p.Val3518Leu 
  FAT3 splice region variant & intron variant c.12938-6A>T  
  ATM splice region variant & intron variant c.5497-8T>C  
  CCND2 splice region variant & synonymous variant c.570C>G p.Thr190Thr 
  CHD4 splice region variant & intron variant c.4371-5C>T  
  CHD4 missense variant c.417G>T p.Glu139Asp 
  KRAS missense variant c.34G>A p.Gly12Ser 
  FLT3 splice region variant & intron variant c.1310-3T>C  
  FLT3 missense variant c.680C>T p.Thr227Met 
  TNFSF11 missense variant c.107C>G p.Pro36Arg 
  PSMB5 missense variant c.70C>T p.Arg24Cys 
  KREMEN2 missense variant c.225C>A p.Ser75Arg 
  KREMEN2 missense variant c.234C>G p.His78Gln 
  KREMEN2 missense variant c.1222G>C p.Ala408Pro 
  WWOX missense variant c.535G>A p.Ala179Thr 
  KDM6B splice region variant & intron variant c.456+6A>G  
  CDH2 missense variant c.352G>A p.Ala118Thr 
  SMAD7 splice region variant & intron variant c.667+8G>A  
  TGFB1 missense variant c.29C>T p.Pro10Leu 
  MMP9 missense variant c.836A>G p.Gln279Arg 
  KREMEN1 missense variant c.203G>A p.Arg68Gln 
  KREMEN1 missense variant c.874C>G p.Leu292Val 
Table 3.11: Somatic variants for #233, only including those considered pathogenic and resulting a protein change 
There were 45 pathogenic variants in this patient, a significant increase on the other 
22 patients which showed an average of 0.91 (range 0-3) potentially pathogenic 
variants. This patient will be discussed further as part of the case studies section in 
this chapter. The 45 pathogenic variants are shown in table 3.11, which details the 
gene in which the variant was seen, the effect of the variant, both the genomic level 
and protein level HGVS (Human Genome Variation Society) variant description 
nomenclature107. 
The KRAS G12 variant has been highlighted in blue, demonstrating the presence of 
this as one of the hotspots seen in the Lohr et al 61 data. 
Overall, the bespoke myeloma NGS assay worked well and picked up known, 
recognised and relevant mutations associated with these genes in myeloma. 
Currently these abnormalities do not contribute to the diagnosis of myeloma or 
change clinical management or treatment in myeloma patients, but current 
literature and trials data suggests that inclusion of this data is consistent with the 





Three cases studies have been prepared with the aim of demonstrating some of the 
more interesting abnormal cases seen as part of the study, but to also highlight 
different aspects detected using the different comparative technologies. The first 
case study is illuminating in showing the strengths of the different techniques 
demonstrating the understanding obtained from the cumulative effect of these 
genetic technologies and their output. The second case describes a rare but 
interesting finding of a jumping translocation, and the third explores the 
hypermutation profile detected as part of the NGS studies. 
 
Patient #113 – Complex genetics associated with myeloma patient at progression 
to plasma cell leukaemia 
Patient #113 is a male, born in 1945, and was 67 years old when diagnosed in 
November 2012 with plasma cell myeloma. He had a 70g/L IgG paraprotein with 80% 
plasma cells. His first line treatment was cyclophosphamide, thalidomide, 
dexamethasone (CTD) and warfarin. He suffered a thigh bleed on warfarin and was 
switched to bortezomib (Velcade), cyclophosphamide, dexamethasone (VCD). 
Following nine courses of VCD, patient #113 showed a partial response to therapy 
(paraprotein level reduced to 9g/l) and proceeded to high dose melphalan and an 
autologous transplant in July 2013. In October 2013, at day 100 post transplant, 
patient #113 was shown to have 80% plasma cells and relapsed disease. Third line 
treatment included lenalidomide (Revlimid) and dexamethasone, which gave a short 
lived partial response before rapid progression to plasma cell leukaemia with hepatic 
plasmacytomas. The bone marrow sample used as part of this study was taken at 
this stage, in December 2013. Patient #113 died later that month. 
The bone marrow sample was processed for cytogenetic analysis, FISH, MLPA and 
array analysis. The cytogenetic karyotype was: 
44,X,-Y,i(1)(q10),add(2)(q31),?add(3)(p1?3),del(6)(q21),add(8)(q24),-13,t(14;20)(q32;q11) 
This shows a complex karyotype (see figure 3.24) with a translocation between 
chromosomes 14 and 20, a recognised IGH rearrangement in MM. The cytogenetics 
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also showed an 8q rearrangement suggesting MYC involvement, an isochromosome 
1q resulting in the loss of the short arm of chromosome 1 and gain of the long arm of 
chromosome 1, monosomy for chromosome 13 and loss of the Y chromosome. 
Further abnormalities of chromosomes 2, 3 and 6 were also identified, but their 
exact nature could not be determined by cytogenetics alone. 
 
 
Figure 3.24: Demonstrates a representative karyotype from patient #113. It shows a translocation between 
chromosome 14 and 20, the presence of the isochromosome 1q, loss of chromosome 13, abnormality of the 
long arm of chromosome 8, and additional abnormalities of chromosomes 2, 3 and 6.  
 
FISH using the Vysis Abbott IGH breakapart probe demonstrated a rearrangement. 
Figure 3.25 shows the IGH probe map (top) with both red and green probes either 
side of the IGH breakpoint. This shows a fusion signal (i.e. yellow) when IGH is not 
rearranged and splits into its component red and green signals when a 
rearrangement is present.  
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Figure 3.25: FISH images from patient #113 using the Vysis Abbott IGH breakapart and IGH/MAFB probes. The 
IGH probe map demonstrates the red and green probes flanking the IGH region of chromosome 14. Image a 
and b show an abnormal rearranged pattern in two interphase cells and a metaphase cell. The second probe 
map shows the IGH gene covered using a green probe and the MAFB gene covered using a red probe. Image c 
shows a red signal on chromosome 20, and green signal on chromosome 14 and two fusion (yellow) signals on 








Figure 3.25a shows a IF1R1G rearranged signal pattern in two interphase cells, and 
figure 3.25b shows this same pattern in an interphase cell allowing the position of 
these signals to been seen. The interphase cell shows the normal fusion signal on a D 
group chromosome consistent with the chromosome 14 and shows the red signal on 
a large D group chromosome likely to be the derivative 14 and the green signal on 
the small derivative chromosome 20.  
To confirm the involvement of chromosome 20, the Abbott Vysis IGH/MAFB probe 
was used. The second probe in figure 3.25 map shows the IGH gene covered using a 
green probe and the MAFB gene covered using a red probe. Figure 3.25c shows a red 
signal on chromosome 20, and green signal on chromosome 14 and two fusion 
(yellow) signals on the derivative 14 and derivative 20 chromosomes, confirming the 
presence of an IGH-MAFB rearrangement. 
The step 1 FISH assessment also included probes for CDKN2C/CKS1B (1p/1q) and the 
TP53/17cen. The CDKN2C/CKS1B (1p/1q) FISH confirmed the loss of the short arm 
and gain of the long arm as expected from the cytogenetic analysis. Figure 3.26 
shows the chromosome 1 array profile (top left) with loss of 1p in red and gain of 1q 
in blue, 3.26a shows the normal chromosome 1 (left) and the isochromosome 1q 
(right) karyotypically and 3.26b shows an interphase FISH image with three copies of 
the red CKS1B probe on 1q and one copy of the green CDKN2C probe on 1p. The 
TP53/17cen probe is shown on an interphase FISH image in figure 3.26c in which 
there are two copies of TP53 in red and two copies of 17cen in green, i.e. a normal 
profile for this probe. 
Figure 3.26 also shows the array profile (bottom left) and the karyotypic image 
(figure 3.26e) of both chromosome 2s, the array profile would suggest both loss and 
gain of the long arm of chromosome 2 confirming the complex nature of the 
rearrangement seen karyotypically. MYC FISH was also completed following the 
finding of the karyotypic abnormality of the long arm of chromosome 8 and 
confirmed a rearrangement of MYC. Figure 3.26 also shows the array profile of 
chromosome 8 (bottom right) and the karyotypic image of chromosome 8 (figure 
3.26f); the array profile suggested gain of the long arm of chromosome 8, and the 
MYC FISH (figure 3.26d) confirmed a non-standard MYC rearrangement with a 
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1F2R1G pattern suggesting rearrangement, with duplication of the derivative 
chromosome. 
 
Figure 3.26: Shows cytogenetic, FISH and array results from patient 113. The isochromosome 1 is shown 
karyotypically in image a, with the array profile (top left) and the FISH (image b) confirming loss of the short 
arm and gain of the long arm. Image c shows a normal profile using the TP53/17cen probe. Image e shows a 
complex rearrangement of chromosome 2 and this is confirmed by the array profile (bottom left). Image f 
shown the karyotypic rearrangement of chromosome 8, with the array profile (bottom right) and the MYC FISH 
(image d) confirming a non-standard 1F2R1G signal pattern consistent with MYC rearrangement and 
duplication of the derivative chromosome. 
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MLPA analysis (figure 3.27), also acts as confirmation of both the loss and gain of 
chromosome 1p and 1q respectively and monosomy for chromosome 13. The other 
regions included in the MLPA probe list are considered within normal limits.  
However, one of the control probes which lies on the long arm of chromosome 2 
(involving gene COL3A1) also demonstrates loss. The control genes have been 
chosen in ‘quiet’ areas of the myeloma genome due to their rarity of involvement in 
myeloma karyotypes. However, as many myeloma karyotypes demonstrate extreme 
complexity, the control areas are frequently involved. The demonstration of loss in 
the region of chromosome 2q provides additional information to the rearrangement 
of chromosome 2 seen cytogenetically. 
 
Figure 3.27: Shows the MLPA graphical representation from patient 113. The quality is poor demonstrated by 
the very large confidence limit bars, but still clearly demonstrates loss (in red) of the short arm of chromosome 
1, gain (in blue) of the long arm of chromosome 1, and loss of chromosome 13. Loss of the control marker on 
chromosome 2 is also noted. 
 
The array had a poor MAPD QC value of 0.294 (values of <0.25 are considered to be 
of high enough quality for a diagnostic report), however, some valuable information 
was still gained from the analysis. The array was able to confirm the isochromosome 
1q with both loss of 1p and gain of 1q, and loss of chromosome 13 (figure 3.28). It 
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also showed loss of a much larger region of chromosome 2 than was determined by 
cytogenetics, and highlighted a more complex rearrangement of MYC with gain 
around the region of 8q24. When revisiting the karyotype, it looks possible that the 
deletion of the long arm of chromosome 2 could be replaced at least in part by the 
derivative chromosome 8 involving the MYC rearrangement. 
 
Figure 3.28: Shows array results from patient 113. The QC for this patient was poor, but losses of 1p and 13 
were confirmed as were gains of the long arm of chromosome 1. 
 
In summary, patient #113 has a plasma cell leukaemia with an IGH-MAFB 
rearrangement. Although IGH rearrangements are seen in approximately 60% of 
myeloma patients, the IGH-MAFB rearrangement is rare, seen in only ~2% of 
patients, and it is associated with a poor prognosis. The rearrangement was seen 
karyotypically and confirmed to involve the IGH and MAFB genes using FISH probes. 
Loss of 1p and gain of 1q (as an isochromosome in our case) was detected 
cytogenetically and then confirmed by FISH, MLPA and array. Gain of 1q is also 
associated with poor prognosis, and has been seen in higher frequencies in patients 
with disease progression. Monosomy 13 was determined by cytogenetics and 
confirmed by MLPA and array. In terms of prognosis, monosomy 13 is no longer 
considered an independent prognostic factor in myeloma, its original poor 
prognostic status is thought to be due to its strong association with t(4;14). The 
 140 
rearrangement of chromosome 8 at the site of the MYC gene was detected 
cytogenetically and then confirmed using FISH probes. The FISH signal pattern 
suggested a non-standard rearrangement, which was also confirmed with the array. 
When the karyotype was revisited with the FISH and array information, a more 
complex rearrangement of MYC involving the long arm of chromosome 2 was 
suspected. 
This case report shows the strengths of each technique in the setting of a complex 
genomic picture. Each of the additional techniques is able to add information to 
create a deeper and clearer understanding of the abnormalities seen. This has been 
useful in demonstrating the cumulative effect of these genetic technologies and 
their output. 
 
Patient #175 – Myeloma patient with hyperdiploidy and a possible jumping 
translocation 
Patient #175 is an Afro Caribbean male who was 58 years old when he presented in 
June 2015 with an IgG kappa monoclone of 62.6g/L, immunoparesis, haemoglobin 
(Hb) of 110g/L, normal creatinine and no evidence of renal failure. His bone marrow 
plasma cells were at a level of 70%. Multiple lytic lesions were detected in his ribs, 
sternum, pelvis and spine, and he was diagnosed at this stage with plasma cell 
myeloma. 
He was treated with cyclophosphamide, thalidomide, dexamethasone (CTD) off trial 
and completed 5 courses. At this stage he demonstrated a VGPR (very good partial 
response) with his IgG monoclone dropping to 4.3g/L.  In January 2016, he received 
an autologous stem cell transplant (ASCT) following induction chemotherapy. In 
March 2018, our patient relapsed and his second line treatment included bortezomib 
(Velcade) and dexamethasone, and he received a second ASCT in June 2018. The six 
cycles of treatment were completed in October 2018 and he is currently in remission 
and clinically well. 
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The bone marrow sample involved in this study was taken at diagnosis (June 2015) 




This demonstrated a male hyperdiploid karyotype with whole chromosome gains of 
3, 5, 7, 9, 11, 15, 19 and 21. The majority of chromosomes show a single extra copy, 
but both chromosomes 5 and 9 were present as two additional copies, four copies 
per cell in total. There was also an unbalanced translocation between chromosomes 
1 and 17; this presented as two normal copies of chromosome 1 with an additional 
copy of the long arm of chromosome 1 on the short arm of chromosome 17, 
resulting in an overall the gain of the long arm of chromosome 1 and loss of the 
short arm of chromosome 17 (See figure 3.29).  
 
Figure 3.29: Demonstrating a representative karyotype from patient #175. This shows a hyperdiploid 
karyotype with a single additional copy of chromosomes 3, 7, 11, 15, 19 and 21, and two additional copies of 
chromosomes 5 and 9. There is also an unbalanced translocation between chromosomes 1 and 17. It should be 
noted that this cell also showed loss of chromosome 20 which was not shown to be clonal. 
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The ‘cp’ as part of the karyotype ISCN indicates that this is a composite karyotype 
made up of nine cells that were fully analysed. In order to be part of a composite 
karyotype and considered clonal, structural abnormalities or chromosomal gains 
must be present in two or more cells, and chromosome losses must be present in 
three or more cells. Three further abnormalities of chromosome 1 were seen in 
which the long arm of chromosome 1 was not present on the short arm of 
chromosome 17. The first cell was poor but suggested the presence of three copies 
of chromosome 1, a single copy of chromosome 2 and two copies of a derivative 
chromosome 2 from a t(1;2) in which the long arm of chromosome 1 appeared on 
the short arm of chromosome 2. The second cell appeared to have two additional 
copies of the long arm of chromosome 1q on an unknown chromosome, this could 
have been chromosome 19, but did not look like a straightforward deletion of the 
short arm of chromosome 1p. The final cell had a marker chromosome in which the 
long arm of chromosome 1 seemed to be involved. These changes are demonstrated 
in figure 3.30 and were seen with the same additional chromosomes associated with 
the patient’s hyperdiploidy, but with two normal copies of chromosome 17. As only 
individual cells were seen with these abnormalities, they could not be included in the 
composite karyotype. Although these abnormalities cannot be considered clonal, 
they do provide evidence for a level of fragility in the chromosomal make up 
resulting in this pattern of non-clonal changes. The movement of the long arm of 
chromosome 1q also raises the possibility of a ‘jumping translocation’. Jumping 
translocations, as referred to in the introduction, are rare chromosomal events in 
which the same donor chromosome segment is translocated onto two or more 
recipient chromosomal sites121. In this case the long arm of chromosome 1 is 
‘jumping’ from the short arm of chromosome 17, to the short arm of chromosome 2, 




Figure 3.30: Partial karyotypes from three cells demonstrating a possible jumping translocation in which the 
long arm of chromosome 1 appears to be present on the short arm of chromosome 2 and present in two copies 
alongside three copies of chromosome 1 in the first cell, then in two further cells the long arm of chromosome 
1 is present on two unrecognisable chromosomes, the first again present in duplicate. These unknown regions 
were considered to be chromosome 19 or 22 in the second cell and possibly chromosome 6 in the third cell. 
These cells also showed the same additional chromosomes as part of the hyperdiploid karyotype but were 
present with tow normal copies of the short arm of chromosome 17. 
 
FISH analysis showed no evidence of rearrangement of the IGH gene, but 
demonstrated duplication of the CKS1B gene on the long arm of chromosome 1 in 
72% of cells scored and a low level deletion of the TP53 gene on the short arm of 
chromosome 17 in 8% of cells scored. The predominant karyotypic evidence of the 
unbalanced t(1;17) would suggest the same level of gain of chromosome 1q and loss 
of chromosome 17p. This is not the pattern seen by FISH, which provides evidence to 
support the likely presence of a jumping translocation involving the long arm of 
chromosome 1. The long arm of chromosome 1 is present in a number of different 
guises not all involving the short arm of chromosome 17. These rearrangements 




Figure 3.31: MLPA ratio chart demonstrating gain of regions of chromosomes 5, 9 and 15, the long arm of 
chromosome 1 and the marker in the FAM46C gene on the short arm of chromosome 1. It should be noted that 
the ratio levels are higher for both chromosomes 5 and 9 consistent with the presence of two additional copies 
of both chromosomes 5 and 9 seen karyotypically. 
 
The MLPA analysis completed on this case is shown in figure 3.31, and shows gain of 
regions of 1q, chromosome 5, 9 and 15 and a single marker in the FAM46C gene on 
the short arm of chromosome 1p. The gain of chromosomes 5, 9 and 15 is reflected 
in the karyotype in which additional copies of these chromosomes are present. It 
should be noted that the ratio levels of the markers associated with chromosome 5 
and 9 are increased in comparison to chromosome 15, confirming the presence of 
four copies each of chromosome 5 and 9 seen karyotypically compared to the three 
copies of chromosome 15. Gain of 1q and FAM46C are seen, but there is no evidence 
of loss of the short arm of chromosome 17 using the markers associated with TP53. 
Loss of TP53 was seen at a level of 8% using FISH probes for the TP53 region. Even 
though both FISH and MLPA analysis have been performed on CD138+ve cell 
selections, MLPA does have difficulty in detecting low level abnormalities (i.e. <15-
20%), and in this case has shown no change in the regions associated with TP53 on 
the short arm of chromosome 17, not even a slight deviation from the normal. 
In conclusion, patient #175 demonstrates a plasma cell myeloma patient with a 
hyperdiploid karyotype. Hyperdiploidy is seen is approaching 50% of myeloma 
 145 
patients. This patient also shows an unbalanced rearrangement of chromosomes 1 
and 17, which results in a loss of the short arm of chromosome 17 and the long arm 
of chromosome 1, both of which are considered poor risk markers according to Boyd 
et al 112, and would be classified as a ‘double hit’ myeloma in this context. 
Although this abnormality was the only clonal abnormality of chromosome 1 
detected by karyotyping, there was some non-clonal evidence of other abnormalities 
involving chromosome 1q which was considered likely to be a ‘jumping 
translocation’ involving 1q. The FISH pattern showed gain of CKS1B on the long arm 
of chromosome 1 at a high level, but loss of TP53 in only 8% providing further 
evidence for the presence of a jumping translocation. MLPA also confirmed the 
hyperdiploidy and gain of chromosome 1q, but did not show any evidence of TP53 
loss, highlighting one of the downfalls of this technique, i.e. the inability to detect 
low level rearrangements. 
From a clinical perspective, this patient would have demonstrated a 1q gain only 
using standard of care genetic diagnosis, although this is currently considered a poor 
prognostic marker it does not change clinical management.  Jumping translocations 
are well documented, but a rare and interesting finding, however, this abnormality 
has no real clinical impact. This patient is currently in a good remission following two 
rounds of treatment and two autologous stem cell transplants. 
 
Patient #233 – Hypermutation detected by NGS in myeloma patient 
Clinically, patient #233 is a 72yr old female who was diagnosed with smouldering 
myeloma in August 2016. At this time point she had an IgG kappa monoclone of 
21.1g/L, her creatinine was 64, haemoglobin (Hb) 110, and her adjusted Calcium 
(adCa) level (this is the value corrected against albumin levels) was 2.4mmol/L. Her 
bone marrow plasma cells were at 45%. Cytogenetics showed a normal female 
karyotype, and FISH demonstrated gain of CKS1B on chromosome 1q. Array analysis 
subsequently showed a hyperdiploid karyotype with whole chromosome gains of 5, 
9, 11, 15 and 19, with regions of gain seen on chromosome X and confirmed the FISH 
finding of gain of the long arm of chromosome 1. Regions of loss were seen on the 
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short arm of chromosome 1, not including the CDKN2C and therefore not seen by 
FISH, and the whole of the long arm of chromosome 16. Her sample was not 
processed for MLPA. 
She was subsequently diagnosed with lung cancer following referral for a lump noted 
on the scan in October 2016. Following this diagnosis, the patient had a lumpectomy 
in February of 2017, but she did not receive chemotherapy at this stage. Therefore, 
at the time of the sample assessed as part of this study (August 2016), the patient 
had had no previous exposure to chemotherapeutic agents. In May 2019, the 
patient’s myeloma demonstrated signs of progression with her Hb dropping to 88, 
and the requirement for a vertebraplasty procedure in response to skeletal damage 
detected at follow up scan. Treatment with Velcade, Thalidomide and 
Dexamethasone (VTD) was commenced at the end of May 2019. 
Patient #233 demonstrates an anomaly in the NGS data and showed dramatically 
more variants compared to the remaining samples in the patient cohort. Figure 3.32 
shows the number of somatic variants seen in all 24 patient samples. The variant 
number in patient #233 was approaching 150 in comparison to less than 10 variants 
in the remaining patients in the cohort.  
Following the step of removing duplicates in the NGS data, the variants in patient 
#233 numbered 89, this compared to an average of 1.32 variants (range 0-4) in the 
remaining 22 patients (one patient failed NGS).  
 147 
 
Figure 3.32: Graph to demonstrate the number of somatic variants detected across 24 patients in the NGS 
patient cohort using the bespoke myeloma / osteome NGS panel. This shows a low level of variants across 23 
patients, but a dramatically increased level in patient #233 
 
 
Following the pathogenic assessment of the variants, the variants likely to result in a 
protein change associated with a high level of pathogenicity were presented in table 
3.11 for patient #233 and in table 3.10 for the remaining patients in the cohort. 
There were 45 pathogenic variants seen in patient #233, which is a significant 
increase based on the other 22 patients who showed an average of 0.91 (range 0-3) 
potentially pathogenic variants. It is acknowledged that the cohort number for the 
NGS processing is small, however, the number of mutations across the cohort is 
extremely consistent with the exception of patient #233. 
Hypermutation is the process of producing an unusually high number of mutations 
or changes122. Patient #233 can be described as hypermutated. 
There are number of explanations for this anomaly including the NGS processing and 
analysis itself. A remarkably similar case was reported in a myeloma patient assessed 
as part of the 100K genome project. However, when explored in more depth, the 
team involved with this patient considered that the high level of mutations detected 
were artefactual based on the poor quality of the starting material, as many variants 
were seen at extremely low allele frequencies. Based on this assessment we 
 148 
analysed our patient; the patient sample quality was good and the sequencing 
quality metrics were also considered good for this patient. We assessed the allele 
frequencies for the somatic variants detected in this patient, which are shown 
graphically in figure 3.33. Although the graph can be seen to have a range of allele 
frequencies, the majority of the somatic mutations are present in approximately 50% 
of the sequencing reads. It is difficult to be sure if this is a true finding or an 
artefactual finding based on the bioinformatics alone, but it is unlikely that the 
mutations would be seen at such a high level if this result was not true. 
 
 
Figure 3.33: Graph to demonstrate the allele frequencies for the somatic variants detected in patient sample 
#233, showing an allele frequency peak at approximately 50%. 
 
Patient #233 is known to have lung cancer, and exposure to the types of 
chemotherapy used for lung cancer could cause this picture of mutation. However, 
revisiting the patient notes and chemotherapy records, confirmed that the patient’s 
initial lung lump was seen in October 2016 whilst the patient’s myeloma treatment 
was ongoing, but the lumpectomy was performed in February 2017. At the time of 
sampling (August 2016), there was no record of chemotherapy for either the lung 
Sample #233 – Somatic Variant Allele Frequency
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cancer or the myeloma, or indeed any other malignancy, and therefore this pattern 
of mutation cannot be related to chemotherapy. 
Having excluded treatment response or poor-quality sequencing data as reasons for 
the hypermutation, this has to be considered a true finding for patient #233. 
The mutation count has been shown to be highly dependent on the tumour type, 
and based on a WES study from Chapman et al, average numbers of gene mutation 
have been shown to range from eight mutations in the more simple leukaemia’s to 
approximately 540 mutations in the genetically more complex epithelial tumours59. 
Chapman et al demonstrated that myeloma patients fell between these two 
extremes with 35 being the average number of gene mutations per patient. In 
general, only modest variations in the number of somatic mutations were seen in the 
majority of patients within a tumour type, however, there is evidence to suggest that 
outliers exist within many cancer types in which dramatically higher mutation levels 
are seen, and this has been described as hypermutation19,122.  
Hypermutation has been shown to be caused by environmental factors such as UV 
light, particularly in association with malignant melanoma, and tobacco smoke, 
particularly in association with lung and larynx tumours. Mutations in genes 
associated with DNA replication repair (POLE and POLD1) or DNA mismatch repair 
(MLH1, MSH2, MSH6 and PMS2) have also been associated with specific cancer 
types122. It may have been prudent to assess these genes in our patient, however, 
additional material was not available to complete this testing. 
In conclusion, patient #233 has myeloma with a hyperdiploid karyotype with a gain 
of the long arm of chromosome 1. Although hyperdiploidy is usually considered a 
standard risk feature, gain of 1q is a high-risk marker. This patient was processed 
through the bespoke NGS panel designed as part of this project and showed a 
hypermutated profile with an approximately 45-fold increase in the number of 
variants seen when compared to the remaining patients in the cohort. Further 
examination, and exclusion of sequencing artefacts and treatment causes, suggested 
this was likely to be a true finding. Hypermutation is a rare finding but these outliers 
with dramatically increased variant numbers have been described in a number of 
cancer types. Potential causes of hypermutation were discussed. 
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Although the expectation from this genetic profile would be a poor outlook, this 
patient continues to be treated for both her myeloma and concurrent lung cancer 





















Proposed Diagnostic Strategies and Best Practice Recommendations 
In conclusion, the five genetic technologies described and explored here for the 
genomic assessment of myeloma offer range of both advantages and disadvantages, 
all of which should be considered in the context of providing a diagnostic testing 
strategy for NHS patients, which has to balance the clinical utility of the information 
provided  with the time and cost of testing.  
Traditional cytogenetics i.e. karyotyping offers a full genomic screen which allows 
the simultaneous assessment of copy number, including hyperdiploidy, and 
structural rearrangements specifically for the IGH gene on chromosome 14, however 
the resolution is low, a high level of skill and expertise is required and it is time 
consuming to carry out the level of analysis required which all contribute to the slow 
and expensive nature of this technology. Added to this, it is notoriously difficult 
technically, to capture plasma cells at the metaphase stage of division, analysis is 
therefore not targeted to the plasma cells and abnormalities are only reported in 
approx. 30% of patients in the literature. Although, when the abnormal cells are 
captured, much information can be gleaned from this analysis, the fact that it is only 
applicable to such a small proportion of patients, excludes the possibility of 
detecting smaller abnormalities including deletions, and cannot detect mutations 
effectively exclude this technology as a robust method for assessing the genetics of 
myeloma patients. 
FISH can be targeted to interphase cells, and specifically can be used on samples that 
have been preselected to enhance the number of plasma cells, overcoming many of 
the difficulties seen with cytogenetic analysis. Many more cells can be reasonably 
analysed when compared to karyotyping, 50-200 cells not being an unreasonable 
analysis level, and probes are available that can assess both copy number and 
rearrangement detection covering the main abnormalities seen in myeloma. FISH 
does have limitations such as probe size and false positive rates. Probe sizes range 
from 150kb-1Mb, and therefore small deletions or mutations within genes or within 
the probe target cannot be detected. Specific probes have an associated false 
positive rate, dependant on the probe set formation. This is often low and quoted as 
1-4% by the manufacturers. FISH probes are designed to specific regions, and 
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although probes are available to cover most abnormalities required in myeloma, 
each requires a specific probe and a single assay. Myeloma panels can, therefore, be 
extremely large. FISH processing is not conducive to high throughput processing, and 
the expense of the probes and the time-consuming nature of the analysis can be 
prohibitive. However, FISH is currently the most widely used methodology in the 
genetic assessment of myeloma and is currently considered gold standard. Much of 
the trials data has been generated using FISH and therefore the literature supports 
the use of FISH also.  
MLPA offers an excellent multiplex methodology, providing information on the loss 
and gain of multiple regions (up to 50 targets), 46 in the case of the myeloma probe 
set from MRC Holland in a single assay. The probes employed in this technology are 
around 60 nucleotides in length and therefore deletions of a single exon can be 
detected, much smaller than conventional FISH techniques.  The technique can also 
detect mutations in the targeted regions but is unable to offer distinction between 
deletion and mutation. Due to its multiplex nature it is cost efficient. MLPA has 
previously been described in studies of multiple myeloma with excellent results118, 
however, MLPA is often considered a difficult technique and is highly sensitive to 
contaminants in the system. It requires a high level of technical skill and good quality 
DNA, and the failure rate is considered quite high, therefore a strategy including 
MLPA would have to have contingency in-built to cover failed samples. MLPA is also 
a copy number detection technology only and therefore only covers a subset of 
those abnormalities seen in myeloma, so there is the requirement of being used in 
conjunction with a technology able to determine IGH rearrangement118.  
DNA arrays offer a high resolution copy number whole genome screen which can be 
targeted at DNA from the CD138+ve plasma cell selections. The array has 
background resolution across the whole genome, but has particularly good coverage 
(25 markers per 100kb region) over key areas which include 533 cancer genes, and in 
the case of the array employed here, includes LOH detection. Balanced 
translocations, rearrangements and mutations are not reliably detected so again 
there is the requirement of being used in conjunction with a technology able to 
determine IGH rearrangement113. Low level abnormalities are also not reliably 
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detected (below the level of approximately 30%). Array processing is time consuming 
and expensive, and it is not considered a high throughput technology. The analysis is 
also time consuming, and the data provided were highly detailed, but in fact 
provides substantially more information than is currently clinical useful. 
Next Generation Sequencing (NGS) can be applied in a number of ways from the 
assessment of the whole genome, whole exome or targeted panel testing. We 
assessed a bespoke panel of myeloma genes designed as part of this project. The 
panel performed well providing good, robust data for the genes chosen. The panel 
was able to show a number of abnormalities consistent with those reported in the 
literature, and in particular detected those mutations associated with the MAPK and 
NF-ĸB pathways known to be associated with myeloma is a proportion of cases. The 
NGS panel has to be considered as additional testing as it does not provide 
information on copy number changes or rearrangement detection. As NGS becomes 
more sophisticated, it can be envisaged that an NGS technology could be designed 
using both DNA and RNA to assess copy number and rearrangement detection for 
those changes commonly seen in myeloma alongside a specific panel of known 
variants / mutations. There are currently difficulties associated with detecting IGH 
rearrangements using some types of NGS, including targeted single nucleotide 
variant panel testing, whole exome sequencing and indeed RNAseq, however WGS 
even at low level coverage could pick these rearrangements up.  
Table 3.12 shows a tabulated comparison of these technologies across a range of 
parameters from sample required, type of abnormalities detected through to costs 
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Table 3.12: Tabulated comparison of the five techniques undertaken as part of this study. 
 
Using the information gathered through the assessment of these five technologies in 
the context of detecting genetic abnormalities associated with myeloma and 
understanding the pros and cons of what each technology can offer, we wanted to 
propose an appropriate diagnostic strategy. Currently, I would consider that a single 
technology cannot provide comprehensive analysis of myeloma genetics, however, 
FISH and MLPA technologies used in tandem provide both a comprehensive and 
cost-effective genetic testing strategy for myeloma. With regard to future proofing, 
there is likely to be a need for mutation analysis in addition to FISH and MLPA. I 
would also consider that as technologies advance and mature, NGS may be able to 
offer a dual DNA and RNA solution that can assess copy number, both ploidy and 
gains and losses known to have clinical significance, a number of rearrangements 
and the mutational spectrum in a single assay, creating a simple bespoke myeloma 
genetic assessment tool. Assessment of IGH rearrangement may remain technically 
difficult for NGS based analysis, so FISH is likely to play a role in diagnostic myeloma 
testing strategies in the foreseeable future. 
As well as considering appropriate technologies for assessment, we need to consider 
the targets to include in the assessment. Currently NICE (National Institute for 
Clinical Excellence) guidelines for myeloma111, the revised International Staging 
System for myeloma114 and the IMWG (International Myeloma Working Group) 
consensus for risk stratification116, state the importance of genetics in providing 
powerful prognostic and potential treatment guiding information. Based on these it 
should be considered that the targets include those regions with prognostic or 
therapeutic importance. These could be divided into mandatory regions for testing; 
including those regions prescribed by NICE and the IMWG, and those used to risk 
stratify patients. Other regions could be considered recommended where the 
information does not direct treatment, but provides a level of prognostic 
information, and then finally regions that are not currently required for testing. My 
views on this are described below: 
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Mandatory regions for testing: 
Adverse IGH rearrangements  
Specifically this relates to the adverse IGH rearrangements seen in >5% of cases i.e. 
t(4;14) IGH-FGFR3 and t(14;16) IGH-MAF. If an IGH breakapart probe is used, then 
the sample must be further assessed (either simultaneously or sequentially) for both 
IGH-FGFR3 and IGH-MAF. IGH/FGFR3 dual colour dual fusion probes can also be 
considered for the front-line screen. The IGH-MAFB rearrangement is not currently 
considered in this group due its very low frequency, and I have included this in the 
‘recommended’ regions for testing. 
TP53 deletion 
Deletion of chromosome 17p (including the TP53 gene) remains the most significant 
prognostic marker and must be included as part of a genetic testing strategy. 
1q gain and 1p loss  
Both 1q gain and 1p loss are prognostically significant, and I, therefore, consider that 
they should be included as part of a diagnostic panel. The adverse prognostic impact 
of 1q amplification (i.e. >4 copies) has been reported to be stronger than gain of 1q 
(i.e. 3 copies) and therefore, the number of additional copies of the long arm of 
chromosome 1 should be reported. Loss of 1p is currently considered to be poor 
prognosis but less powerful than the prognosis associated with 1q 
gain/amplification. However, the FISH testing for these regions utilises the same 
probe in the majority of cases and therefore can be considered together when 
testing.  
 
Recommended regions for testing: 
Other IGH rearrangements  
An extended panel to assess IGH rearrangement partners may include testing for 
t(11;14) IGH-CCND1, t(14;20) IGH-MAFB and t(6;14) IGH-CCND3. IGH-MAFB is 
considered a high risk IGH rearrangement but is seen at a very low frequency (1-2%) 
in myeloma patients. 
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Hyperdiploidy  
Hyperdiploidy is generally considered a standard risk prognostic marker and can be 
confidently assessed using a 3-chromosome combination of probes (chromosomes 5, 
9 & 15). The presence of two of the three chromosomes is a highly specific indicator 
of hyperdiploidy. 
MYC rearrangement  
MYC rearrangements have recently been shown to be a marker of poor prognosis 
irrespective of the fusion partner, and could be considered as part of a genetic 
testing panel38,49. MYC rearrangements are seen in 15% of diagnostic patients and 
are associated with disease progression. Recent UK myeloma trials suggest that MYC 
rearrangement can be considered as strongly prognostic as TP53 deletion, and based 
on this, I would suggest that this region is likely to become a mandatory region for 
testing in the near future. 
 
Regions of testing that are not currently required: 
Chromosome 13 deletion 
Chromosome 13 deletion / monosomy, and loss of other loci such as 12p, 8p, 14q, 
16q and 22q are not considered to be prognostically or therapeutically useful and 
are, therefore, not required to be part of a genetic testing strategy. It should be 
noted, however, that a number of these regions are included in the commercially 
available myeloma MLPA assay. 
Gene mutation 
Mutational assessment in myeloma currently remains in the research / trials arena. A 
number of gene mutations have been associated with favourable and negative 
impacts on survival, and others may confer specific treatment regimens. I would 
consider that this area of testing is likely to change in the very near future and is 




In 2018, NHS England reconfigured the genomics services creating seven genomics 
laboratory hubs (GLH) across England resulting from a collaboration of a number of 
the existing NHS diagnostic testing laboratories. This aim of this reconfiguration, as 
well as efficiency savings and financial savings is to introduce an element of 
consistency to the diagnostic genomics testing across England to remove the so 
called ‘postcode lottery’.  As part of this reconfiguration a Genomics Test Directory 
has been produced which details the genomic testing that NHSE consider should be 
available, and in turn what they will consider funding.  
Myeloma genomics testing is recognised as part of the new NHSE test directory and 
covers an extensive list of abnormalities for assessment. Detailed below are the 
suggested regions for testing for myeloma from the most current Test Directory 
published in January 2019: 






The test directory states that these abnormalities could also be detected using an 
NGS fusion panel even though IGH rearrangement is technically difficult using NGS 
panels. There is also a FISH test listed for IGH rearrangement testing to cover the use 
of a breakapart probe. 
FISH for copy number changes of: 
 Hyperdidploidy 
 CDKN2C (deletion of 1p) 
 CKS1B (gain of 1q) 
 TP53 deletion 
The test directory currently makes no reference to MLPA or indeed array analysis as 
an alternative methodology for copy number detection, however recent discussions 
have concluded that other technologies considered equivalent are valid alternatives. 
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Multi-target NGS panel for: 
 KRAS, NRAS, BRAF, TP53, DIS3, FAM46C & IRF4 
The test directory has been contributed to by a range of personnel both as experts in 
their field, and scientists and clinicians from both diagnostic laboratory and research 
settings. However, it is also acknowledged that there are errors and inconsistencies 
in the test directory and that it has not been through the rigorous assessment 
initially hoped for. It is recognised that the test directory will ‘direct’ the testing that 
will be available and more importantly determine testing that will be funded from 
NHSE. In the last few months, three ‘expert working groups’ have been set up to 
review and manage changes to the test directories. These three groups will cover 
one each of the three test directory areas; rare disease, cancer and a newly formed 
pharmacogenomics section. I am now part of this cancer expert working group. 
These changes can be seen as removing a degree of autonomy over the testing 
strategies employed by different laboratories. The test directory proposals are not 
entirely consistent with the proposals suggested here, although it is mostly 
consistent. The test directory tests are considered mandatory in part, although NHSE 
recognise that laboratories are not currently reaching the levels set. The test 
directory goes as far as including a mutation panel for myeloma when this is not 
employed by any diagnostic centres in the UK. There is no real consensus for the 
genes to be included in a mutation panel, although a panel of genes has been 
proposed by Walker et al which would include 13 significantly mutated genes which 
included, KRAS, NRAS, TRAF3, TP53, FAM46C, DIS3, BRAF, LTB, CYLD, RB1, HIST1H1E, 
IRF4 and MAX38, the test directory includes a set of seven genes excluding some 
genes that have been associated with a poorer outcome. The test directory also 
covers the five IGH rearrangements irrespective of their prognosis or their 
frequency, but does not include assessment of the MYC gene which is known to be 
associated with disease progression. 
With regard to the technologies and the targets for assessment that we have 
discussed here, the following process detailed in figure 3.34 would be an example of 
how to implement this proposed strategy: 
 
 
Figure 3.34: To describe a proposed genetic testing strategy for myeloma at diagnosis. 
Whilst completing this work, and through my involvement with GenQA, I have been 
part of a group who have written and published ‘European recommendations and 
quality assurance for cytogenomic analysis of haematological neoplasms’ in 
Leukemia in 2019123. I specifically wrote the section devoted to myeloma.  This 
raised the need for specific myeloma laboratory guidelines, which are currently 
being prepared and we hope to publish. These guidelines would cover the targets 
required as discussed in the general guidelines, but also cover in more detail the 
technologies that could be employed. There are disease specific concerns that could 
also be covered, such as whether to limit testing to myeloma patients or whether 
MGUS patients would also benefit, whether follow up genetic testing is appropriate 
or whether this would be better managed with flow cytometry, the age of patients 
to be tested, the requirement for testing specific cell selections, and understanding 
the consequences and how to manage reporting if this is not possible. The 
recommendations also cover how to report these, sometimes, complex results and 
discusses appropriate turnaround times and quality assessment. 
Whilst the proposed testing strategy is appropriate for the current timepoint both 
from the perspective of the diagnostic laboratories and the way in which genomic 
information is used in the treatment and clinical management within UK guidelines, 
it is perhaps useful to consider a more forward thinking and future approach to the 
genomic diagnosis of myeloma. Gene expression signatures (sometimes known as 
the SKY92 signature based on the assessment of a 92 gene classifier developed using 
RNAseq data) have recently been shown to robustly identify a group of high-risk 
patients with myeloma124. The clinical validity was validated in two independent UK 
trial datasets as well as multiple other international datasets. Data from MRC 
Myeloma IX and XI furthermore demonstrated that the test identifies 10% of 
patients with short progression free and overall survival that were not identified by 
genetic tests described on the current testing strategy. This could inform treatment 
intensification decisions based on current trials but would require NICE approval to 
be included in standard clinical practice. 
It could be considered that testing for these gene expression profiles (SKY92) 
alongside low coverage WGS and WES could provide information on IGH 
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rearrangements & copy number changes (from low coverage WGS), mutational 
profiling (from the WES or RNAseq) and high-risk gene expression profile (from the 
SKY92 expression data) would provide a future proof risk assessment genomic 
strategy. Although highly informative, this would require a step change for the 
diagnostic genetic laboratories, as currently neither gene expression profiling nor 
WGS is offered outside of the research realm. 
 
In summary, this chapter describes the introduction and validation of a CD138+ve 
magnetic cell separation assay for all samples received from myeloma patients. The 
patient cohort included samples from 101 patients in total, 91 were karyotyped, 101 
were FISHed using a small panel, 45 had MLPA analysis, 36 were processed using the 
Affymetrix DNA array. A bespoke NGS gene panel analysis was designed covering 
both a myeloma gene panel and the ‘osteome’ panel which covered a number of 
bone related genes, and 24 paired patient tumour sample and germline blood were 
assessed using this technology. 
This chapter describes the results seen using the five different technologies and 
assesses the pros and cons for each technology. This information has been used 
alongside information taken from the literature and the new NHSE test directory, to 
devise a proposed genetic testing strategy for myeloma patients informing best 
practice recommendations. This demonstrates the importance of translational 
research in direct patient impact in the shaping of services offered to patients 
through our NHS system. The results pertaining to the osteome work will be 
presented in Chapter 4.  
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Chapter 4: NGS Analysis of the Osteome in Myeloma 
Introduction 
Bone disease is a key feature of plasma cell myeloma, and is seen in 67% of patients 
presenting with plasma cell myeloma, and up to 90% of patients with myeloma 
exhibit bone related complications at some stage of their disease125,126.  
Osteoclasts and osteoblasts are cells which work in tandem in the bone marrow and 
are responsible for the constant renewal and remodelling of the skeleton. 
Osteoclasts are responsible for resorbing and breaking down the bone matrix, and 
osteoblasts rebuild the bone matrix. Osteocytes are mature osteoblasts which 
become trapped in the matrix they have rebuilt. Neoplastic plasma cells secrete 
osteoclast activating factors and osteoblast deactivating factors, resulting in 
increased numbers and activity of the osteoclasts and a decrease in the number and 
activity of the osteoblasts. This imbalance between the osteoblasts and osteoclasts 
disrupts the normal balanced process of physiological bone remodelling, leading to 
accelerated osteoporosis and the development of lytic lesions and osteolytic bone 
disease. The resulting bone lesions are considered a marker of end organ damage, 
and therefore a criterion for the definition of a diagnosis of plasma cell myeloma1,2.  
Consequences of osteolytic bone disease are often seen as the presenting features 
of myeloma, and skeletal disease can manifest in a number of ways; this can be as 
generalised bone loss (osteoporosis) or focal lytic lesions. These can both lead to 
pathological fractures, spinal cord compression or collapse and hypercalcaemia. Less 
critical symptoms such as backache or bone pain are also seen. Myeloma bone 
disease can cause severe morbidity in myeloma patients leading to distressing pain, 




Figure 4.1: Radiological manifestations of myeloma bone disease. Image i) shows an X-ray of a classical ‘pepper 
pot’ skull in myeloma. Images ii) & iii) show X-ray images of lytic lesions and a pathological fracture 
respectively in the left arm. iv) & v) show a large lytic lesion in the patients left femur, which is then 
subsequently pinned. Images vi) and vii) demonstrate an osseous plasmacytoma leading to vertebrae 
destruction and spinal cord compression. Image viii) shows and MRI of a large plasmacytoma in the lower 
mandible destroying a large portion of the mandible and image ix) shows a fracture of the femur. Images used 
thanks to Dr Andrew Chantry. 
 
The aim of treatment for myeloma can be considered threefold: 
• To reduce the myeloma tumour burden or the bulk of disease 
• To prevent and treat bone and tissue damage 
• To improve quality of life and survival 
With regard to the bone disease, treatment remains a substantial clinical problem 
with frequent catastrophic manifestations. Current strategies for managing and 
treating myeloma bone disease achieve some success in the prevention of 
subsequent skeletal events, but do virtually nothing to repair the damage that may 
already be present. Bisphosphonates are an important class of drugs, which are used 
to treat bone manifestations in myeloma, in fact myeloma bone disease treatment 
continues to rely almost exclusively on bisphosphonate therapy. Bisphosphonates 
are absorbed by macrophages (the cells from which osteoclasts are derived) and by 




i.	 ii.	 iii.	 iv.	 v.	
vi.	 vii.	 viii.	 ix.	
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reducing elevated bone resorption associated with myeloma. The most commonly 
used bisphosphonate in myeloma is zoledronic acid. A series of trials were 
undertaken using different bisphosphonates, the MRC Myeloma IX trial127 showed 
significant benefit of treating with zoledronic acid, measured by the number of 
skeletal related events and overall survival. Bisphosphonates are also the most 
commonly prescribed drugs used to treat osteoporosis. There are advantages and 
disadvantages in using bisphosphonates; it is a relatively cheap treatment, but 
requires intravenous administration. It can cause renal problems; renal function is 
already compromised in myeloma patients so requires careful monitoring. There are 
side effects including flu like symptoms, bone, joint or muscle pain and a risk of 
osteonecrosis of the jaw (seen in 3.5% in MRC Myeloma IX trial)127,128 which can be 
extremely difficult to manage clinically. There remains little consensus in the 
management of bisphosphonate treatment; some patients are treated early to 
prevent bone manifestations, some receive indefinite treatment based on the 
proven survival advantage, others have breaks in treatment coinciding with 
remission (quiescent disease states) and some receive very little treatment based on 
the side effect concerns89.    
Treatment of myeloma bone disease has relied almost exclusively on the use of 
bisphosphonates which work in an anti-resorptive manner (by inhibiting osteoclasts), 
but attention has begun to be focussed on anabolic therapies which act to promote 
bone formation through enhancement of osteoblastic activity. Anabolic therapies 
are widely used in osteoporosis, with a range of therapies available such as 
parathyroid hormone (PTH) and its analogues, romosozumab (a sclerostin 
neutralising antibody) and a number of newer, more experimental drugs88,90. 
Currently, these treatments are less frequently used for bone disease in myeloma, 
although it is likely that their use will impact myeloma management also. 
A number of additional targets associated with signalling pathways including 
RANK/RANKL/OPG, WNT, TNF and Notch, and specific signalling molecules such as 
DKK1, sclerostin, periostin, osteopontin, TGFβ84,85 and activin A86 amongst others, 
known to be implicated in myeloma and its associated bone disease are also being 
explored39,83. 
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A promising agent targeting the RANK/RANKL/OPG pathway is denosumab, which is 
able to prevent RANK activation, and subsequent osteoclast activation39. Inhibition 
of the deregulated WNT pathway is also demonstrating some encouraging results 
with the use of WNT pathway inhibitors such as anti-sclerostin39, anti-DKK139,87. 
Objective two of this thesis was to explore and assess the hypothesis that 
relationships exist between the genetic mutations associated with bone related 
genes (the osteome) and the likelihood or extent of myeloma related bone damage. 
The ability to highlight a cohort of patients who may be considered at risk of a severe 
bone phenotype associated with their myeloma, or to predict those patients likely to 
benefit from treatment, may allow the opportunity to treat more proactively with 
early or extended bisphosphonate treatment to slow the advancement of the bone 
manifestations, or may identify patients who would benefit from treatment with 
anabolic agents. It may also be possible to speculate that a more personalised 
medicine approach could be adopted matching specific novel anabolic agents to the 
abnormalities detected in the osteome panel.  
 
Materials and Methods 
The materials and methods for this chapter have previously been described in 
Chapter 2 as part of the Next Generation Sequencing section. Although this chapter 
aims to assess different questions and relates to the osteome genes included in the 
panel, the NGS panel was designed as a single entity and processed as a single panel, 
using the same cohort of patients and under exactly the same conditions. 
The bone related genes included in the panel were derived from a process of 
literature review and discussion with the SMaRT (Sheffield Myeloma Research Team) 
as bone disease in myeloma patients is a particular interest of this group. A starting 
point for selecting genes to include in the osteome NGS panel was a review paper 
covering bone manifestations in myeloma published by Walker et al89 from the 




SMaRT NGS Osteome Probe Panel  
ACVR1 AKT1 CCL3 CCL4 CCR1 CCR3 CDH2 CER1 CSF2 CTNNB1 
DCN DKK1 DKK2 FRZB FZD1 FZD2 FZD3 FZD4 HGF ICAM1 
JAG1 KREMEN1 KREMEN2 LRP5 LRP6 MET MMP9 NOG NOTCH1 POSTN 
RUNX2 SDC1 SFRP1 SFRP2 SFRP4 SMAD2 SMAD3 SMAD4 SMAD7 SOST 
TAZ TGFB1 TGFB2 TGFB3 TNF TNFRSF11A TNFRSF11B TNFRSF13B TNFSF11 TNFSF12 
TNFSF13 TNFSF13B VCAM1 VEGFA WIF1 WNT10A WNT10B WNT3 WNT3A WNT5A 
Table 4.1: Detailing the genes included in the bespoke NGS panel covering the ‘osteome’ - bone related genes. 
 
Walker et al describe a series of osteoclast activating factors, osteoblast inhibitory 
factors and adhesion molecules associated with myeloma bone disease89. A number 
of osteoclast activating factors have been described and identified including 
interleukin-6 / 1β / 3, macrophage inhibitory protein 1α (HUGO (Human Genome 
Organisation) gene name CCL3), tumour necrosis factor α (TNF), hepatocyte growth 
factor (HGF) and vascular endothelial growth factor (VEGFA). CCL3 is a chemotactic 
cytokine which can attract amongst other cells, osteoclasts and induces activity via 
ATK and MAPK pathways. TNF is potent upregulator of interleukin 6, it is able to 
induce osteoclast development in conjunction with RANKL and can prevent 
osteoblast maturation via downregulation of RUNX2 and TAZ. Osteoblasts produce 
interleukin 3 and granulocyte-macrophage colony stimulating factor (CSF2). IL3 is 
thought to increase osteoclastogenesis through interaction with activin A (ACVR1). 
CCL4 is also a chemotactic cytokine closely related to CCL3; the CCL4 gene produces 
the macrophage inhibitory protein 1β. These cytokines work through interaction 
with a number of chemokine receptors including CCR1 and CCR389. Many of these 
activating factors are associated with the NFκB pathway, specifically the receptor 
activator of NFκB (RANK, also known as TNFRSF11A), its ligand (RANKL, or TNFSF11) 
and its inhibitor, osteoprogerin (TNFRSF11B). These genes as well as other members 
of the TNF family of genes; TNFRSF13B, TNFSF12, TNFSF13 & TNFSF13B were also 
included in the gene panel. 
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Conversely, a series of factors have been shown to be osteoblast inhibitory factors, 
which include hepatocyte growth factor (HGF), transforming growth factor β1 
(TGFB1) and the WNT signalling inhibitors; Dickkopf 1 (DDK1), soluble frizzled-related 
protein 3 (FRZB) and sclerostin (SOST). These have been shown to be produced by 
bone marrow stromal cells and some malignant plasma cells. Plasma cells also 
express the HGF receptor (MET) which binds to HGF driving proliferation of 
malignant plasma cells and inhibition of apoptosis via the RAS pathway. MET also 
regulates osteoclast development and inhibition of osteoblast differentiation. There 
are two other closely related members of the transforming growth factor β family 
(TGFB2 and TGFB3). These TGFB family proteins tightly regulate the SMAD proteins 
which act as transcription factors: SMAD2, SMAD3, SMAD4 and SMAD789. Decorin 
(DCN) is also known to interact directly with the TGFB1 protein, and all these genes 
were also included as part of the osteome panel. 
The WNT signalling pathway influences osteoblastogenesis; the WNT proteins bind 
to cell surface receptors made up of a complex of LRP5/LRP6 and frizzled 
transmembrane proteins (FZD1-4), and this complex in turn induces a cellular 
cascade preventing phosphorylation of beta-catenin (CTNNB1) and preventing its 
breakdown. There are a number of endogenous inhibitors of this pathway which 
include the secreted frizzled proteins (SFRP1, SFRP2 & SFRP4), WNT inhibitory factor 
1 (WIF1) and the dickkopfs (DKK1 and DKK2). For the dickkopfs to work in an 
inhibitory fashion, DKK1 protein binds LRP6 and KREMEN1 & KREMEN2 proteins to 
create a complex that causes internalisation of the WNT receptor. Other members of 
the WNT signalling pathway were included; WNT10A, WNT10B, WNT3, WNT3A and 
WNT5A. Cerberus (CER1) is a cytokine associated with the WNT pathway and has the 
effect of inhibiting the bone morphogenic protein (BMP) activity. 
Malignant plasma cells are known to occupy the same bone marrow niches that 
normal quiescent state plasma cells occupy before differentiation. The normal 
interactions between the quiescent plasma cells and the bone marrow niches are 
likely to be mediated by chemotactic factors and adhesion molecules.  
Many of these factors have also been implicated in aspects of myelomagenesis, as 
well as disease proliferation, treatment resistance and, through their association 
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with osteoblast and osteoclast activity, myeloma-related osteolytic disease. These 
adhesion molecules include integrins (for example, vascular cell adhesion molecule 
1, VCAM1 and intercellular adhesion molecule 1, ICAM1) and syndecan 1 (SDC1), 
which have been shown to have a role in malignant plasma cell proliferation and cell 
adhesion-mediated drug resistance129. There are also studies assessing the role of 
other adhesion molecules such as Notch-1 (NOTCH1), Jagged-1 (JAG1) and N-
cadherin (CDH2). Expression of these genes has been shown to be greatly increased 
in patients with myeloma and indeed MGUS, and their role in proliferation in early 
myelomagenesis has been suggested89,130. The serine-threonine protein kinase 
encoded by the AKT1 gene is also known to have a role in cell migration and was also 
included in this gene panel. 
Finally, three genes with specific bone or tissue related functions were included. 
Periostin is a protein encoded by the POSTN gene. Periostin binds to integrins which 
support adhesion and migration of epithelial cells. This protein plays a role in cancer, 
when periostin binds to the integrins on cancer cells, activation of specific pathways 
leads to increased cell survival and promotes invasion, metatasis and 
angiogenesis131. The NOG gene encodes the Noggin protein, which is involved in the 
development of many tissues, NOG is required for osteoclast accumulation in normal 
skeletal development. NOG has also been shown to mediate breast cancer 
metastatic bone colonization by osteoclast differentiation132. The MMP9 gene 
encodes for one of the matrix metalloproteinase family. It has a normal function in 
tissue remodelling through the breakdown of the extracellular matrix. It has also 
been implicated in cancer pathology involved metastasis and tissue invasion133. 
DNA samples (from both CD138+ve cells from the bone marrow and from blood 
lymphocytes) from 24 patients were processed and analysed using the NGS panel. Of 
those patients, five patients were asymptomatic myeloma (aMM), 18 patients were 
myeloma, and one patient was a relapsed myeloma (rMM), as detailed in table 4.2. 



















Table 4.2: Demonstrating the samples processed and analysed using the NGS osteome panel. Twenty four 
patients were processed; five patients were asymptomatic myeloma (aMM), 18 were newly diagnosed 
myeloma (MM) and one patient had relapsed myeloma (rMM). The cohort was split evenly into those that had 
bone lesions and those that did not. 
 
Table 4.3 details the type of bone lesions seen in those patients with bone lesions, 
and these range in number from one lesion to multiple and include lesions of the 
vertebrae, ribs, femur, hips and pelvis, as well as cord compression. The table also 
indicates the gender, ethnicity, diagnosis and the percentage of plasma cells 













#140 Male British Myeloma 3 
Lesion at L5, 
T12 and in the 
9th rib 
15% 
#144 Male British Myeloma multiple 
Multiple lytic 




#88 Male British Myeloma 0   40% 
#161 Male British Myeloma 0   75% 





#44 Female British rMM 2 
Sternal lytic 
lesion and 
one in rib 
56% 
#179 Male British Myeloma 0 
2 tiny queries 
on the R hip 
35% 
#180 Female British Myeloma >5 
3/5th rib. T5. 
L1 & L2 and 
pelvic bone 
20% 




#191 Female Caribbean Myeloma 2   25% 
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#198 Male British Myeloma 0   70% 
#200 Female British Myeloma 1 
Left 8th rib 
plasmacytoma 
50% 




#202 Male British Myeloma Multiple 
L3 / pelvis / 
ribs 
20% 
#209 Female Caribbean aMM 0   14% 
#208 Female British Myeloma 0   12% 
#215 Male African aMM 0   36% 
#217 Male British Myeloma 0   24% 
#230 Male British Myeloma 0   45% 
#232 Male British aMM 0   17% 
#233 Female British aMM 0   45% 
#235 Male British aMM 0   42% 




Table 4.3: Samples processed using the osteome NGS panel with additional details of the gender, the ethnicity, 
the disease classification, and the percentage of plasma cells. The number and type of bone lesions seen are 
also detailed demonstrating an even split (twelve samples each) in the bone lesion vs non-bone lesion cohorts. 
 
Results 
As previously described, the NGS panel applied in this project was designed as a 
single panel of 139 genes, but is essentially split into two functional panels from an 
analytical point of view; the myeloma gene panel with 79 genes and the osteome 
bone gene panel with 60 genes. The samples were processed as pairs, DNA from the 
bone marrow CD138+ve cell selected sample to represent the tumour (myeloma) 
and DNA from a blood sample, which represents the patients’ germline DNA. The 
analysis process is exactly as described in Chapter 3, in which a bioinformatics 
pipeline was employed to assess the variants seen and assign a likelihood of 
pathogenicity based on a consensus of the three main tools applied. Lists of both 
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somatic and germline variants were produced, which included further annotation 
with ClinVar and ExAC allele frequencies and could be divided into the two individual 
panels. Details relating to the performance and quality of the panel, such as the 
mapped and paired reads, coverage and gaps in coverage, are presented in Chapter 
3. The variants associated with the osteome panel are presented here. 
The first part of the analysis assessed the variants observed in the germline samples 
in order to pick up potential variants in bone genes that are part of the constitutional 
genetic make-up and therefore potentially providing a predisposition to bone related 
manifestations associated with myeloma. The numbers of variants called in the 
germline samples following analysis through the bioinformatics pipeline were large 
and additional manual selection analysis was required to prioritise variants for 
analysis. Table 4.4 details the number of variants at each stage of the process of 
variant selection. Column two shows the total number of germline variants called by 
the bioinformatic pipeline which includes single nucleotide variants (SNVs) events, 
that could be either synonymous or non-synonymous, and small insertion or deletion 
(indels) events. The average number of germline variants was 188.7 per patient 
(range 172-200). The first filtering step involved selecting variants in those genes 
included in the osteome panel and this was recorded in column three ‘osteome only 
variant count’. The average number of germline variants seen within the osteome 
genes was 66.1 per patient (range 59-73). The next selection step excluded those 
variants seen outside of the coding regions of the osteome genes and the variant 
number was recorded in column four ‘coding only’. The average number of variants 
seen in coding regions of the osteome panel genes was 18.3 per patient (range 10-
26).  The numbers of variants per individual at each stage was remarkably similar 
with a small range in number. Then finally the ExAC population frequencies were 
used to exclude those mutations seen at a high level in the population and therefore 
most likely to be considered polymorphisms. Population frequencies differ across 
different populations explaining the need to know the ethnicity of the patient. 
Additionally, ethnicity has a particular bearing on myeloma analysis as it is known to 
be a disease with a higher frequency in black people than in people of Asian or 
Caucasian descent (ratio ~2:1)1,5. The African/American ExAC population frequency 
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was used in the three patients (#191, #209 and #215 marked with an * in the ExAC 
frequency column) known to fit this ethnicity group. The average number of variants 
per patient following the full additional filtering is 3.0 (range 0-6). 
Following this described series of filtering, the variants could then be classified 
according to their pathogenicity. This was based on the use of three bioinformatic 
tools designed to assess the likelihood of associated pathogenicity; mutect2, strelka 
and vardict. Those variants considered ‘pathogenic’, ‘risk’ or ‘conflicting’ (where the 
evidence seen included either ‘pathogenic’ or ‘risk’ information) have been 
highlighted in blue. Variants were also classified as ‘benign’ or ‘likely benign’, or as 
VUS (variant of unknown significance). NA (not applicable) was also used where 
there was not enough evidence to classify the variants, and in this scenario were 
considered to be equivalent to the VUS category. 
Nine variants were classified as Pathogenic, Risk or Conflicting (described here as a 
group of risk variants) and these were seen across six genes. Three variants were 
described in the gene, WNT10A, two variants in MET and one variant in each of 



















#44 193 66 13 1 FRZB NA 
#88 178 59 26 6 FZD4 Pathogenic 
     
TNFSF11 Likely Benign 
     
CCL3 NA 
     
CDH2 NA 
     
MMP9 Likely Benign  
     
MMP9 NA 
#136 189 66 21 2 DKK2 NA 
     
SMAD3 Likely Benign 
#140 183 63 10 3 TNFRSF11A VUS 
     
ICAM1 Risk 
     
TGFB1 Benign 
#144 186 64 17 4 SDC1 NA 
     
WNT10B NA 
     
HGF Likely Benign 
     
LRP5 Likely Benign 
#161 194 69 19 2 NOTCH1 Benign 
     
POSTN NA 
#162 179 68 18 3 LRP5 Likely benign 
     
MMP9 Likely benign 
     
MMP9 NA 
#179 191 67 13 1 SDC1 NA 
#180 183 65 20 5 TGFB2 VUS 
     
WNT10A VUS 
     
NOTCH1 NA 
     
CDH2 NA 
     
LRP5 Likely benign 
#184 193 69 20 0 
  
#191 196 68 18 3* NOTCH1 Benign      
LRP6 NA      
TNFRSF13B NA 
#198 200 71 18 4 WNT10A VUS 
     
HGF Likely benign 
     
NOTCH1 Likely benign 
     
POSTN NA 
#199 183 60 15 1 CDH2 NA 
#200 180 62 19 3 TGFB2 Conflicting 
     
CDH2 NA 
     
ICAM1 NA 
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#202 189 69 22 5 CCR3 NA 
     
CCR3 NA 
     
FZD1 NA 
     
MET Conflicting 
     
SOST VUS 
#208 200 73 20 2 MET Likely benign 
     
FZD4 Likely benign 
#209 198 65 19 2* MET NA      
TNFRSF11A NA 
#215 199 63 21 4* VEGFRA NA      
TNFSF13B NA      
SMAD7 NA      
JAG1 Benign 
#217 195 67 21 3 FRZB NA 
     
WNT10A Conflicting 
     
MET Conflicting 
#230 190 73 20 2 LRP5 Likely benign 
     
FZD4 Likely benign 
#232 185 69 19 5 WNT10A Conflicting 
     
NOG Conflicting 
     
TGFB1 Benign 
     
POSTN NA 
     
CDH2 NA 
#233 172 61 18 6 FRZB NA 
     
CDH2 NA 
     
WNT10A Conflicting 
     
TGFB1 Benign 
     
FZD4 Benign 
     
NOTCH1 Benign 
#234 Sample Failed NGS Analysis 
   
#235 185 64 15 2 HGF Benign 
     MET VUS 
Table 4.4: Detailing the germline results seen as part of the NGS osteome panel. Twenty-four samples were 
processed and 23 gave a result. Multiple variants were detected in the germline samples and these were 
manually filtered to give variants seen in the coding regions of the osteome genes with a population frequency 
of less than 0.05. The appropriate population frequency was applied, three patients were assessed using the 
African/American population frequency, marked with an *. The variants following this additional filtering were 
then assigned a pathogenicity classification using bioinformatic tools; Pathogenic, Risk, Conflicting, VUS 
(variant of unknown significance), Likely Benign, Benign and NA (not applicable). The NA group was used 
where there was not enough evidence to assign a specific category and for the purposes of this analysis these 
were considered in the same category as the VUSs. Those falling into the Pathogenic, Risk or Conflicting 




Of the 23 patients with results from the NGS panel, the nine variants classified as risk 
variants in the osteome genes were seen in seven patients (30.4%). A single patient 
showed no variants. Of this list, a number of potentially druggable targets were 
noted, including TGFB1, TGFB2, DKK2, SDC1 and HGF, raising the potential as 
discussed previously of a more personalised medicine approach to treatment. 
Of the seven patients with risk variants, two patients showed two variants and five 
patients showed a single variant and are detailed in table 4.5. Of these seven 
patients, five patients were classified as myeloma and two patients were 
asymptomatic myeloma. Three patients were part of the patient cohort with bone 
lesions and four were patients with no bone lesions. 
Excluding those variants classified as ‘conflicting’ within the appropriate population 
frequency assessment, left a group of only two variants assessed as Pathogenic or 
Risk (considered here as high-risk variants). These two high risk variants were seen in 
two genes; ICAM1 and FZD4 and seen in two patients (#88 and #140). These patients 
were both classified as myeloma, but one patient belonged to the patient cohort 
with bone lesions and the second patient was part of the non-bone lesion cohort. 
These two high risk variants were assessed using the tools available through Alamut 
to provide a more in depth and what would be considered as a ‘diagnostic’ 
interpretation level; both are considered variants of unknown significance (VUS), 
once again demonstrating that the variant calling tools used within the 
bioinformatics pipeline err towards the more pathogenic end of the scale. The FZD4 
variant has a number of indications suggesting pathogenicity, but the ICAM1 variant 





















#88 FZD4 Pathogenic 
c.766A>G 
p.Ile256Val 0 MM 
#140 ICAM1 Risk 
c.167A>T 
p.Lys56Met 3 MM 
#200 TGFB2 Conflicting  1 MM 
#202 MET Conflicting  Multiple MM 
#217 WNT10A Conflicting  0 MM 
  MET Conflicting      
#232 WNT10A Conflicting  0 aMM 
  NOG Conflicting      
#233 WNT10A Conflicting  0 aMM 
Table 4.5: Detailing those patients with risk variants, the gene involved, the disease classification and the 
number of bone lesions seen in the patient (i.e. whether they belong to the bone lesion vs no bone lesions 
cohort). 
   
For completeness, somatic changes seen in the osteome NGS panel genes were also 
assessed. These represent additional changes seen in the osteome present as part of 
the tumour, i.e. only seen in the DNA of the plasma cells. These changes are detailed 




Numbers Gene Effect HGVS.c / HGVS.p 
#161 1 TNF 
downstream gene 
variant c.*4020A>G 
#209 1 NOTCH1 synonymous variant 
c.2703G>A 
p.Gly901Gly 
Table 4.6: Detailing those patients with somatic variants detected in the osteome genes, the number of 
variants, the gene involved, the likely effect and HGVS nomenclature for both the DNA and protein change 
(where appropriate). 
 
Two variants were detected, one in each of two patients in the cohort. The variants 
were seen in the genes TNF and NOTCH1. Neither variant is considered pathogenic; 
the TNF variant is a downstream variant resulting in no protein change, and the 
NOTCH1 variant is synonymous, meaning that the base substitution results in no 
change to the protein, in this case a glycine is replaced with a glycine. Both patients 
#161 and #209 belong to the non-bone lesion cohort. 
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Discussion 
Bone disease associated with myeloma is a key feature of the disease. It is associated 
with 67% of patients at diagnosis, but up to 90% of patients have some bone related 
complication through the course of their disease125,126. Treatment of these bone 
manifestations in myeloma remains a clinical problem. Bisphosphonates are an 
important class of drugs used for the treatment of myeloma bone disease, and 
although some success is seen in the prevention and protection from further skeletal 
events, little can be done to repair or reverse the already existing bone damage. This 
poses the question of whether bisphosphonates should or could be used as a 
preventative measure, i.e. treating patients before the bone disease is present or as 
early as possible following evidence of bone disease. However, although 
bisphosphonate treatment has the advantage of being cheap, it has a number of 
disadvantages including the requirement for intravenous administration, and side 
effects including renal damage (which is particularly problematical in myeloma 
patients who already have issues related to renal function), flu-like symptoms, bone, 
joint or muscle pain and a risk of osteonecrosis of the jaw which can be extremely 
difficult to manage clinically. Guidelines for the use of bisphosphonates are currently 
vague, and therefore patients can receive indefinite bisphosphonate treatment, but 
others receive very little, in part as a result of these disadvantages. Anabolic agents 
act to promote bone formation through enhancement of osteoblastic activity and 
have been shown to have a positive effect in osteoporotic and myeloma patients. 
However, although anabolic therapies are widely used in osteoporosis, with a range 
of therapies available such as parathyroid hormone (PTH) and its analogues, 
romosozumab (a sclerostin neutralising antibody) and a number of newer, more 
experimental drugs88,90, currently, these treatments are less frequently used in 
myeloma management. 
Objective two of this thesis was to explore and assess the hypothesis that 
relationships exist between the genetic mutations associated with bone related 
genes and the likelihood or extent of myeloma related bone damage. This proposed 
relationship could even go so far as to predict those patients who would be more 
likely to benefit from early or extended bisphosphonate treatment or the use of 
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more novel anabolic agents for their osteolytic disease. Highlighting a cohort of 
patients who may be considered at risk of a severe bone phenotype associated with 
their myeloma at diagnosis may offer the opportunity to treat more proactively and 
slow the advancement of the bone manifestations.  
The genes included as part of the osteome NGS panel were derived from a process 
of research and discussion with the SMaRT (Sheffield Myeloma Research Team) as 
bone disease in myeloma patients is a particular interest of this research group. 
Although the NGS Myeloma and Osteome panels have been presented as separate 
panels for the purpose of data analysis and results discussion, the NGS panel was 
created as a single panel of 139 genes, 60 of these being genes associated with the 
osteome. Twenty-four patients were processed and analysed using the NGS panel. 
Of those patients, five patients were classified as asymptomatic myeloma (aMM), 18 
patients had myeloma and one patient had relapsed myeloma (rMM). Twelve 
patients demonstrated bone lesions, and 12 patients did not. The bone lesions 
ranged in number from one lesion to multiple and include lesions of the vertebrae, 
ribs, femur, hips and pelvis, as well as cord compression.  
The samples were processed as pairs, DNA from the bone marrow CD138+ve cell 
selected sample to represent the tumour (myeloma) and DNA from a blood sample, 
which represents the patient’s germline sample. The quality metrics associated with 
the NGS run are reported and discussed in Chapter 3, as the osteome NGS panel was 
simply part of the full NGS panel the quality metrics for this part of the work are 
exactly the same as those reported previously. A single patient failed the NGS 
assessment completely, therefore results were available on 23/24 patients. This 
patient was part of the bone lesion cohort and showed multiple lesions including a 
2cm femur lesion. 
For analysis of the variants associated with the osteome panel, both the germline 
samples and the CD138+ selected plasma cells (the tumour samples) were assessed. 
Somatic changes of the osteome panel associated with the tumour plasma cells were 
assessed, based on the hypothesis that variants seen in these cells may affect genes 
and proteins directly involved in the interaction and communication between the 
plasma cells and the bone marrow niche, resulting in a more severe bone 
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phenotype. Only two somatic variants were detected involving the genes TNF and 
NOTCH1, one in each of two patients. Neither variant would be considered 
pathogenic; the change detected in TNF was a downstream variant, and the NOTCH1 
variant resulted in a synonymous change, so the protein consequences of the 
variants would be nil. Both variants were detected in patients in the non-bone 
phenotype cohort. Based on this experiment no association with somatic changes in 
the osteome panel was detected. 
Germline changes in the osteome panel were assessed based on the hypothesis that 
variants in the genes as part of the patient’s constitutional genetic make-up may 
predispose patients with myeloma to a more severe bone phenotype. As such high 
numbers of variants were called in the germline samples using the bioinformatics 
pipeline, further manual assessment of the variants was performed. Analysis was 
limited to those variants seen in the 60 osteome genes, only those seen in coding 
regions of these genes and then utilising the ExAC population frequencies, only those 
variants at a population frequency of <0.05% using the appropriate population 
frequency data. The average number of variants per patient following the full 
additional filtering is 3.0 (range 0-6). 
The bioinformatic pipeline used a variety of tools to assess the pathogenicity. Those 
variants considered ‘pathogenic’, ‘risk’ or ‘conflicting’ were considered a risk group, 
and those where the variants were ‘pathogenic’ or ‘risk’ only were considered the 
high risk group. Variants were also classified as ‘benign’ or ‘likely benign’, or as VUS 
(variant of unknown significance) or NA (not applicable) where the variants did not 
have evidence to classify them as disease or predisposition causing, these were 
considered low risk variants. 
Nine germline variants were classified as part of the risk group, these variants were 
seen in six genes, three variants in WNT10A, two variants in MET and one variant in 
each of ICAM1, FZD4, TGFB1 and NOG. Of the 23 patients with NGS panel results, the 
nine variants classified as risk variants in the osteome genes were seen in seven 
patients (30.4%). A single patient showed no variants, and the remaining 15 patients 
showed low risk variants. Of the seven patients with risk variants, two patients 
showed two variants and five patients showed a single variant. Of these seven 
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patients, five patients were classified as myeloma and two patients were 
asymptomatic myeloma. Three patients were part of the patient cohort with bone 
lesions and four were patient with no bone lesions. Although it is recognised that the 
sample numbers are low, no association of the number of risk variants was seen with 
the cohort of patients with bone lesions. 
The high-risk variants were also assessed to ensure that the variants with conflicting 
data were not skewing the analysis. Once appropriate populations frequencies were 
applied only two variants were classified as either ‘pathogenic’ or ‘risk’. These two 
high risk variants were seen in two genes; ICAM1 and FZD4 and were seen in two 
patients (#88 and #140).  
Plasma cells are part of the adaptive component of our immune system and are 
required to produce antibodies in response to antigenic assault. Normal quiescent 
plasma cells occupy niches in the bone marrow until this antigenic assault occurs. 
Interactions between the niche and the quiescent plasma cells are likely to be 
mediated by chemotactic factors and adhesion molecules.  The ICAM1 gene encodes 
an intercellular adhesion protein known to be part of these interactions. A number 
of adhesion molecules have been implicated in proliferation, bone disease and even 
treatment resistance. ICAM1 is thought to be part of this group129. 
FZD4 is one of the frizzled transmembrane proteins that make up a cell surface 
complex that WNT proteins are able to bind to. It is part of a complex cascade event 
that influences the production of osteoblasts89. 
Both patients carrying the pathogenic variants were classified as myeloma, but one 
patient belonged to the patient cohort with bone lesions and the second patient was 
part of the non-bone lesion cohort. We were not able to demonstrate any 
association of these high-risk variants with the cohort of patients known to have 
bone lesions. 
Again, based on the large numbers of variants, the assessment of pathogenic vs 
benign status for each variant was taken from the bioinformatic pipeline which 
utilised three tools (mutect2, vardict and strelka) to gather information on this 
status. Within a diagnostic setting, a more rigorous assessment is completed, and it 
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would have been an ideal scenario to have assessed each variant to that level, but 
within the project timescales this would not have been possible. A more in depth 
analysis akin to that utilised in diagnostic laboratories was undertaken on these two 
high risk variants using the tools available through Alamut, and both the FZD4 and 
the ICAM1 variants would be considered variants of unknown significance (VUS). The 
information for the FZD4 variant would suggest it more likely to be pathogenic. The 
amino acid is highly conserved with evidence from ClinVar, dbSNP and Uniprot 
suggesting pathogenicity, but without enough evidence to definitively state it is a 
pathogenic variant. Conversely, the ICAM1 variant involves a weakly conserved 
amino acid, with some evidence suggesting that this could be a polymorphism, but 
again without the strength of evidence to call this.  This information can be found in 
appendix 6.   
As for the somatic variant calling associated with the myeloma gene panel described 
in chapter 3, it seems that the pathogenicity calling tools incorporated in the 
bioinformatics pipeline show a leaning towards over calling the pathogenicity status, 
however, it does not exclude the possibility that important variants have been 
classified at a lower level or within the NA category based on insufficient information 
available within these three databases. 
It is recognised that the number of samples used in this part of the study is small. We 
processed 48 samples which equates to 24 patients with both tumour bone marrow 
samples and control (germline) blood samples. These patients were split into two 
cohorts, those with bone lesions and those with no bone lesions resulting in 12 
patients per cohort. We had one sample fail, belonging to the bone lesion cohort. A 
sample size of 24 has 71% power to detect the presence of a somatic variant which is 
present in the tumour population at a frequency of 5%. Thus, our observations of a 
number of unique variants in the group of 24 is consistent with this expectation. 
However, the power to detect a difference in frequency between those with and 
without bone lesions will be much lower than this. For example, to detect a doubling 
in frequency from 5% to 10%, with 80% power requires over 470 cases in each group 
(Cox, personal communication).  
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The sample of 24 has good power (91%) to detect germline variants present in the 
population at an allele frequency of 5%, but the sample of 24 only has 21% power to 
detect rare mutations (for example allele frequencies of around 0.5%) (Cox, personal 
communication). Therefore, we were not able to detect any rare germline mutations 
that might be expected to have a major effect on risk of bone lesions. More common 
variants (polymorphisms) can also affect risk of myeloma and might also be expected 
to affect risk of bone lesions, but these effects tend to be small, with relative risks 
(odds ratios) of 1.4 or less. So although a larger number of genes were associated 
with variants in the germline samples, assessing associations that may provide a 
predisposition to a worse bone phenotype would really require extensive GWAS 
studies, like those described by Houlston et al74, who assessed over 7,000 myeloma 
patients and over 200,000 control samples. Those sample numbers and levels of 
analysis are beyond the scope of a project like this. 
The sample number was limited in part by the funding we had available for the 
project as NGS processing and bioinformatic analysis remains a costly process. It was 
also limited by the number of samples that had sufficient bone marrow sample DNA 
following the previous testing as part of the project and those patients who also had 
a blood sample taken at the time of the bone marrow sample. Although samples 
taken to be used as part of the SMaRT patient research cohort did request a blood 
sample, many did not have this germline sample. This is, in part, due to fact that the 
blood sample does not represent the patient’s disease and therefore the need to 
take this sample was not recognised by all involved in sample collection. 
The design of the NGS panel was limited by the number of genes that could be 
included based on sequencing capacity and based on the cost of the panel. A 
number of genes that could have been included were not part of this analysis. With 
the hindsight of analysis and increased understanding of the pathways involved, 
other genes that could have been included are the interleukins, IL6, IL1B and IL3, 
Sclerostin domain containing 1 (SOSTDC1) gene and the insulin-like growth factor 1 
(IGF1).   
Patients in this study were assigned to the bone lesion or non-bone lesion cohorts 
based on an assessment and review of the patient notes. Whilst some notes were 
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extremely ordered and detailed and the data were easy to access, others were more 
difficult and required more clinical interpretation and lacked some detail. The bone 
lesion information was taken from the timepoint at which the bone marrow sample 
was taken. Whilst this would be considered an appropriate time period for 
assessment of bone lesions, a number of patients with no recorded bone lesions may 
have gone on to develop a more aggressive bone phenotype as their disease 
progressed. Therefore, this analysis is only an assessment of an association at the 
time of sampling and may misrepresent the myeloma patients who have the most 
severe bone manifestations. Initially we had considered assessing three groups of 
bone lesions; none vs 1-3 bone lesions vs multiple ≥3 bone lesions. This reduced the 
cohort numbers further and it was decided to limit the analysis to two disease 
cohorts; no bone lesions vs bone lesions. 
In conclusion, the work presented as part of this chapter has allowed some initial 
work to be completed to explore the presence of variants in bone related genes in 
both the germline and somatic samples processed using the NGS osteome panel. It is 
understood that the power of the current study is not strong enough to show 
positive or negative relationships, however, this exploratory work has not been able 
to demonstrate any evidence to support a hypothesis that relationships exist 
between the genetic mutations in bone related genes and the likelihood or extent of 
myeloma related bone damage. Within the somatic changes seen, no variants were 
considered pathogenic, and those germline variants associated with risk (according 
to the bioinformatic pathogenicity callers), and indeed high risk, were seen in both 
the bone lesion and the non-bone lesion cohorts. 
Based on the discussion above, there may many be reasons why an association was 
not seen in this study. This could be based on sample size, the genes and indeed the 
number of genes chosen as part of the osteome cohort, the level of filtering required 
to make a manageable data set, the depth of analysis undertaken on each variant, 
and the selection of the bone lesion vs non-bone lesion cohort.  
We had considered this work could direct treatment to a cohort of patients likely to 
have a poorer bone phenotype, as long term treatment with bisphosphonates has 
some drawbacks, but perhaps this opens up the discussion about the more 
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widespread use of anabolic therapies in myeloma which have shown the ability to 
stimulate bone formation and therefore the ability to counteract the bone 
devastation caused by the disease in many patients. 
Further work that may be considered within the SMaRT, may be to repeat this 
analysis adjusting a number of these factors; a larger patient cohort to meet the 
requirements of the power calculations, with follow up data on the bone lesions 
over the course of their disease, an increased number of genes, and a deeper level of 
variant assessment looking at variants in all gene regions. A similar project could also 
be undertaken using RNAseq or gene expression profiling instead of the osteome 
gene panel.  
The RNAseq assessment allows analysis of the gene expression levels. It covers all 
genes in single sequencing event and therefore genes cannot be missed out. The 
analysis can start in a more selective manner looking at specific genes i.e. the 
osteome but could be extended to include other genes if a negative result is seen 
initially. There are some downsides to using RNAseq, as this analysis can be 
hampered by 3’ bias. This is a phenomenon seen when cDNA fragments are 
sequenced; the number of reads corresponding to each transcript is proportional to 
the number of cDNA fragments rather than the number of transcripts. Since longer 
transcripts are generally sheared into more fragments, more reads are assigned to 
longer transcripts than shorter transcripts. Therefore, when assessing differential 
expression analysis, the differentially expressed genes are more likely to be enriched 
for longer transcripts resulting in this bias.   
Recent work has shown the utility of gene expression signatures in robustly 
identifying a group of high risk myeloma patients124. Assessing gene expression 
rather than changes in the DNA, may prove a more sensitive assessment of any 
relationship between bone genes and the status of the bone phenotype associated 
with the disease. It may also be prudent to consider which cells are being assessed, 
i.e. the germline analysis will examine a predisposition to a more severe bone 
phenotype, but it may be interesting to assess somatic changes in cells of the bone 
marrow niche where you might expect bone related genes to be expressed, and not 
specifically the plasma cells associated with the bone marrow disease. 
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Chapter 5: Myeloma Quality Assessment Scheme 
UK NEQAS and GenQA Introduction 
The previous chapters have described extensive assessment of five genetic 
technologies suitable for the assessment of myeloma, and how these could be 
translated and utilised in a diagnostic NHS setting. The testing has to demonstrate 
clinical utility, be comprehensive, but also fit into a reasonable time frame and 
financial envelope to be able to justify the testing. Alongside the assessment of 
technologies has to be consideration of quality assessment and best practice. Many 
NHS diagnostic genetic tests have External Quality Assessment (EQA) schemes 
available that can be accessed by laboratories; completion of these schemes 
provides a certification that the test meets a suitable standard. The EQA schemes are 
often used to consider best practice, and to offer standardisation across the cohort 
involved, and this educative element is extremely valuable to participants. At the 
outset of the project, there was no EQA scheme available for myeloma, and it was 
considered a crucial aspect of the project to assess this need and work towards 
provision of an EQA scheme. 
UK NEQAS (UK National External Quality Assessment Scheme) is a charitable, not-for 
profit consortium of external quality assessment providers for pathology services. UK 
NEQAS offers an independent, international service managed by experts in specific 
pathology fields and assured via specialist advisory groups (SAGs) made up of 
medical and scientific experts, and Boards of Trustees.  
The aim of the individual EQAs is to improve patient care through monitoring the 
quality of tests and their reporting. Test results should be comparable, safe and 
clinically useful to the patient irrespective of where or when the test is performed. 
UK NEQAS also provides an educational component; the schemes are continually 
improved to fit the tests provided and EQA data are continually improved to support 
and train participating laboratories and to use the experience to embed and inform 
best practice and critical thinking.  
https://ukneqas.org.uk/about/educate-me-about-uk-neqas/ 
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In 2014, Cytogenomic External Quality Assessment Service (CEQAS) was established. 
This was a result of a merger of Cytogenetic European Quality Assessment (CEQA) 
and UK NEQAS for Clinical Cytogenetics, the two largest internationally operating 
EQA schemes at the time. In 2018, a further merger of CEQAS and the UKNEQAS for 
molecular genetics resulted in GenQA (Genomics Quality Assessment). GenQA is 
accredited through United Kingdom Accreditation Service (UKAS) as a proficiency 
testing provider and remains a member of the UK NEQAS Consortium. From the 
website https://www.genqa.org/ the aims of GenQA are to: 
Provide professionally lead and scientifically based EQAs with an educational 
objective 
Assess technical, analytical and interpretative performance of a laboratory 
Help the laboratory appraise its performance and monitor improvements 
externally 
Achieve this through continuous operation, frequent distributions of samples 
and performance feedback 
Produce reports which are designed to be clear, informative, intelligible and 
structured to assist interpretation and use by different levels of laboratory 
staff. 
 
GenQA Scheme Design and Implementation 
I sit on the Haematological-Oncology (HaemOnc) disease group Specialist Advisory 
Group (SAG), and this involvement with GenQA provided an ideal platform from 
which to introduce and implement a scheme for myeloma genetic diagnosis. At the 
point of myeloma EQA scheme inception, genetic diagnosis for myeloma patients 
was considered ad hoc and often available only in centres with a specialist or 
research interest, and frequently dependent on whether the patient was enrolled in 
national trials which included myeloma genetics as part of trial data collation.  An 
EQA scheme for myeloma genetics was missing from the repertoire of any of the 
NEQAS organisations, and GenQA offered a good fit from which to launch this. 
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In conjunction with Ros Hastings (GenQA Director) and the GenQA SAG, a small team 
was devised to make up the myeloma EQA assessment panel. I was part of this team, 
and the following people were chosen for their interest, expertise and background:  
Ros Hastings - Director of GenQA. Ros was keen to set up a myeloma EQA, initially as 
a pilot EQA, and was able to provide the infrastructure required to launch the 
scheme through GenQA. 
Katrina Rack - Deputy Director of GenQA, and lead for the oncology schemes. 
Katrina was taken on by GenQA in 2015. At this point she became involved in the 
assessment of the myeloma EQA, but Ros remained involved from scheme 
management point of view. 
Nicola Foot - Deputy Head of the Oncology Section, Cytogenetics Laboratory, Guy’s 
and St Thomas’ NHS Foundation Trust, London, UK. Nicky is a clinical scientist in a 
busy HaemOnc department and has many years of cytogenetic experience and offers 
a myeloma service for a large number of patients. 
Jacqueline Schoumans - Head of Oncology Genetics, Medical Genetics Service, 
Lausanne University Hospital, Switzerland. Jacqueline has many years’ experience in 
HaemOnc. The Lausanne laboratory offers an array service for their myeloma 
patients, but Jacqueline also has extensive FISH experience. She was also involved in 
writing the current laboratory guidelines for the use of arrays in HaemOnc disorders. 
Sheila O’Connor - Haematology Clinical Scientist, Haematological Diagnostic 
Malignancy Service (HMDS), St James’s University Hospital, Leeds, UK. Sheila is a 
haematologist by training with extensive experience in FISH. Sheila works in HMDS, 
the largest integrated HaemOnc specialist centre in the UK. 
 
The pilot EQA scheme for myeloma was launched through GenQA in 2014 and 
included two cases of myeloma. These are described in detail below to illustrate the 
format of the EQA scheme. The first case in the 2014 pilot, was presented to the 
laboratories as fixed cells (bone marrow samples treated with 3:1 methanol:acetic 
acid), a referral form describing the case scenario and immunophenotyping results. 
Laboratories were expected to process the FISH for this case according to their 
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current in-house myeloma testing strategy and complete the analysis of the FISH 
testing.  
The second case was available for analysis on the GenQA website. It included a 
referral form describing the patient case scenario, immunophenotyping results and 
morphology results and a number of FISH probes which could be selected for 
analysis. Ten probes were provided, six of those as a set of FISH images, and four 
probes sets had results given as text only.  
The six probe sets that had images provided were:  
Cytocell IGH Breakapart probe 
Abbott IGH/CCND1 Dual colour dual fusion probe 
Abbott IGH/FRGR3 Dual colour dual fusion probe  
Abbott IGH/MAF Dual colour dual fusion probe  
Cytocell TP53/17cen deletion probe 
Cytocell 13q14.3/13q34 deletion probe 
Images covering approximately 20 cells were provided for analysis and participants 
were instructed to assume that each cell represented 10 cells in a standard analysis. 
Examples of the images provided for each of these probe sets are demonstrated in 
figure 5.1. 
These remaining probes sets listed below, were supplied with result given as text, 
e.g. MYC showed no evidence of rearrangement in 200 cells scored.  
Abbott MYC Breakapart probe 
Cytocell CKS1B/CDKN2C (1p/1q) Amplification/Deletion probe 
Cytocell IGH/CCND3 plus Dual colour dual fusion 

















Figure 5.1: Demonstrating example images for the online EQA case presented as part of the pilot EQA for 
Myeloma 2014 
 
Participants were expected to analyse the probe sets with FISH images, or with text-
based results according to the standard strategy employed in their laboratory. For 
both cases, following FISH analysis, submission was in the form of an interpretative 
genetic report which was uploaded via the GenQA website. Table 5.1 shows the 
patient information for case 1 and 2, presented as part of the pilot Myeloma EQA 
including the expected, validated results. It should be noted that the names and 
dates of birth are fictitious, allowing the reports to be written and formatted 




Case Name DoB Referral Reason Validated Results 
1 
 
Sara ECRU 18/07/1950 Cough, ascites, pleural 
effusion. Confirmed 
Myeloma 
 IGH rearranged plus extra copies of IGH. 
 MAF-IGH rearrangement. 
 No FGFR3-IGH or CCNDI-IGH rearrangement. 
 Monosomy for 13q14 & 13q34  
TP53/17cen 
IGH/CCND1/11cen IGH/FGFR3 IGH BA 
IGH/MAF 13q14.3/13q34 
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 Normal for TP53 
 No abnormality for 5, 9 & 15 centromeres. 
 Sub-population with MYC rearrangement. 
2 Seth EBONE 18/08/1951 Confirmed Myeloma. 
FISH please for 
prognostic indicators 
 IGH rearranged plus extra copies of IGH. 
 CCND1-IGH rearrangement. 
 No MAF-IGH or FGFR3-IGH rearrangement.  
 Normal for 13q14, 13q34, MYC & TP53 
 No abnormality for 5,9 & 15 centromeres. 
Table 5.1: Detailing the validated results of the two cases presented as part of the pilot EQA for Myeloma 2014 
 
Both cases were validated by four assessors independently and without prior 
knowledge of the FISH results; all results were consistent and confirmed. Assessment 
of the laboratory reports submitted to the GenQA website was performed by the 
same panel of four assessors and the scheme organiser, against pre-specified 
criteria, (see table 5.2), relevant to these cases and in-line with other schemes 
offered by GenQA. These criteria looked at the areas of analysis, interpretation and 
clerical accuracy. The ‘analysis’ category includes assessing the result obtained from 
the laboratory, how this is expressed either as a summary statement or in correct 
ISCN (International System for Cytogenetic Nomenclature), the nomenclature 
devised for describing cytogenetic and FISH abnormalities, and a clear written 
description of the correct findings with no ambiguity. The ‘interpretation’ 
assessment was based on providing a correct interpretation of the abnormalities 
found, including a statement of the genes involved and a prognosis comment. Finally 
the ‘clerical accuracy’ category covers a range of points relating the way the report is 
structured, and assesses the report against guidelines134,135 produced describing 
requirements of a genetic report, i.e. the correct patient identifying information, the 
inclusion of the sample type and the probes types used, including manufacturer, and 
the overall report quality. Poor performance is defined as a critical analytical error or 
a critical interpretative error. Whilst scoring is completed in all scheme rounds, 
performance status is not assigned to the individual laboratories in the pilot rounds. 
Performance status is awarded once full scheme status is obtained.  
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Case Category Criteria Marks 
1 
 
Analysis  Result is correct 
 Result is correctly given in ISCN or as a summary statement 
 Clear written description (marks deducted if written description is 
misleading or incorrect)  
 TP53 & IGH (FGFR3, MAF if IGH rearranged) FISH undertaken  
   2.0 marks 
   0.5 marks 
 
   0.5 marks 
   0.5 marks 
Interpretation  Interpretation present and correct, comprising of: 
 Stating the gene fusion or genes involved 
 The prognosis is given 
   2.0 marks 
   0.5 marks   
   0.5 marks 
Clerical 
Accuracy 
 Correct patient name 
 Correct date of birth 
 Correct sample type 
 Probe manufacturer given if applicable 
 Two patient identifiers present 
 Absence of multiple typographical errors 
   0.5 marks 
   0.5 marks 
   0.5 marks 
   0.5 marks 
   0.5 marks 
   0.5 marks 
2 Analysis  Result is correct 
 Result is correctly given in ISCN or as a summary statement 
 Clear written description (marks deducted if written description is 
misleading or incorrect)  
 TP53 & IGH (FGFR3, MAF if IGH rearranged) FISH undertaken  
   2.0 marks 
   0.5 marks 
 
   0.5 marks 
   0.5 marks 
Interpretation  Interpretation present and correct, comprising of: 
 Stating the gene fusion or genes involved 
 The prognosis is given 
   2.0 marks 
   0.5 marks   
   0.5 marks 
Clerical 
Accuracy 
 Correct patient name 
 Correct date of birth 
 Correct sample type 
 Probe manufacturer given if applicable 
 Two patient identifiers present 
 Absence of multiple typographical errors 
   0.5 marks 
   0.5 marks 
   0.5 marks 
   0.5 marks 
   0.5 marks 
   0.5 marks 
Table 5.2: Detailing the pre-specified assessment criteria of the two cases presented as part of the pilot EQA 
for Myeloma 2014 
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As part of each scheme, an individual laboratory report (ILR) is provided to each 
participating laboratory which details specific comments and observations under the 
three described areas based on their submission. In addition to the ILR, a scheme 
letter is produced which aims to describe the cases chosen, expected results, 
assessment criteria, the range of submissions seen and educational / learning points 
that have arisen throughout the assessment. This provides a valuable teaching and 
learning tool associated with the EQA scheme, and has been used to encourage and 
direct best practice. 
 
GenQA Scheme Results and Progress  
The format of the scheme has remained the same for subsequent years, year 2 
(2015) was also run as a pilot and then in year three the myeloma EQA scheme was 
awarded full scheme status following ratification at the HaemOnc Specialist Advisory 
Group (SAG). The scheme has completed seven years and is now part of the 
substantive GenQA scheme repertoire. The cases included in the schemes for the 
first five years are summarised in table 5.3. 
 
Scheme Year EQA Case / Name EQA Result 
2014 
Year 1 Pilot 
Case 1: Sara ECRU MAF-IGH rearrangement. 
Chromosome 13 monosomy 
Case 2: Seth EBONE CCND1-IGH rearrangement. 
2015 
Year 2 Pilot 
Case 1: Edgar MANN MAF-IGH rearrangement. 
Chromosome 13 monosomy 
MYC deletion, no rearrangement. 
IGH-MYC rearrangement (with dual fusion probe) 
Case 2: Mia CANNE FGFR3-IGH rearrangement. 
Loss of DLEU (13q14) 
2016 
Year 3 
Case 1:Marc SYLVAN No IGH rearrangement 
Gain of CKS1B (1q21.3) 
Loss of CDKN2C (arrays only) 
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Case 2: Greta MERTENS IGH-FGFR3 rearrangement detected 
Gain of MYC, but no rearrangement 
Gain of TP53 (17p13) 
Loss of DLEU (13q14) 
Gain of CKS1B (1q21.3) – 4 copies 
2017 
Year 4 
Case 1: Roger WEST No IGH rearrangement 
Gain of CKS1B (1q21.3) (3-4 copies) 
Gain of 5, 9 and 15 (3 copies) 
Chromosome 13 monosomy 
Case 2: Maria KAAS IGH-FGFR3 rearrangement detected 
Gain of CKS1B (1q21.3) 
MYC rearrangement detected 
Loss of DLEU (13q14) 
2018 
Year 5 
Case 1: Jake BIRCH IGH-CCND1 rearrangement (non-standard pattern) 
Gain of CKS1B (1q21.3) 
Loss of TP53 (17p13) 
Complex MYC rearrangement (by array) 
Case 2: Samuel OKEKE IGH-MAF rearrangement 
Loss of CDKN2C (1p32.2) 
Table 5.3: Detailing the validated results of the two cases presented as part of the Myeloma EQA scheme from 
2014-2018 
 
At scheme introduction in 2014, 39 laboratories participated; of those 33 (84.6%) 
obtained the correct results and produced satisfactory reports. 
Participation has increased and plateaued over the period of five years; 39, 56, 65, 
61 and 64 participants per year (2014-2018) respectively, shown in figure 5.2. This is 
in part due to expansion in the number of laboratories accessing the GenQA services, 
but also reflects an increase in UK laboratories offering this testing. This is likely to 
be due in part to this scheme being offered, but also as a result of myeloma being 
higher on the national genomics radar, which culminated in the publication of NICE 
guidance early in 2016111. 
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Based on the scores, poor performance was recorded as 15.4%, 10.7%, 3.1%, 14.8% 
and 4.7% of participants over 2014, 2015, 2016, 2017 and 2018 respectively. See 
figure 5.2.  
 
Figure 5.2: Graph to show the number of participants and the % of poor performance over the five years of the 
Myeloma EQA 2014-2018 
 
Poor performance has fluctuated, but has, in general, shown a downward trend. This 
is likely to be related to the educational component of the scheme, and due to the 
increased profile of this testing with publication of the NICE guidelines on Myeloma: 
Diagnosis and Management111. The myeloma EQA scheme run in 2017 showed an 
increase in the poor performance; this peak in poor performance was due to a 
change in testing strategy employed by some laboratories, with penalties being 
applied to the use of specific probes in an inappropriate context.  In more detail, 
assessors expected that the IGH-FGFR3 rearrangement and the TP53 deletion status 
should be determined as a minimum. IGH-FGFR3 rearrangement can be excluded 
using an IGH breakapart probe or the IGH/FGFR3 dual colour dual fusion probes. In 
this scheme round, other IGH dual fusion probes, such as IGH/CCND1 or IGH/ MAF 
dual fusion probes were being used to detect rearrangements of IGH as a first line 
test. Whilst in the great majority of cases, these probes will pick up an IGH-FGFR3 
rearrangement, often seen as an additional copy of the IGH green signal, there are 



















2014 2015 2016 2017 2018
Poor performance  %
Participants
 196 
be lost. This signal loss can be due to either loss of the whole chromosome or partial 
deletion of chromosome 14, a not uncommon finding, or loss of the derivative 
chromosome 14 involved in the rearrangement; both situations could result in a 
normal signal pattern using IGH/CCND1 or IGH/MAF dual fusion probes. Therefore, it 
was deemed that if participants had used a different IGH dual fusion probe to detect 
an IGH rearrangement, other than the IGH-FGFR3 considered the minimum 
rearrangement to determine, then in these, albeit rare scenarios, an IGH 
rearrangement had not been conclusively ruled out. In these cases, laboratories 
were assigned a poor performance. This was described in the educational scheme 
letter and there were no laboratories employing this testing strategy the following 
year, demonstrating a change in practice.  
In general, case 1 in which the sample is sent out to laboratories to complete their 
own FISH testing, results in more poor performance. However, this case also allows 
assessment of a number of different criteria; the testing strategy employed, the 
technical ability to perform the FISH processing and analytical ability of participating 
laboratories. When presented with a range of FISH probes to analyse on the website, 
many participants analyse everything available when this does not reflect the 
strategies undertaken on a real-life sample. The images provided are usually clear 
and unambiguous when chosen for the website, and again this may not reflect the 
quality of the FISH produced in individual laboratories.  
Managing the samples for each GenQA round can be challenging; providing images 
for cases is relatively straightforward, but as the number of participants rise, 
increased starting material is required for the wet work round.  Approximately 200µl 
of fixed cells are provided to each participating laboratory, so in the most recent 
round a total of 13ml of fixed cells were required. Currently these samples are 
accessed through two large laboratories who have been willing to prepare and 
supply samples when diagnostic samples are seen with very high plasma cell 
percentages. The expense of separating CD138 positive cells has financially excluded 
this step as a possibility in preparing EQA samples, and therefore accessing samples 
from myeloma patients with high plasma cell content, best reflects the samples 
processed routinely through diagnostic genetic laboratories. It is easier to manage an 
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EQA scheme based on online images alone due to the challenging issues described in 
access, expense, and preparation of the wet samples. However, it is not possible to 
fully and accurately assess the laboratories testing strategies and technical FISH 
ability without providing the wet sample.  For the foreseeable future, we would 
choose to use both methodologies over the two cases provided. 
A further challenge seen in the provision of an EQA for myeloma, is the scoring and 
assessment that is applied when assigning prognosis in the reports. Interpretation 
and prognostic reporting is expected, but given that genomic testing in myeloma is a 
rapidly changing field, it is recognised that prognostic variables may lose or gain 
significance as a consequence of changes in patient management and clinical trial 
outcomes, and indeed are different amongst publications and recommendations 
internationally. When assessing this EQA round we have aimed to use the consensus 
of the different current recommendations to inform the minimum genetic tests 
expected. This is particularly relevant to 1q gain and 1p loss, where the prognostic 
significance has no clear consensus within international publications and guidelines. 
We have made this clear via the scheme letter that although omission of 1q/1p 
testing has not been penalised, that this may change in future EQA rounds if further 
guidance becomes available. 
 
 
CEQAS Scheme Survey 
Inaugural Scheme Survey 2014 
Alongside the first pilot myeloma EQA scheme, a survey of current diagnostic genetic 
practice was conducted with the aim of gauging the breadth of testing available at 
the time of scheme inception. 
The survey was short and simple to encourage participation and focussed on three 
main areas: 
• The type of lab and location 
• The referral type, samples & turnaround times (TAT) 
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• The techniques employed and the gene regions examined 
The survey questions are included as appendix 7.  
At scheme introduction, Autumn 2014, 39 participants took part from across Europe, 
and 18/39 (46%) completed the survey. Laboratories that completed the survey 
were all considered diagnostic laboratories, although approximately 13% were also 
considered research laboratories in part. The majority of laboratories were 
considered to be from the public sector (88%), with participation from a single 
private laboratory and a single laboratory from a private/public partnership. The 
majority, 10/17 laboratories (59%), were from the UK, but with laboratories from the 
following countries also participating: Italy, Belgium, Sweden, Switzerland and 
Greece, one laboratory did not supply this information. See figures 5.3 and 5.4. 
Laboratories processed between 25 and 400 samples per year as detailed in graph 
5.5. Where ranges were given, average figures were used and where specific figures 
were given they were attributed to the nearest group. The same applies to the turn 
around times (TATs) given in the survey shown in graph 5.6. Based on the averages, 
an overall average of 18.7 days TAT was calculated. 
 
 
Figure 5.3: Demonstrating the range of public, private and public/private partnership laboratories participating 
in the GenQA survey in 2014. 
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Figure 5.4: Demonstrating the range of countries participating in the GenQA survey in 2014. 
 
 
Figure 5.5: Demonstrating the number of samples processed per annum. 
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Figure 5.6: Showing the range of TATs reported by laboratories in the survey performed in 2014. 
 
Sixteen of the 18 (89%) laboratories employed a plasma cell separation method, all 
of whom utilised the CD138 postive methodology as described in the materials and 
methods chapter. Of the 16 laboratories who separate the plasma cells, 6 (38%) 
assess the purity of the sample. Five of the 16 labs utilise morphological methods 
and 1 lab uses flow cytometry to assess the plasma cell purity. Only a single 
laboratory (1/18) utilises the fluorescent cytoplasmic immunoglobulin (cIg) method. 
The following chart  (figure 5.7) shows the methodologies employed for myeloma 
analysis. The majority of laboratories offered FISH testing as a sole technique, one 
laboratory offered FISH and DNA arrays, one laboratory offered karyotyping and 
FISH, and one laboratory offered a combination of all three methods. 
Only the two laboratories employing arrays for myeloma analysis completed the 
section on DNA requirements as it was not applicable to the other respondents. No 
laboratories participating in the survey are routinely using MLPA for analysis of 
myeloma although two laboratories report that assessment and validation is 





























Figure 5.7: Demonstrating the methodologies employed for myeloma genetics analysis based of the survey 
results received in 2014. 
 
One of the cases provided to the GenQA participants in 2014 was a cell suspension 
sample for FISH processing in-house. Based on the testing methodology employed 
for the GenQA case we can infer the testing provided by the 39 laboratories that 
took part in the pilot scheme. This information is provided in table 5.4. 
All 39 labs offered IGH testing, and 37/39 (95%) offered FGFR3 and MAF testing as a 
follow-on test if the IGH proved abnormal. Of the remaining five common partner 
genes, CCND1 testing was offered by 18/39 (46%), MAFB testing by 6/39 (15%) and 
CCND3 testing by only 1/39 (3%) laboratories. 15/18 labs describe a multistep FISH 
process with additional probes added based on the outcome of an initial IGH 
assessment. 
TP53 testing, which can be considered one of the most important prognostic 
indicators in myeloma, was only offered by 37/39 (95%) labs. Chromosome 1 
abnormality testing was offered by 30/39 (77%) laboratories and 13q abnormalities 
by 24/39 (62%).  A minority of labs offered hyperdiploidy assessment, 8/39 (21%), 













1q only 2 
13q 24 
MYC 3 
Hyperdiploid assessment 8 
Table 5.4: Probes used by the laboratories who took part in the GenQA myeloma pilot scheme in 2014 
 
Eight laboratories routinely accept referrals of MGUS and eight laboratories do not. 
Two labs report that they will analyse MGUS samples if specifically requested. 
Only 3/18 laboratories employ an age limit to the requests for myeloma FISH. The 
age limit is <70 years for 1 of the 3 laboratories and <75 years in the remaining two 
laboratories.  
The inaugural scheme survey, provided evidence for the ad hoc nature of genetic 




2018 Scheme Survey 
The survey was repeated alongside the 2018 scheme in order to reassess the 
findings and to determine changes in practice seen over this period. The questions 
remained similar and can found in appendix 7. Thirty one of the 65 (48%) 
laboratories enrolled in the 2018 myeloma EQA scheme completed the survey. 
Laboratories that completed the survey fall into two of the following three 
categories (diagnostic, research or both): 29/31 (94%) are considered diagnostic and 
2/31 (6%) are considered both diagnostic and research. Most laboratories (61%) are 
part of a public hospital, 26% are part of a public university and 10% are considered 
private laboratories, and single laboratory described themselves as ‘other’, see 
figure 5.8.  
Countries represented by the survey contributors are shown in figure 5.9, and whilst 
the majority are UK laboratories, the spread of countries covered is far greater than 
was seen in the original survey. 
 
Figure 5.8: Demonstrating the range of public (hospital or university based), private and public/private 









Figure 5.9: Demonstrating the range of countries participating in the GenQA survey in 2018. 
 
Laboratories processed between 26 and 650 samples per year, with an average of 
228 samples/year, and this related to populations served ranging from 230,000 - 
6,000,000 with an average population of 2.5 million. The average TAT was 21.5 days, 
but with a huge range from 4 to 120 days (see figure 5.10). If the two outliers were 
removed the mean TAT was 16.8 days. This compares to a mean TAT of 18.7 days 
from the previous 2014 survey, although it is acknowledged that this figure is based 
on averages assumed from numerical ranges supplied in both survey responses. The 
TAT is affected by the testing strategies employed; many laboratories are employing 
sequential testing strategies, which, whilst offering a cost saving overall (as some 
























Figure 5.10: Showing the range of TATs reported by laboratories in the survey performed in 2018. 
 
The mean abnormality rate was 72% but with a range of 30-100%, and the failure 
rates were reported as between 0-32% with a mean of 6%. 
20/31 (65%) laboratories routinely accept referrals of MGUS and 11/31 laboratories 
do not. This compares to 50% of laboratories accepting MGUS referrals in 2014. Only 
2/31 (6%) laboratories employ an age limit to the requests for myeloma FISH, and 
the age limit is 75 years and 85 years for those two laboratories. This compares to 
3/18 (17%) seen in the survey results from 2014. 
29/31 (94%) laboratories employ a plasma cell separation method, all of whom 
separate using CD138 postivity. Three laboratories also utilise CD38+ separations, 
and one laboratory describes the use of CD19+ and CD56+ separations in a 
proportion of cases. 23/28 (82%) of laboratories who described the technique used 
employed a magnetic cell sorting strategy, one described a FACS based methodology 
and 4/28 used ‘other’ to describe their strategy. 
Of the 29 laboratories who separate plasma cells, 11 (40%) assess the purity of the 
sample. Six labs utilise morphological methods and five laboratories use flow 
cytometry to assess the plasma cell purity. This has not changed dramatically since 
2014. Only a single laboratory (3%) utilises the fluorescent cytoplasmic 
immunoglobulin (cIg) method, and this is the same as 2014. 
The following chart (figure 5.11) shows the methodologies employed for myeloma 
genetic analysis. The majority, 22/31 (71%) use FISH only as their testing strategy. 
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One laboratory used array analysis only, and 4/31 (13%) laboratories employed both 
FISH and array. One laboratory completed FISH and karyotyping and a further 
laboratory used this strategy with TP53 sequencing in addition. Two laboratories 
undertook a combination of FISH, array and TP53 sequencing. 
 
Figure 5.11: Demonstrating the methodologies employed for myeloma genetics analysis based of the survey 
results received in 2018. 
 
Based on both the survey and case 1 in which the wet work was completed in house, 
we were able to determine the chromosomes or gene regions tested for, and the 
testing strategies undertaken by different laboratories. These results in the table are 
based on the 63 participants of the 2018 myeloma EQA scheme, and the survey 
results received. 













Table 5.5: Probes used by the laboratories who took part in the GenQA myeloma EQA scheme in 2018 
 
 
All 63 laboratories performed IGH rearrangement testing, although different 
strategies were employed. These individual differing strategies are outlined in table 
5.6. Overall 28 laboratories used a combination of an IGH breakapart probe and dual 
fusion translocation probes and 35 laboratories used dual fusion translocation 
probes alone. It is recognised that the IGH testing strategy may be sequential or 
simultaneous and that the tests performed are therefore case dependent. Of the 63 
participants, all laboratories assessed TP53 status; 61 (97%) laboratories assessed 
1p/1q copy number; 19 (30%) laboratories assessed chromosome 13 deletion/loss; 
17 (27%) laboratories tested for hyperdiploidy and five (8%) laboratories tested for 











Testing Panel* Number of laboratories 
IGH-FGFR3 1 
t(11;14) only 3 
IGH-FGFR3 and IGH-MAF 10 
IGH-FGFR3, and t(11;14) 4 
IGH-FGFR3, IGH-MAF and t(11;14) 11 
IGH-FGFR3, IGH-MAF and IGH-MAFB 4 
IGH-FGFR3, IGH-MAF, IGH-MAFB and 
t(11;14) 
2 
IGH BA and probes specific for IGH-
FGFR3, IGH-MAF and t(11;14) 
9 
IGH BA and probes specific for IGH-
FGFR3, and IGH-MAF 
6 
IGH BA and probes specific for t(11;14) 5 
IGH BA and probes specific for IGH-
FGFR3 and t(11;14) 
4 
IGH BA and probes specific for IGH-
FGFR3, IGH-MAF, t(11;14) and IGH-
MAFB 
2 
IGH BA and probes specific for IGH-
FGFR3, IGH-MAF and IGH-MAFB 
2 
Table 5.6: Table detailing the FISH panels employed by laboratories to determine the IGH rearrangements in 
the 2018 myeloma EQA scheme. * different probes sets are used for the detection of the t(11;14), but have 
been considered a single test 
 
Forty laboratories undertook testing for the t(11;14) rearrangement. Different 
approaches were taken: a single laboratory used a CCND1 break apart probe, 32 
laboratories used an IGH-CCND1 dual fusion probe and 7 laboratories used an IGH-
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MYEOV dual fusion probe. In table 5.6, these different probe combinations have 
been considered as a single test for the purposes of understanding the testing panels 
employed. 
All laboratories included IGH and TP53 in their assessment of myeloma genetics. This 
demonstrates a shift from the survey performed in 2014 where all laboratories 
performed IGH assessment, but only 95% included TP53 deletion testing. TP53 and 
IGH, leading to an assessment of FGFR3-IGH and MAF-IGH, are considered a 
minimum testing set according to Ross et al, 2012. 
A range of 100-200 cells were scored per FISH set, and the cut-off was usually given 
as 10% although some labs use a probe specific cut off and this ranged from 2-30%. 
Only the laboratories employing arrays for myeloma analysis completed the section 
on DNA requirements as it was not applicable to the other respondents. No 
laboratories participating in the survey routinely use MLPA for analysis of myeloma, 
although it is known that at least one UK laboratory uses MLPA assessment for their 
copy number determination. 
Twenty laboratories stated that they were not currently considering NGS for their 
myeloma testing, whilst eight laboratories are either using NGS or considering it. Of 
those eight laboratories, three are using NGS for TP53 testing only, one for BRAF 
testing only, and a single lab described a panel of KRAS, NRAS, BRAF, IRF4, TP53, DIS3 
and FAM46C which was being validated. The remaining three labs did describe the 
NGS testing that was being considered. 
 
Survey Conclusions 
In conclusion, these surveys have demonstrated a change over the period of 
implementation of the myeloma EQA scheme. In 2014, although all laboratories 
assessed IGH rearrangement in myeloma referrals, 5% of laboratories did not include 
TP53 testing in their panel. In 2018, the picture has changed with 100% of labs now 
including tests that meet the requirements laid out in both the NICE guidance and 
the BSH guidance to assess patient for both IGH-FGFR3 and IGH-MAF 
rearrangements and TP53 deletion testing. However, although the essential tests are 
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being provided by all of the laboratories enrolled in the scheme, an inequitable 
service is provided due to the variability of testing offered and indeed the quality of 
service provided. 
In 2014, 89% of labs reported completing their testing on separated plasma cells, 
which rose to 94% in 2018; however, a proportion of laboratories are completing 
their testing on whole bone marrow which would not be considered best practice. 
Average TATs have improved from 18.7 days to 16.8 days. In general this fits with the 
diagnostic pathway for myeloma, but may need further improvement if treatments 
are to be based on these findings.  
FISH is by far the methodology of choice currently, but with a minority of 
laboratories including MLPA and array in their current testing strategies. The 2018 
survey showed that four labs were considering including mutational analysis NGS 
panels as part of their genetic testing, although no labs are offering this at present. 
 
Diaceutics Study 
During the period of this PhD study, I also contributed to a data collection exercise 
run by Diaceutics on behalf of Takeda Oncology. Diaceutics are a commercial 
company that provide consulting services to Pharmaceutical companies; they 
provide data research and understanding of the diganostic pathways and markets, 
and create plans for the integration of the Pharma companies therapies into the 
diagnostic and therapeutic pathway. This study was published in the Myeloma Hub 
Connect in January 2018136.   
Their data are extremely interesting and complements information we have 
gathered through the GenQA surveys. The Diaceutics data are limited to the UK and 
Ireland, but extends the data collection and information to cover populations served, 
and an understanding of the funding streams covering this testing and the future 
requirements of a testing strategy. 
Their study concludes, as ours does, that the genetic testing in the UK is variable 
with regards to the methodologies employed. They state that the ‘NICE and BSH 
guidance to test for the high-risk abnormalities del(17p), t(4;14) and t(14;16) are 
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being followed, but a significant proportion of patients are not screened for 
cytogenetic abnormalities at diagnosis’. They go on to suggest that inequity of access 
to testing is due to the lack of central funding, and this limitiation on funding means 
that local funding has to be sourced or that haematologists have to be selective in 
the patients they choose to test. They also recognise that the TATs in this area of 
testing are relatively high, affected by the sequential testing methodologies 
employed. A change in this TAT would result in the need for parallel testing and an 
increased financial burden. Finally, they conclude that future genetic testing for 
myeloma is likely to increase with the introduction of further targeted therapies, 
highlighting the potential use of Vemurafenib and Venetoclax in BRAF mutated and 
t(11;14) myeloma respectively, and indeed touch on the need to complete testing at 
more than one time point in a patients disease. 
 
NHS England Rationalisation of Genomics Services 
At this stage, by way of background understanding, it becomes ncessary to discuss 
National changes we are seeing as part of NHS Englands reconfiguration of genomics 
services. Genomic laboratories were invited to tender for the provision of genomics 
services as seven regions covering England, not as the 20+ laboratories currently 
offering genomics services. In October 2018, the seven genomics laboratory hubs 
(GLH) were announced following the complex tender process. 
As part of this reconfiguration process, a National Test Directory has been produced 
detailing the testing repertoire to be covered by each GLH, and ultimately funded by 
NHS England from April 2021.  For myeloma this testing covers: 
Structural IGH rearrangement testing: t(4;14) IGH-FGFR3, t(6;14) IGH-CCND3, 
t(11;14) IGH-CCND1, t(14;16) IGH-MAF and t(14;20) IGH-MAFB, and this can 
be offered as part of an NGS panel 
Hyperdiploidy copy number changes 
del(1p) copy number detection 
Gain(1q) copy number detection 
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del(17p) TP53 copy number detection 
Small variant detection; to include KRAS, NRAS, BRAF, TP53, DIS3, FAM46C 
and IRF4 
Currently the copy number changes are recorded as FISH testing, but we are aware 
of a small number of laboratories offering array or MLPA testing for these tests. As 
these technologies may represent a cost saving over large panels of FISH tests, 
proposals to include this as alternative test have been accepted. 
The small variant detection is listed as a multi-target NGS panel, and information 
from the most recent GenQA survey shows only a single laboratory considering 
offering NGS panel testing covering these genes. 
The reconfiguration of genomics services remains in flux with many unanswered 
questions in relation to the finances, the operational functions of the main central 
laboratories and indeed the ‘spoke’ laboratories, the IT infrastructure, quality 
processes, research and development, and staffing. However, from a testing 
perspective, and specifically for myeloma, this could drive the standardisation of 
testing, and indeed financial standardisation in turn leading to equity of access to 
diagnostic testing. 
The most current test directory published in August 2020 describes the following 
testing myeloma: 






The test directory states that these abnormalities could also be detected using an 
NGS fusion panel. As IGH rearrangements are not standard fusion rearrangements 
these remain difficult to detect with panel based NGS, and would require the 
application of low coverage WGS.  There is also a FISH test listed for IGH 
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rearrangement testing to cover the use of a breakapart probe, and MYC 
rearrangement by FISH has been added to this iteration. 
FISH for copy number changes of: 
 Hyperdidploidy 
 CDKN2C (deletion of 1p) 
 CKS1B (gain of 1q) 
 TP53 deletion 
The test directory now makes reference to MLPA and NGS (but not array analysis) as 
suitable alternative methodologies for copy number detection. 









Best Practice Recommendations  
It was clear from the survey carried out in 2014, that there was a need for 
standardisation and best practice recommendations. As part of the GenQA 
consortium, we considered that generalised guidelines were required for the whole 
of haemato-oncology diagnostic testing and led by Katrina Rack, we have completed 
and published recommendation in Leukemia. My role in this was to complete the 
myeloma recommendations section. 
• Rack et al (2019). European recommendations and quality assurance for 
cytogenomic analysis of haematological neoplasms. Leukemia 33(8):1851-
1867123. 
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These recommendations are brief, and production of myeloma specific guidelines 
including additional detail are also in production, but have not yet been published. 
These guidelines would cover the genomic targets required as discussed in the 
general guidelines, but also cover in more detail the technologies that could be 
employed. There are disease specific concerns that could also be covered, such as 
whether to limit testing to myeloma patients or whether MGUS patients would also 
benefit, whether follow up genetic testing is appropriate or whether this would be 
better managed with flow cytometry, consideration of the age of patients to be 
tested, the requirement for testing specific cell selections, and understanding the 
consequences and how to manage reporting if this is not possible. The 
recommendations also cover how to report these, sometimes, complex results and 
discusses appropriate turnaround times and quality assessment. 
 
GenQA Scheme Concluding Remarks 
To summarise this chapter, we have been able to describe the successful 
introduction and implementation of an EQA for genetic diagnosis in myeloma 
through GenQA and my involvement on the Haematological-Oncology SAG. This ran 
for two years as a pilot scheme and has now run for a further five years with full EQA 
scheme status. The involvement of the EQA scheme into the overall project was 
considered crucial; suggesting potential genomic testing strategies for myeloma in a 
diagnostic NHS laboratory, has a requirement of an EQA scheme to complement the 
service. The EQA scheme validates the testing strategies. The EQA scheme goes 
further allowing the educational component to guide participants, and reduce the ad 
hoc nature of testing, it also offers a spring board from which to access expertise 
required to produce and recommend best practice. 
The EQA participation has gradually increased over the scheme period from 39 in 
2014 to 64 in 2018, showing a 64% increase in participation from 2014 to 2018. 2018 
saw participation from all UK laboratories offering myeloma testing, and a number of 
European and International laboratories Although the performance status over the 
five years has fluctuated, there is an overall downward trend in poor performance 
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from 15.4% in 2014 to 4.7% in 2018, demonstrating a positive effect of the 
educational component provided by the scheme and increased awareness of the 
requirements of a diagnostic genomics strategy for myeloma over this time period.  
As part of this EQA scheme, a survey was issued in 2014 alongside the pilot, and the 
further similar survey was issued in 2018 alongside the fifth EQA scheme. The 
inaugural scheme survey confirmed the suspicion that the genetic diagnosis in 
myeloma at this time was indeed ad hoc, and demonstrated that the quality and 
extent of testing provided was inequitable. This highlighted the requirement, not 
only for the educational component provided by the EQA scheme, but for the 
production of best practice recommendations in this area. Broad best practice 
recommendations covering genomic testing for all haem-onc disease groups have 
been produced and published123, and further work to produce more in depth 
myeloma specific best practice guidelines are also currently being produced.  
Over the period that the EQA scheme has run, we have seen a degree of 
harmonsation of genetic testing, with a more consistent, equitable approach to the 
strategies employed by diagnostic genetic laboratories, demonstrating the impact 
that EQA can have through participation and education. Although all laboratories are 
now offering what are considered to be the essential tests in the genomic testing of 
myeloma, not all laboratories are carrying out this analysis on plasma cell 
populations, (which is considered best practice) and the extent and quality of testing 
can still be considered inequitable. The majority of laboratories only employ FISH 
methodologies, but the 2018 scheme and survey show a small number of 
laboratories using both MLPA and array, and indeed four laboratories describing the 
future validation of NGS technologies as part of their testing regimes. 
A similar study undertaken by a commercial company has confirmed very similar 
findings to our own, but has gone further to suggest that based on population sizes 
and patient numbers receiving testing, a number of myeloma patients are still not 
receiving any kind of genomics testing as part of their diagnosis. This study suggests 
this is related to the funding of this testing; direct NHS funding is currently not 
available, so laboratories are offering this as cost per test or have found innovative 
local funding sources. With the imminent changes in NHS Englands reconfiguration 
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of genomics services, we know that myeloma testing does appear on the National 
Test Directory which in turn means that this test should be funded nationally from 
April 2021.  
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Chapter 6: Discussion  
During the time of this project I have held positions within both Sheffield Diagnostic 
Genetics Service (SDGS) at Sheffield Children’s Hospital NHS Trust and at the 
Haematological Malignancy Diagnostic Service (HMDS) based at St James’s Hospital 
Cancer Centre within Leeds Teaching Hospitals Trust.  These roles have driven a 
strong interest in translational research, and I have been keen to ensure that the 
results from this work directly influence the strategy for genetic testing for myeloma 
patients, inform best practice and result in setting up of a quality assessment 
scheme across the UK.  
The project aims to explore a number of different objectives: 
Objective 1 was to compare five different genetic technologies, readily available in a 
diagnostic genetic laboratory, and their ability to identify genetic signatures 
associated with plasma cell neoplasms. Karyotyping, FISH, MLPA, DNA array analysis 
& targeted NGS were applied to a cohort of patients in order to assess the results 
obtained, and their ability to do this in an effective and efficient manner, within the 
time constraints required of a diagnostic testing scenario. A number of genetic 
changes have been shown to provide valuable information about disease prognosis 
and are beginning to guide treatment decisions.  
Objective 2 was to explore a possible or potential relationship between the genetic 
signatures associated with bone related genes, the ‘osteome’, and the likelihood or 
extent of bone damage associated with the patient’s myeloma disease. This 
objective worked to the strengths of the research group and their interest in 
myeloma bone disease. A targeted NGS panel was created including genes 
associated with the ‘osteome’; genes involved in the development, influence, 
maintenance and destruction of bone. Treating the bone manifestations of myeloma 
is challenging; current treatments are able to offer protection and slowing of bone 
degradation but can rarely reverse the process. If correlations between the 
mutations and variants in these genes and the extent of bone disease can be made, 
it may be possible to identify patients considered at increased risk of a severe bone 
phenotype associated with their myeloma. This, in turn, may offer the opportunity to 
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treat this group of patients more proactively, slowing the advancement of the bone 
manifestations or open up the discussion about the use of anabolic treatments in 
myeloma and the potential opportunity to adopt a more personalised medicine 
approach. 
Finally, objective 3 involves using the evidence gathered in objective 1 to devise an 
all-encompassing diagnostic genetic testing panel for use in a diagnostic genetic 
laboratory considering and proposing best practice guidelines to create a more 
consistent, equitable harmonisation of diagnostic genetic testing for MM within the 
UK. Quality assessment schemes exist for the majority of genetic tests completed as 
part of a diagnostic laboratory. At the start of this project, this was not available for 
myeloma genetic testing, and this objective includes the introduction, through links 
with NEQAS, of a quality assessment scheme for the genetic testing for myeloma 
patients.   
 
Discussion of the Genetic Results and Techniques Employed 
As described, the initial part of this project has focussed on collection and processing 
of patient bone marrow samples and exploring the genetic signatures associated 
with plasma cells neoplasms, consistent with the first objective described in the 
project aims. Five main genetic technologies have been explored with respect to 
analysis of myeloma patient samples; cytogenetics (karyotyping), FISH, MLPA, DNA 
arrays and NGS, all of which are available within a diagnostic genetic laboratory. 
Over the period of this project, bone marrow samples were received from 113 
patients with a plasma cell neoplasm, all consented as part of the research project 
being conducted by Dr Andrew Chantry. Twelve patients were removed from the 
cohort following diagnosis of an unrelated condition or following confirmation that 
no plasma cell neoplasm was present. 
Of the remaining 101 patients, 91 patient samples had their marrows cultured and 
processed for karyotyping, 101 of these samples were FISHed, 45 patients had MLPA 
analysis, 36 patient samples were analysed using the Affymetrix DNA array, and 24 
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patient samples were assessed using a bespoke NGS panel designed to assess both 
genes associated with myeloma, and a set of genes, considered the osteome, which 
are known to be involved with bone and myeloma interactions. The ideal scenario 
would have been to assess all samples using all five technologies, however the 
quality and quantity of bone marrow sample, and the CD138+ve cell selections from 
the bone marrow varied dramatically. Therefore, many samples were insufficient to 
analyse in parallel using all five platforms. In addition to the sample limitations, 
genetic technologies are expensive, and the number of samples processed for each 
technology was carefully planned to fit within the finances available to fund this 
project. 
At the beginning of the project a number of samples were processed for FISH using 
the whole marrow, and it became clear very quickly that samples must be selected in 
order to assess the CD138+ve plasma cells only. The final project cohort only 
included samples with CD138+ve cell selections, except for a single patient with 
plasma cell leukaemia who demonstrated an extremely high level of plasma cells as 
part of his disease. This must be considered part of the best practice 
recommendations, and indeed it is recognised throughout the literature, that 
analysis of whole bone marrow samples is not suitable. The disease can be present in 
10% of cells and the abnormalities can also present at a low level within the plasma 
cells. Therefore, to increase the chance of detecting genetic abnormalities a method 
of plasma cell selection must be employed. 
The five genetic technologies explored demonstrate a range of results and these are 
explored and described in depth in chapter 3, the advantages and disadvantages of 
these technologies are also discussed. In summary, conventional G banded 
cytogenetic analysis (karyotyping) offers the benefit of whole genome analysis, albeit 
at a low resolution, which allows the simultaneous assessment of rearrangements, 
including the IGH rearrangements (except t(4;14) which is cytogenetically cryptic) 
and copy number changes including ploidy changes. Small changes (<5-10Mb) and 
mutations cannot be detected using this technology. The requirement for cells in 
metaphase can be extremely problematic due to the low proliferative rate of the 
terminally-differentiated mature plasma cell and is recognised as technically 
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challenging. Although adaptations to the culturing process are possible to increase 
the level of dividing plasma cells, it cannot create the equivalent of a cell selection 
process, and therefore cytogenetic abnormalities are only reported in approximately 
30% of myeloma patients42. Our project cohort showed a failure rate of 14.3%, and 
an abnormality rate of 24.4%. Karyotyping requires a high level of skill and training, 
carries a degree of analytical subjectivity and is time-consuming which contribute to 
the slow and expensive nature of this technology. The cumulative effect of these 
factors excludes karyotyping as a robust method for the genetic assessment of 
myeloma patient samples.  
FISH has the ability to utilise interphase cells, eliminating the problems associated 
with metaphase capture. FISH allows the analysis of increased cell numbers; 50-200 
cells not being an unreasonable analysis level. FISH can also be performed on bone 
marrow samples that have undergone a CD138+ve cell selection process, each of 
these aspects offer a distinct advantage over karyotypic analysis. FISH is generally 
considered a robust technique, and in this project, the failure rate was just 0.7%. 
We have described a two-step FISH process in this project, including IGH 
rearrangement, TP53 and 1p/1q in step 1 and then assessment of the partner gene 
(FGFR3, MAF or CCND1) in step 2 if IGH was shown to be rearranged. The panel does 
not currently include hyperdiploidy assessment. 
Of the 101 cases processed using FISH in this study, 55 patients (54.4%) 
demonstrated abnormality. Based on the literature, 60% is the approximate FISH 
abnormality rate expected utilising the probe panel described here25,42,113. An 
abnormality rate of 90% has been reported in myeloma samples where extended 
FISH panels including hyperdiploidy assessment are employed42. Our abnormality 
rate (54.4%) is likely to reflect our patient cohort which included a range of plasma 
cell neoplasms, not simply myeloma.  
FISH does have limitations such as probe size and false positive rates. Probe sizes 
range from 150kb-1Mb, and therefore small deletions or mutations within genes or 
within the probe target cannot be detected. Specific probes have an associated false 
positive rate, dependant on the probe set formation. This is often low and quoted as 
1-4% by the manufacturers. Myeloma genetics can be extremely complex, and this 
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complexity is represented in the FISH probes which can generate non-standard signal 
patterns. This reflects a strong need to ensure robust training of personnel involved 
in this analysis to ensure that non-standard patterns are understood and correctly 
interpreted. 
Although the FISH technique itself is not considered expensive, FISH processing is not 
conducive to high throughput processing, and the application of multiple probe sets 
and the time consuming nature of the test and analysis can become costly. 
Currently, FISH remains the most widely used methodology in the genetic 
assessment of myeloma. 
Within our cohort, 11/14 (78%) cases with FISH abnormalities were cytogenetically 
normal, confirming that normal non-neoplastic populations had been analysed 
cytogenetically in these cases. Conversely those patients with abnormal karyotypes 
and a normal FISH profile, were all hyperdiploid cases and would have been detected 
with an extended panel, or a further technique to assess hyperdiploidy. Therefore, 
based on clinical utility, FISH offers a much superior test compared to karyotyping. 
In conclusion, small FISH panels offer an efficient and accurate way to detect 
rearrangements and copy number changes in myeloma. However, FISH can be an 
expensive and time-consuming technique when multiple probes are used within 
panels, and has limitations based on probe size and an associated false positive rate, 
as well as a need to have well trained personnel who fully understand the genomic 
basis of the signal patterns allowing correct and robust interpretation to be made. 
The MRC Holland MLPA kit offers a multiplex technique designed to detect gain and 
loss of ~60 nucleotide length probes. It is considered a cost-effective technique and 
can determine both hyperdiploidy and the prognostic copy number changes seen in 
myeloma using DNA from selected cell populations. Abnormalities were detected at 
a high level (93.1%) in our cohort. As the probes are so small, MLPA can pick up 
much smaller deletions than FISH, and the ease of analysis is also attractive. MLPA is 
part of the analysis undertaken as part of the UK myeloma trials. 
However, MLPA can only detect copy number changes, and only in the regions 
targeted by the probe set. It cannot distinguish between mutation and deletion, as 
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both scenarios result in non-amplification. Therefore, MLPA would have to be 
considered alongside a technique to determine IGH rearrangement status118. Low 
level abnormal populations can also be problematic, and in the case of multiple 
myeloma, plasma cell purification to a minimum level of 50% purification would be a 
prerequisite. 
We demonstrated a high failure rate for the technique. This is likely to be related to 
the requirement for high quality DNA and the MLPA process can be highly sensitive 
to contaminants in the system. If this technique were to be included in a testing 
strategy, contingency would be required for those samples with poor quality DNA. 
The Affymetrix CytoScan HD DNA array allows whole genome copy-number analysis 
and LOH detection at a high level of resolution which can targeted at DNA from 
CD138+ve cell selections. However, balanced translocations and rearrangements, 
and mutations at a base pair level are not detectable. A number of rearrangements 
do show small regions of loss and/or gain at, or around, the breakpoint regions, but 
this cannot be considered definitive evidence of rearrangement. Therefore, if arrays 
were to be utilised as part of a genomic testing strategy for myeloma, then this 
would need to be alongside a technique for IGH rearrangement detection.  
This specific array methodology is highly sensitive to DNA quality, and has shown a 
high level of variability in the quality of the results. 85.7% of cases in this cohort 
showed an abnormal result, lower than the reported abnormality rate in the MLPA 
cohort. Array analysis requires the abnormality to be present in approximately 30% 
of cells, and even processing DNA extracted from selected CD138+ve cells, some 
abnormalities will be missed. This has created a degree of discordance with the array 
results and other techniques used in this study. 
Array processing is time consuming and expensive, and it is not considered a high 
throughput technology. Whilst the arrays do provide highly detailed, good quality 
information at a whole genome level and potentially more than offers true clinical 
utility. This, in turn requires extensive, time-consuming analysis resulting in an 
ultimately expensive technology based on the cost of the arrays and the personnel 
time.  
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Implementation of NGS technology into NHS diagnostic laboratories is moving at a 
very fast pace. This has been encouraged, in part, by the NHS England changes of the 
delivery of genomics services. There remain issues and concerns with the expense, 
the magnitude of data, the time-consuming analysis and interpretation, the minimal 
analytical tools and the issues of consent and ethics relating to the transition 
towards this technology. 
There are number of ways of applying NGS technology in a more manageable way, 
from both a technological, analytical and financial point of view. NGS panels offer a 
chance to harness the accuracy and depth of NGS analysis in a more targeted fashion 
by selecting a set of genes than, for example, WGS or WES. As part of this project, a 
targeted panel was created to include myeloma genes which could be considered 
part of a diagnostic testing strategy and osteome genes designed to address the 
second hypothesis; to assess whether specific bone related genetic signatures can 
indicate the extent or severity of bone involvement in MM, allowing proactive 
preventative and protective treatment. Using this approach, the analysis is clearly 
limited to the set of genes that are involved in the panel and loses the functionality 
of novel gene discovery. 
The panel performed well, providing good, robust data for the genes chosen. The 
panel was able to show a number of abnormalities consistent with those reported in 
the literature, and in particular detected those mutations associated with the MAPK 
and NFĸB pathways known to be associated with myeloma is a proportion of cases. 
The NGS panel has to be considered as additional testing as it does not provide 
information on copy number changes or rearrangement detection. 
This information is not currently used to direct treatment or clinical management of 
myeloma patients, but this is likely to be incorporated into clinical decision making in 
the future. As NGS becomes more sophisticated, it can be envisaged that an NGS 
panel could be designed using both DNA and RNA to assess copy number, 
rearrangement detection for those commonly seen in myeloma and a specific panel 
of mutations. However, currently this is not available within the context of NHS 
diagnostic testing.  
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In conclusion, the five genetic technologies described and explored here for the 
genomic assessment of myeloma offer a range of both advantages and 
disadvantages, all of which should be considered in the context of providing a 
diagnostic testing strategy for NHS patients, which has to balance the clinical utility 
of the information provided and the cost and turnaround times of the testing.  
 
Proposed Diagnostic Strategies and Best Practice Recommendations 
Based on the assessment of the five technologies described here, understanding the 
pros and cons, and the limitations of each, it is clear that a single technology solution 
is not possible for all aspects of the genetic assessment of myeloma. It is also clear 
that all analysis should be targeted to selected cell populations in order to capture 
abnormalities present in the plasma cells. FISH is still considered by many to be the 
gold standard, and indeed, based on the information collected as part of the quality 
assessment chapter (Chapter 5), FISH is overwhelmingly the most common strategy. 
However, FISH is not conducive to high throughput processing, and as FISH panels 
become larger, the expense and the time-consuming nature of the processing and 
analysis becomes difficult to manage within a busy diagnostics laboratory. We have 
proposed that the tandem use of FISH and MLPA provide a more cost-effective 
testing strategy. FISH would be used for the assessment of the IGH rearrangements, 
whereas the copy number targets can be assessed in a higher throughput and 
multiplexed MLPA assay. It is understood from the assessment of these 
technologies, that MLPA does have a relatively high failure rate, and a contingency 
FISH pathway for these failed MLPA samples would be required. 
Karyotyping has essentially been excluded from the proposed strategies, as it cannot 
be targeted to plasma cells (robustly), the abnormality rate is low (so clearly cannot 
detect the abnormal population in the majority of cases), the resolution is poor and 
the expertise and time required for analysis makes this technique expensive. Array 
analysis has also been excluded from our proposed strategies; the technique cannot 
detect IGH rearrangements (although some cases do show copy number changes 
around the breakpoints) and essentially assess copy number only, and compared to 
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MLPA, which does similar, is time consuming costly and provides a level of resolution 
and detail that is not clinically required. 
Our proposed testing strategies, also, exclude the assessment of the mutational 
status of myeloma related genes. Currently, there is no real clinical need for this, 
although many publications suggest both a prognostic and therapeutic benefit. With 
regard to future proofing a testing strategy, the NGS mutational assessment would 
be a requirement. Currently this would mean adding a third technology to the 
strategy, although as NGS technologies mature, it is possible that a dual DNA and 
RNA NGS testing strategy could provide the full rearrangement, copy number and 
mutational assessment required in a bespoke NGS panel. However, the IGH 
rearrangements currently remain difficult to determine using an NGS strategy, 
therefore it may be that FISH is the most appropriate technique for this assessment 
for the foreseeable future. 
Whilst the proposed testing strategy is currently appropriate based on available 
technologies in diagnostic laboratories and the clinical utility of myeloma genomics, 
a more forward thinking and future approach to the genomic diagnosis of myeloma 
was also proposed considering the use of low coverage WGS, WES and expression 
profiling124.  
As well as considering the technologies that would be suitable for myeloma genetic 
testing, it is important to assess the regions that should be targeted by such 
strategies focussing on those regions associated with a prognostic or therapeutic 
indication. As part of chapter 3, and indeed through the quality assessment work as 
part of chapter 5, I have presented my views on the target regions for inclusion 
ranking them from mandatory, highly recommended and recommended, and then 
regions that are not currently required, some of which however, are likely to become 
future requirements. Changes in technology, therapeutic advancements and 
increased knowledge from trials and publications are likely to mean this remains a 
dynamic area with a requirement for regular review. 
During the period of this PhD project we have seen quite dramatic changes in the 
way in which genomics services are managed. NHS England have undertaken a 
reconfiguration process resulting in genomics services being offered by seven 
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genomics laboratory hubs (GLHs) across England. This process has had the aim of 
creating efficiency and financial savings, but also introducing consistency to the 
services offered. This has been managed through a procurement process against a 
specified test directory of services for which delivery will be mandatory. It is 
recognised that the initial test directory did not include all required tests, and steps 
are now in place in which an expert group of clinicians and scientists have been 
assigned to each of three test directories; rare disease, cancer and 
pharmacogenomics, in order to manage the changes and amendments to those test 
directories going forward. I am now part of the cancer test directory expert group. 
Currently, for myeloma the test directory includes assessment of the IGH 
rearrangements (including five partners FGFR3, MAF, MAFB, CCND1 and CCND3), 
deletion of 1p (CDKN2C), gain of 1q (CKS1B), TP53 deletion, MYC rearrangement and 
hyperdiploidy assessment. It also includes suggests a multi-target NGS panel to 
include variant detection of seven genes: KRAS, NRAS, BRAF, TP53, DIS3, FAM46C 
and IRF4. Although the current test directory does not make any reference to this for 
myeloma, it has since been recognised that a level of ‘essential’ and ‘desirable’ 
should be added to the test directory, and we are likely to see this for myeloma in 
future iterations. Whilst the test directory indications do not entirely support the 
proposed testing strategy from this project, it does give some indication of what 
testing would be commissioned from NHS England. 
As part of the GenQA consortium, from the initial survey described in chapter 5, and 
with the changes proposed by NHS England, it was considered that generalised 
guidelines were required for the whole of haemato-oncology diagnostic testing.  Led 
by Katrina Rack (GenQA), we have completed and published recommendations in 
Leukemia. My role in this was to complete the myeloma recommendations section. 
These recommendations are brief, and production of myeloma specific guidelines 
including additional detail are also in production, but have not yet been published. 
These guidelines would cover the genomic targets required as discussed in the 
general guidelines, but also cover in more detail the technologies that could be 
employed. There are disease specific concerns that could also be covered, such as 
whether to limit testing to myeloma patients or whether MGUS patients would also 
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benefit, whether follow up genetic testing is appropriate or whether this would be 
better managed with flow cytometry, consideration of the age of patients to be 
tested, the requirement for testing specific cell selections, and understanding the 
consequences and how to manage reporting if cell selection is not possible. The 
recommendations also cover reporting results and discusses appropriate turnaround 
times and quality assessment. 
 
Case Report Discussion 
Three cases were presented to demonstrate a range of abnormalities and clinical 
scenarios that have made up the patient cohort in this study. 
Patient #113 had plasma cell leukaemia and showed a complex karyotype with an 
IGH-MAFB rearrangement. Although IGH rearrangements are seen in approximately 
60% of myeloma patients, the IGH-MAFB rearrangement is rare, seen in only ~2% of 
patients and considered one of the poor prognostic IGH rearrangements. The 
t(14;20) translocation was seen karyotypically and then confirmed by FISH. Loss of 
1p, gain of 1q and loss of chromosome 13 were seen karyotypically and confirmed by 
MLPA and array. A rearrangement of chromosome 8 seen cytogenetically raised the 
suspicion of a MYC rearrangement, which was confirmed by FISH. Array analysis 
provided additional information to support a more complex non-standard 
rearrangement involving chromosome 2 and duplication of chromosome 8. This case 
report demonstrates the additive value of utilising the techniques described in this 
project, providing practical evidence of the strengths and weaknesses of each 
technique. Each additional technique provides additional information to the overall 
genomics picture creating a deeper and clearer understanding of the abnormalities 
present. The time-consuming nature, and cost of this strategy for each case 
precludes diagnostic use but demonstrates the cumulative effect of each technology 
and provides information for both the first and third hypotheses. 
Patient #175 describes a patient with plasma cell myeloma and a hyperdiploid 
karyotype. Hyperdiploidy is seen in approaching 50% of myeloma patients. This 
patient also had an unbalanced rearrangement of chromosomes 1 and 17, which 
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results in loss of the short arm of chromosome 17 and gain of the long arm of 
chromosome 1, both of which are considered poor risk markers according to Boyd et 
al, and would be classified as a ‘double hit’ myeloma in this context112. However, 
perhaps more interestingly, this patient also shows evidence (non-clonally by 
cytogenetic analysis) of a possible jumping translocation in which the long arm of 
chromosome 1 was shown to be associated with a number of different chromosomal 
partners. The FISH pattern offered further evidence of the clonal nature of this 
phenomenon with gain of CKS1B on the long arm of chromosome 1 seen at a 
dramatically higher level that the loss of TP53. MLPA also confirmed the 
hyperdiploidy and gain of chromosome 1q, but did not show any evidence of TP53 
loss, highlighting one of the downfalls of this technique, i.e. the inability to detect 
low level rearrangements. Jumping translocations are well documented, but a rare 
and interesting finding, however, this abnormality has no real clinical impact.  
Finally, the third case report described patient #233 who presented with plasma cell 
myeloma with a hyperdiploid karyotype with a gain of the long arm of chromosome 
1. A few months following the myeloma diagnosis, this patient was also diagnosed 
with lung cancer. NGS panel analysis of this patient showed a hypermutated profile 
with an approximately 50-fold increase in the number of variants seen when 
compared to the remaining patients in the cohort. Further examination, and 
exclusion of possible sequencing artefacts and treatment causes, suggested this was 
likely to be a true finding. Hypermutation is a rare finding, but small numbers of 
cases with dramatically increased variant numbers have now been described in a 
number of cancer types. The expectation from this type of genetic profile would be a 
poor outlook, however, this patient continues to be treated for both her myeloma 
and concurrent lung cancer and is clinically well. 
 
NGS Analysis of the Osteome  
Bone disease associated with myeloma is seen in approximately two thirds of 
patients at diagnosis, and is involved in up to 90% of patients throughout the disease 
course. This bone phenotype can, however, be extremely variable, as can the 
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treatment of these bone manifestations. Bisphosphonates are readily used, but 
although prevention and protection from further skeletal events has been shown, 
there is little evidence of reversing or repairing existing bone disease. Anabolic 
therapies currently used in osteoporosis may have a role in myeloma and have been 
shown to stimulate bone formation. Objective two of the thesis aimed to explore the 
hypothesis that a relationship between genetic mutations associated with the 
osteome and the likelihood or extent of the bone disease associated with the 
patient’s myeloma exists. A relationship of this type could potentially highlight a 
cohort of patients that could be treated more proactively or intensively to prevent or 
slow the bone disease associated with the myeloma. A number of genes associated 
with the osteome were identified and added to the bespoke NGS panel created as 
part of this project. The cohort assessed using the NGS panel was made up of 24 
patients, 12 with bone lesions and 12 who demonstrated no evidence of bone 
lesions. 
Excluding one patient, in which the NGS failed completely, high risk germline variants 
were detected in six different genes present in seven of the remaining 23 patients. 
Three of the seven patients belonged to the patient cohort with bone lesions and 
four of the patients demonstrated no bone lesions. Two somatic variants were 
detected in the CD138+ve cell selection DNA, one each in two patients, but neither 
variant was considered pathogenic. It is acknowledged that the sample numbers 
were extremely low, but these results provide no evidence to suggest an association 
or relationship of risk variants and bone damage. High risk variants in the germline 
samples were present in both the bone lesion and non-bone lesion cohorts. 
The discussion in chapter 4 details reasons why an association was not seen in this 
study; the number of patients included in this analysis cohort, the genes and indeed 
the number of genes chosen as part of the osteome cohort, the level of filtering 
required to make a manageable data set, the depth of analysis undertaken on each 
variant, the tissues available for analysis and the selection of the bone lesion vs non-
bone lesion cohort. Repeating this analysis adjusting a number of these factors; a 
larger patient cohort, with follow up data on the bone lesions over the course of 
their disease, an increased number of genes, and a deeper level of variant 
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assessment looking at variants in all gene regions would address a number of issues 
seen in this part of the analysis. A similar project could also be undertaken using 
RNAseq instead of the osteome gene panel. The RNAseq assessment allows analysis 
of the gene expression levels, it covers all genes in single sequencing event. 
A larger number of genes were associated with variants in the germline samples, and 
assessing associations that may provide a predisposition to a worse bone phenotype 
would really require extensive GWAS studies, like those described by Houlston et 
al74, who assessed over 7,000 myeloma patients and over 200,000 control samples. 
Those sample numbers and levels of analysis are beyond the scope of a project like 
this. 
In conclusion, the work presented as part of chapter 4 on the osteome has allowed 
some initial work to be completed to explore the presence of variants in bone 
related genes in both the germline and somatic samples processed using the NGS 
osteome panel. The power of the current study is not strong enough to show 
positive or negative relationships, however, this exploratory work has not been able 
to demonstrate any evidence to support a hypothesis that relationships exist 
between the genetic mutations in bone related genes and the likelihood or extent of 
myeloma related bone damage. Within the somatic changes seen, no variants were 
considered pathogenic, and those germline variants associated with risk, and indeed 
high risk, were seen in both the bone lesion and the non-bone lesion cohorts. We 
had considered this work could direct treatment to a cohort of patients likely to have 
a poorer bone phenotype, as long term treatment with bisphosphonates has some 
drawbacks, but perhaps this opens up the discussion about the more widespread use 
of anabolic therapies in myeloma which have shown the ability to stimulate bone 
formation and therefore the ability to counteract the bone devastation caused by 
the disease in many patients. 
 
Quality Assessment Scheme for Myeloma  
Objective three describes the more translational aspects of this project by way of 
proposing strategies to provide an all-encompassing diagnostic genetic testing panel, 
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introducing a quality assessment scheme for myeloma genetic testing in 
collaboration with colleagues within NEQAS (GenQA), both with the aim of 
influencing best practice through GenQA and the Association for Clinical Genetic 
Science (ACGS) to encourage a more consistent, equitable and harmonised approach 
to diagnostic testing.   
Chapter 5 describes the successful introduction and implementation of an EQA 
scheme for genetic diagnosis in myeloma through GenQA and my involvement on 
the Haematological-Oncology SAG, and demonstrates the impact that more 
translational research like this can have. The EQA scheme ran for two years as a pilot 
scheme and has now run for a further five years with full EQA scheme status. As well 
as providing a forum for validation of the genetic services aimed at providing 
myeloma genetic testing, the EQA scheme goes further providing an educational 
component to guide participants, which in turn has the effect of reducing the ad hoc 
nature of genetic testing.  
The EQA scheme was first offered as a pilot scheme in 2014. The EQA scheme 
participation has gradually increased over the scheme period from 39 in 2014 to 64 
in 2018, showing a 64% increase in participation from 2014 to 2018. 2018 saw 
participation from all UK laboratories offering myeloma testing, and a number of 
European and International laboratories. Although the performance status over the 
five years has fluctuated, there is an overall downward trend in poor performance 
from 15.4% in 2014 to 4.7% in 2018, demonstrating a positive effect of the 
educational component provided by the scheme and increased awareness of the 
requirements of a diagnostic genomics strategy for myeloma over this time period. It 
should be noted that the scheme has continued in 2019, and will be performed again 
in the Autumn of 2020. 
As part of this EQA scheme, a survey was issued in 2014 alongside the pilot, and then 
a further similar survey was issued in 2018 alongside the fifth EQA scheme. The 
inaugural scheme survey confirmed the suspicion that the genetic diagnosis in 
myeloma at this time was indeed ad hoc, and demonstrated that the quality and 
extent of testing provided was inequitable. This highlighted the requirement, not 
only for the educational component provided by the EQA scheme, but for the 
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production of best practice recommendations in this area. These have now been 
published as described.  
Over the period that the EQA scheme has run, we have seen a degree of 
harmonisation of genetic testing, with a more consistent, equitable approach to the 
strategies employed by diagnostic genetic laboratories, demonstrating the impact 
that EQA can have through participation and education. Although all laboratories are 
now offering what are considered to be the essential tests in the genomic testing of 
myeloma, not all laboratories are carrying out this analysis on plasma cell 
populations, (which is considered best practice) and the extent and quality of testing 
can still be considered inequitable. The majority of laboratories only employ FISH 
methodologies, but the 2018 scheme and survey show a small number of 
laboratories using both MLPA and array, and indeed four laboratories describing the 
future validation of NGS technologies as part of their testing regimes in line with the 
chnanges proposed by the new NHS England test directory. 
 
Conclusions and Further work 
At the outset, this project set out three objectives: 
Objective 1: To compare five different genetic technologies, readily available in a 
diagnostic genetic laboratory, and their ability to identify genetic signatures 
associated with plasma cell neoplasms. 
Objective 2: To explore and assess possible or potential relationships between the 
genetic signatures associated with bone related genes, the ‘osteome’, and the 
likelihood or extent of bone damage associated with the patient’s myeloma disease. 
Objective 3: To propose testing strategies for an all-encompassing diagnostic 
genetic panel for use in a diagnostic genetic laboratory, to introduce a quality 
assessment scheme for myeloma genetic testing and consider the requirement for 
best practice guidelines to create a more consistent, equitable harmonisation of 
diagnostic genetic testing for MM within the UK. 
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Approximately 100 myeloma patient samples were processed for genetic testing. 
Resources and indeed sample quantities were not available for all samples to be 
processed with all technologies; the majority of samples were processed for both 
karyotyping and FISH, approximately half had MLPA analysis, one third had DNA 
array analysis and one quarter were processed for NGS analysis. The results from this 
work are presented to complete objective one, including a number of interesting 
cases reports. A number of genetic changes have been shown to provide valuable 
information about disease prognosis and are beginning to guide treatment decisions. 
The results from these techniques were assessed based on the quality, effectiveness 
and utility of the diagnostic information provided within the financial and time 
constraints required of a diagnostic testing scenario. Understanding the techniques 
and the results provided allowed diagnostic testing strategy proposals to be 
presented, as well as looking to the future changes we are likely to see in this area, 
covering parts of objective three. 
The NGS work completed as part of the technology platform assessment was 
extended to include a number of ‘osteome’ genes. Chapter 4 focussed on this work, 
specifically addressing objective two aiming to explore the possibility of association 
with high risk variants in these bone genes and more severe bone phenotypes seen 
in patients with myeloma. Looking at these variants within both a somatic and 
germline context showed no evidence of association, although it is recognised that 
the sample numbers and experimental design was unlikely to demonstrate true 
association. It was considered that understanding the likelihood of whether a 
myeloma patient would exhibit a severe bone phenotype at the start of their disease 
could help target bisphosphonate therapy which is associated with some side effects 
and therefore treatment is often limited. This does open up the discussion of the 
blanket use of anabolic therapies in myeloma which have been shown stimulate 
bone formation in patients with other bone disorders. 
Objective three involved working with colleagues in NEQAS (GenQA) to introduce 
and implement an EQA scheme for genetic testing in myeloma. This was successfully 
implemented in 2014 as a pilot EQA initially, and has continued to run as part of the 
establishment schemes on a yearly basis since 2016. This included an educational 
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component to the scheme. Assessing the role and performance of the different 
genetic technologies associated with objective one, provided valuable information to 
guide the translational aspects of the project described in objective three. This 
allowed informed decisions to be made based on this information and on clinical 
guidelines to propose appropriate diagnostic genetic testing panel so for myeloma 
that not only provide clinical utility, but that also offer a diagnostic and financial fit in 
line with current NHS services. A survey was undertaken alongside the scheme in 
2014 and then repeated in 2018. We were able to demonstrate the impact that 
participation in the scheme, including the educational component, had on the 
strategies and testing programmes undertaken in the UK, with all laboratories 
conforming to the guidelines based on results from the 2018 survey. Collaboration 
with our NEQAS (GenQA) colleagues has also resulted in the production of best 
practice recommendations which we published recently in Leukemia. 
A number of areas of this project would benefit from further work. Objective two 
focussed on changes seen in the osteome, genes associated with bone formation 
and maintenance. The numbers of patients assessed did not offer the required 
power to assess a true relationship in this area. We looked at variants in somatic 
tissue and in the germline. The somatic tissue showed no pathogenic variants, and 
although a small number of potentially pathogenic variants were detected in the 
germline samples, they were seen equally in both bone and non-bone lesion cohorts. 
In order to determine germline variants that may carry a predisposition to a more 
severe bone phenotype, GWAS studies would be more appropriate requiring 
dramatically increased sample sizes, beyond the scope of this project. It may also be 
interesting to consider a similar project using RNAseq instead of the osteome gene 
panel. The RNAseq assessment allows analysis of the gene expression levels, and it 
covers all genes in single sequencing event. 
The work to introduce a NEQAS (GenQA) EQA scheme for genetic testing in myeloma 
has proven a success, and it is important to maintain this scheme allowing it to flex 
with the changes we are likely to see in both technology and breadth of testing in 
the coming years. 
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Finally, although publication of best practice recommendations provides an excellent 
outcome for this project, the current guidelines are broad and cover genetic testing 
and reporting for a range of leukaemia types. There are more specific and more 
detailed considerations associated with genetic testing and reporting in myeloma, 
and I would consider that more in depth myeloma specific recommendations are 
required. Work towards this goal is ongoing. 
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Appendix 1: Ethics Statement & Letter  
 
Ethics Statement: 
All procedures involving animals has been approved by the Home Office (PPL 
70/8799) and the University of Sheffield’s Animal Ethics Committee. Patient cells will 
be acquired with appropriate ethical permission (REC reference: 05/Q2305/96). All 
participants will provide written consent to participate in this study. Original consent 
forms will be stored in a secure location, and patient demographics and disease 
features entered into an encrypted database governed by the Research and 
Development Service Sheffield Teaching Hospitals, NHS Foundation Trust UK. This 
consent procedure was approved by the South Sheffield Research Ethics Committee 
in August 2005 and subsequently ratified by the NHS Health Research Authority, 
National Research Ethics Committee Yorkshire and the Humber - Sheffield in 




Copy of Ethics Letter, held by Dr Chantry, Programme Grant PI, and PhD project 
supervisor: 
 





Appendix 2: Reagent Recipes Associated with Culturing of Bone 
Marrow & FISH 
Bone Marrow Medium         
250mls McCoys 5A 
1.5ml 200mM L-Glutamine  
2.5ml Pen/Strep Antibiotic Mixture 
5mls 1M Hepes solution  
Filter into this 20mls Fetal Calf Serum  
 
Colcemid             
In ready diluted vials 10µg/ml  
Use PBS to dilute to concentration required (10mls colcemid to 10mls PBS) 
 
KCl Sweller (Potassium Chloride)   
Stock Solution (0.075M) 
Dissolve 11.2g of Potassium Chloride power into 2 litres of Deionised Distilled Water (DDW) 
Autoclave and store in fridge  
 
Banding Trypsin         
2.4g Trypsin 1:250 diluted in 2 Litres Sorensons  
Mix together on stirrer until just dissolved, and pot into 100mls aliquots  
 
Gurrs        
Add 1 Gurrs tablet to 1 litre DDW. 
Mix together well and pH to 6.8 
 
Hoescht 33258            
Stock Solution (50g/ml) 
Use Oxford Series-S weighing scales with glass doors and wear face mask. 
Add 0.025g of Bisbenzimide (light sensitive) to 500mls Gurrs buffer and mix. 
Wrap bottle in foil to avoid exposure to light. 
 
20xSSC (VYSIS)       
Dissolve 20xSSC powder (Abbott-Vysis/30-805850/66g) into 200ml DDW 
pH to 5.3 
2xSSC          
900ml DDW and 100ml 20xSSC (Fridge F1) 





Pepsin         
Mix 250mg Pepsin 3,300 U/mg (Sigma/P6887/5g) into 2.5ml DDW 
Aliquot into eppendorfs and store at -20oC  
 
Ethanol series       
(Hayman Absolute Alcohol A.R. Quality/2.5L) 
100% ~ 500ml Ethanol  
95%  ~ 475ml Ethanol + 25ml DDW 
70% ~ 350ml Ethanol + 150ml DDW 
 
Hybridisation Mixture    
5ml Formamide (BDH Analar/103266T/2.5L) 
10µl Tween 20 (Sigma/P7949/500ml) 
1ml 20xSSC 
4ml DDW 
1g Dextran Sulphate (Sigma/D8906/10g) - add slowly to dissolve 
Aliquot into eppendorfs and store at -20oC  
 
0.4xSSCT        
970ml DDW and 20ml 20xSSC  
3ml NP40 (Abbott-Vysis/30-804820) or Tween 20 (Sigma/P7949/500ml) 
Mix together and make final volume up to 1000ml  
















XT HS libraries (= all CD138 samples + 4 blood libraries):
Ref No.
SureSelect XT HS 
index primer
Index 
sequence (i7) i5 Peak size Average size Conc. (ng/ul)
Qubit conc 
(ng/ul)
Molarity (nM, from 
Qubit and average 
size)
#144 A03 AGCAGGAA NNNNNNNNNN 294 318 18.8 17.8 84.8
#88 B03 AGCCATGC NNNNNNNNNN 280 317 18.5 15.1 72.2
#161 C03 TGGCTTCA NNNNNNNNNN 277 309 15.3 13 63.7
#162 D03 CATCAAGT NNNNNNNNNN 279 308 16.8 12.9 63.5
#44 E03 CTAAGGTC NNNNNNNNNN 269 299 17 13.6 68.9
#179 F03 AGTGGTCA NNNNNNNNNN 283 320 19 16.6 78.6
#180 G03 AGATCGCA NNNNNNNNNN 287 322 19 14.7 69.2
#184 H03 ATCCTGTA NNNNNNNNNN 280 312 36.1 30.4 147.6
#136 A01 GTCTGTCA NNNNNNNNNN 356 392 1.5 1.69 6.5
#140 B01 TGAAGAGA NNNNNNNNNN 301 374 1.51 1.39 5.6
#191 C01 TTCACGCA NNNNNNNNNN 323 362 2.12 1.89 7.9
#198 D01 AACGTGAT NNNNNNNNNN 293 385 1.35 1.42 5.6
#200 E01 ACCACTGT NNNNNNNNNN 325 372 2.16 2.08 8.5
#199 F01 ACCTCCAA NNNNNNNNNN 306 369 0.714 0.766 3.1
#202 G01 ATTGAGGA NNNNNNNNNN 336 380 1.66 1.69 6.7
#209 H01 ACACAGAA NNNNNNNNNN 290 374 1.53 1.65 6.7
#232 A02 GCGAGTAA NNNNNNNNNN 298 373 1.37 1.32 5.4
#233 B02 GTCGTAGA NNNNNNNNNN 336 377 1.68 1.63 6.6
#235 C02 GTGTTCTA NNNNNNNNNN 337 367 0.907 0.805 3.3
GIAB A04 CCGTGAGA NNNNNNNNNN 403 422 1.52 2.5 9.0
#215 F02 TGGTGGTA NNNNNNNNNN 330 385 4.33 3.37 13.3
#230 G02 ACTATGCA NNNNNNNNNN 340 386 3.21 3.4 13.3
#234 D02 TATCAGCA NNNNNNNNNN 337 373 3.54 3.03 12.3
#208 B04 GACTAGTA NNNNNNNNNN 365 404 4.01 3.12 11.7
#217 C04 GATAGACA NNNNNNNNNN 356 402 3.53 2.79 10.5
Blood libraries prepared with XT HS
#202 E04 GGTGCGAA NNNNNNNNNN 318 350 3.89 3.43 14.8
#179 F04 AACAACCA NNNNNNNNNN 301 338 1.95 1.58 7.1
#208 G04 CGGATTGC NNNNNNNNNN 299 353 1.59 1.13 4.9

























from Qubit and 
average size)
#136 P5 i14 CTCTCTAT P7 i1 TAAGGCGA 385 441 1.29 4.84 1.31 4.5
#140 P5 i14 CTCTCTAT P7 i2 CGTACTAG 335 389 2.1 8.9 1.71 6.7
#198 P5 i13 TAGATCGC P7 i4 TCCTGAGC 384 445 12.3 45.8 12.7 43.2
#200 P5 i13 TAGATCGC P7 i5 GTAGAGGA 409 457 6.21 22.4 9.82 32.6
#199 P5 i13 TAGATCGC P7 i6 TAGGCATG 363 423 10.1 39.5 14 50.1
#234 P5 i14 CTCTCTAT P7 i5 GTAGAGGA 415 459 6.45 23.3 7.05 23.3
#232 P5 i13 TAGATCGC P7 i1 TAAGGCGA 357 422 4.94 19.4 5.56 20.0
#233 P5 i13 TAGATCGC P7 i2 CGTACTAG 393 447 7.27 27 9.41 31.9
#209 P5 i14 CTCTCTAT P7 i8 CAGAGAGG 348 409 4.44 5.58 20.7
#235 P5 i13 TAGATCGC P7 i3 AGGCAGAA 403 450 5.92 6.99 23.5
#144 P5 i13 TAGATCGC P7 i4 TCCTGAGC 406 449 6.44 7.02 23.7
#88 P5 i13 TAGATCGC P7 i5 GTAGAGGA 345 412 4.79 8.72 32.1
#44 P5 i13 TAGATCGC P7 i8 CAGAGAGG 381 439 9.75 11.6 40.0
#180 P5 i14 CTCTCTAT P7 i2 CGTACTAG 344 395 7.04 7.22 27.7
#184 P5 i14 CTCTCTAT P7 i3 AGGCAGAA 334 395 5.46 6.04 23.2
#215 P5 i14 CTCTCTAT P7 i4 TCCTGAGC 376 432 6.7 6.97 24.4
#230 P5 i14 CTCTCTAT P7 i7 CTCTCTAC 355 418 3.72 5.67 20.6
#191 P5 i13 TAGATCGC P7 i3 AGGCAGAA 358 430 20.4 19.2 67.7
#161 P5 i13 TAGATCGC P7 i6 TAGGCATG 463 483 11.6 13 40.8
#162 P5 i13 TAGATCGC P7 i7 CTCTCTAC 457 486 16.5 21.7 67.7
GIAB P5 i14 CTCTCTAT P7 i8 CAGAGAGG 428 463 10.5 9.39 30.7






(ng/ul ) Qubit molarity
Lane 1 (XT HS) 13 x XT HS CD138 l ibraries 1/14 each 363 0.673 2.8
4 x XT HS blood l ibraries 1/4 x 1/14 each
Lane 2 (XT HS) 14 x XT HS CD138 l ibraries 1/14 each 380 0.578 2.3
Lane 3 (QXT) External  NGS Run 33/100 435 0.547 1.9
External  NGS Run 33/100
10 x QXT Germl ine  blood l ibraries 1/100 each
External  NGS Run 17/100
Lane 4 (QXT) External  NGS Run 33/100 433 0.544 1.9
External  NGS Run 33/100
11 x QXT Germl ine blood l ibraries 1/100 each
External  NGS Run 16/100
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Appendix 4: Bioinformatic Reference Files & Software Tools applied to 
the NGS data 
Reference Files: 
Genome Resource Version 
GRCh37 seq broad-20120813 
GRCh37 GA4GH_problem_regions 20180317 
GRCh37 capture_regions 20161202 
GRCh37 MIG 20150730 
GRCh37 prioritize 20160215 
GRCh37 dbsnp 150-20170710-1 
GRCh37 hapmap 3.3 
GRCh37 1000g_omni_snps 2.5 
GRCh37 ACMG56_genes 20160810 
GRCh37 1000g_snps 2.8 
GRCh37 mills_indels 2.8 
GRCh37 clinvar 20170905 
GRCh37 cosmic 68-20180114 
GRCh37 ancestral 20141010 
GRCh37 qsignature 20140703 
GRCh37 genesplicer 2004.04.03 
GRCh37 effects_transcript 16/03/2017 
GRCh37 vcfanno 20171008 
GRCh37 viral 2017.02.04 
GRCh37 transcripts 01/12/2015 
GRCh37 RADAR v2-20180202 
GRCh37 srnaseq 20180122 
GRCh37 giab-NA12878 v3_3_2 
GRCh37 giab-NA24385 v3_3_2-sv_v0.5.0 
GRCh37 giab-NA24631 v3_3_2 
GRCh37 dream-syn3 04/08/2014 
GRCh37 dream-syn4 11/06/2016 
GRCh37 giab-NA12878-NA24385-somatic v3_2_2 









Tool Version Tool Version 
bamtools 2.4.0 mirdeep2 2.0.0.7 
bcbio-nextgen 1.0.9 mutect 1.1.5 
bcbio-variation 0.2.6 novoalign 3.07.00 
bcftools 1.7 novosort V3.00.02 
bedtools 2.27.1 oncofuse 1.1.1 
biobambam 2.0.87 phylowgs 20180317 
bioconductor-bubbletree 2.8.0 picard 2.18.4 
bowtie2 2.2.8 platypus-variant 0.8.1.1 
break-point-inspector 1.5 preseq 2.0.3 
bwa 0.7.17 qualimap 2.2.2a 
chanjo   rna-star   
cnvkit 0.9.3 rtg-tools 3.9 
cufflinks 2.2.1 sailfish 0.10.1 
cutadapt 1.16 salmon 0.9.1 
fastqc 0.11.7 sambamba 0.6.6 
featurecounts 1.4.4 samblaster 0.1.24 
freebayes 1.1.0.46 samtools 1.7 
gatk 3.8 scalpel 0.5.3 
gatk4 4.0.3.0 seqbuster 3.1 
gemini 0.20.1 snpeff 4.3.1t 
grabix 0.1.8 vardict 2018.04.27 
hisat2 2.1.0 vardict-java 1.5.1 
htseq 0.9.1 variant-effect-predictor   
lumpy-sv 0.2.14a varscan 2.4.3 
manta 1.4.0 vcflib 1.0.0_rc1 
metasv 0.4.0 vt 2015.11.10 








Gene Effect HGVS.p HGVS.c Alamut 




c.731T>G Not in Lohrs hotspot list, but in the same region 
Transversion from T to G in exon 2. 
Missense substitution: Leu244 is changed to Arg. 
Nothing on google 
 
Additional information 
• Highly conserved nucleotide (phyloP: 4.97 [-14.1;6.4]) 
• Highly conserved amino acid, up to C. elegans (considering 12 species) 
• Moderate physicochemical difference between Leu and Arg (Grantham dist.: 102 [0-215]) 
• This variant is in protein domain: Domain of unknown function DUF1693 
• Align GVGD (v2007): C65 (GV: 0.00 - GD: 101.88) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 3.56) 








c.6848A>C Transversion from A to C in exon 10. 
Missense substitution: Lys2283 is changed to Thr. 
Nothing on google 
 
Additional information 
• Highly conserved nucleotide (phyloP: 4.56 [-14.1;6.4]) 
• Highly conserved amino acid, up to Chicken (considering 9 species) 
• Moderate physicochemical difference between Lys and Thr (Grantham dist.: 78 [0-215]) 
• This variant is in protein domain: Homeobox 
• Align GVGD (v2007): C65 (GV: 0.00 - GD: 77.74) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32) 








c.1405G>A Transition from G to A in exon 14. 
Missense substitution: Asp469 is changed to Asn. 
Nothing on google 
 
Additional information 
• Highly conserved nucleotide (phyloP: 4.89 [-14.1;6.4]) 
• Highly conserved amino acid, up to Zebrafish (considering 12 species) 
• Small physicochemical difference between Asp and Asn (Grantham dist.: 23 [0-215])  
• Align GVGD (v2007): C0 (GV: 226.93 - GD: 0.00) 
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• SIFT (v6.2.0): Tolerated (score: 0.06, median: 3.15) 
• MutationTaster (v2013): disease causing (prob: 1) 
 
VUS 





c.2458C>T Not in Lohrs hotspot list 
Transition from C to T in exon 18. 
Missense substitution: Arg820 is changed to Trp. 
 
COSM3469577  flagged as a SNP (low frequency) 
This variant is known to dbSNP (151): rs372878316 (validated dbSNP entry). 
This variant is known to ESP (ESP6500SIV2): Eur. Am.: A=0.01% - Afr. Am.: A=0.00% 
This variant is known to gnomAD (2.1) <Exomes+Genomes>: ALL:0.0032% - AMR:0.014% - 
ASJ:0.0097% - SAS:0.0033% - NFE:0.0016% 
 
Additional information 
• Weakly conserved nucleotide (phyloP: 1.42 [-14.1;6.4]) 
• Highly conserved amino acid, up to C. elegans (considering 13 species) 
• Moderate physicochemical difference between Arg and Trp (Grantham dist.: 101 [0-215])  
• Align GVGD (v2007): C35 (GV: 26.00 - GD: 95.78) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 3.38) 









c.182A>G Known G61R hotspot seen in Lohr supplementary data 
 
Transition from A to G in exon 3. 
Missense substitution: Gln61 is changed to Arg. 
This variant is known to ClinVar (July-2020 RCV000431883.1 (Likely pathogenic - Multiple myeloma) 
This variant is reported as possibly pathogenic by Uniprot (view report). 
This variant is known to dbSNP (151): rs11554290 (not validated dbSNP entry - Clinical significance: 
CLIN_likely_pathogenic,CLIN_pathogenic). 
Additional information 
• Highly conserved nucleotide (phyloP: 4.89 [-14.1;6.4]) 
• Highly conserved amino acid, up to Baker's yeast (considering 13 species) 
• Small physicochemical difference between Gln and Arg (Grantham dist.: 43 [0-215]) 
• This variant is in protein domains:  
o Small GTPase superfamily 
o Mitochondrial Rho-like 
o Small GTPase superfamily, ARF/SAR type 
o Elongation factor, GTP-binding domain 
o Small GTP-binding protein domain 
o Small GTPase superfamily, Ras type 
o Small GTPase superfamily, Rab type 
o Small GTPase superfamily, Rho type 
o P-loop containing nucleoside triphosphate hydrolase 
• Align GVGD (v2007): C0 (GV: 223.30 - GD: 39.51) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32) 
• MutationTaster (v2013): disease causing (prob: 1) 
 
PATHOGENIC 





c.89A>G Not in Lohrs hotspot list, but in the same region 
Transition from A to G in exon 1. 
Missense substitution: Asp30 is changed to Gly 
 
Additional information 
• Moderately conserved nucleotide (phyloP: 3.19 [-14.1;6.4]) 
• Highly conserved amino acid, up to Frog (considering 11 species) 
• Moderate physicochemical difference between Asp and Gly (Grantham dist.: 94 [0-215])  
• Align GVGD (v2007): C0 (GV: 213.16 - GD: 64.73) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32) 









c.190T>G Known Y64D hotspot seen in Lohr supplementary data 
 
Transversion from T to G in exon 3. 
Missense substitution: Tyr64 is changed to Asp. 
This variant is known to dbSNP (151): rs752508313 (validated dbSNP entry). 
This variant is known to gnomAD (2.1) <Exomes>: ALL:0% (Filter: AC0;RF) 
 
Additional information 
• Highly conserved nucleotide (phyloP: 4.89 [-14.1;6.4]) 
• Highly conserved amino acid, up to Baker's yeast (considering 13 species) 
• Large physicochemical difference between Tyr and Asp (Grantham dist.: 160 [0-215]) 
• This variant is in protein domains:  
o Small GTPase superfamily 
o Mitochondrial Rho-like 
o Small GTPase superfamily, ARF/SAR type 
o Elongation factor, GTP-binding domain 
o Small GTP-binding protein domain 
o Small GTPase superfamily, Ras type 
o Small GTPase superfamily, Rab type 
o Small GTPase superfamily, Rho type 
o P-loop containing nucleoside triphosphate hydrolase 
• Align GVGD (v2007): C0 (GV: 247.85 - GD: 110.05) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32) 








c.174G>C Transversion from G to C in exon 1. 
Missense substitution: Lys58 is changed to Asn. 
 
Additional information 
• Weakly conserved nucleotide (phyloP: 0.37 [-14.1;6.4]) 
• Moderately conserved amino acid (considering 13 species) 
• Moderate physicochemical difference between Lys and Asn (Grantham dist.: 94 [0-215]) 
• This variant is in protein domains:  
o Cyclin, N-terminal 
o Cyclin-like 
o Cyclin A/B/D/E 
• Align GVGD (v2007): C0 (GV: 247.33 - GD: 0.00) 
• SIFT (v6.2.0): Tolerated (score: 0.35, median: 2.81) 









c.2389T>C Transition from T to C in exon 1. 
Missense substitution: Tyr797 is changed to His. 
 
Additional information 
• Moderately conserved nucleotide (phyloP: 3.35 [-14.1;6.4]) 
• Highly conserved amino acid, up to Chicken (considering 7 species) 
• Moderate physicochemical difference between Tyr and His (Grantham dist.: 83 [0-215]) 
• This variant is in protein domain: Cadherin 
• Align GVGD (v2007): C65 (GV: 0.00 - GD: 83.33) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32) 
MutationTaster (v2013): disease causing (prob: 0.996) 
 
VUS 
   
NF1 frameshift 
variant 
p.Ile679fs  c.2033dupC 
Duplication (1 bp) in exon 18. 
This variation creates a frame shift starting at codon Ile679. The new reading frame ends in a STOP 
codon at position 21.  
This variant is known to ClinVar (July-2020): RCV000130078.2 (Pathogenic* - Hereditary cancer-
predisposing syndrome), RCV000204850.9 (Pathogenic** - Neurofibromatosis), RCV000265986.2 
(Pathogenic* - not provided), RCV001009578.1 (Pathogenic* - Neurofibromatosis). 
This variant is known to dbSNP (151): rs1232596244 (validated dbSNP entry). 
This variant is known to gnomAD (2.1) <Exomes>: ALL:0.0016% - SAS:0.0065% - NFE:0.00090% - 









c.181C>A Known G61K hotspot seen in Lohr supplementary data 
 
Transversion from C to A in exon 3. 
Missense substitution: Gln61 is changed to Lys. 
This variant is known to ClinVar (July-2020): RCV000444882.1 (Likely pathogenic - Multiple 
myeloma),  
This variant is reported as possibly pathogenic by Uniprot (view report). 
This variant is known to dbSNP (151): rs121913254 (validated dbSNP entry - Clinical significance: 
CLIN_not_provided,CLIN_likely_pathogenic,CLIN_pathogenic,CLIN_drug_response). 
This variant is known to gnomAD (2.1) <Exomes>: ALL:0% (Filter: AC0) 
Additional information 
• Highly conserved nucleotide (phyloP: 5.94 [-14.1;6.4]) 
• Highly conserved amino acid, up to Baker's yeast (considering 13 species) 
• Small physicochemical difference between Gln and Lys (Grantham dist.: 53 [0-215]) 
• This variant is in protein domains:  
o Small GTPase superfamily 
o Mitochondrial Rho-like 
o Small GTPase superfamily, ARF/SAR type 
o Elongation factor, GTP-binding domain 
o Small GTP-binding protein domain 
o Small GTPase superfamily, Ras type 
o Small GTPase superfamily, Rab type 
o Small GTPase superfamily, Rho type 
o P-loop containing nucleoside triphosphate hydrolase 
• Align GVGD (v2007): C0 (GV: 223.30 - GD: 36.80) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32) 
• MutationTaster (v2013): disease causing (prob: 1) 
 
PATHOGENIC 




p.Asn352del c.1054_1056delAAC Deletion (3 bps) in exon 2. 
This variation leads to the loss of residue Asn352. 









c.1780G>A D594G seen in Lohr supplementary data (very similar) 
 
Transition from G to A in exon 15. 
Missense substitution: Asp594 is changed to Asn. 
This variant is known to ClinVar (July-2020): RCV000432575.1 (Likely pathogenic - 
Multiple myeloma),  




• Highly conserved nucleotide (phyloP: 6.18 [-14.1;6.4]) 
• Highly conserved amino acid, up to C. elegans (considering 12 species) 
• Small physicochemical difference between Asp and Asn (Grantham dist.: 23 [0-
215])  
• Align GVGD (v2007): C15 (GV: 0.00 - GD: 23.01) 










c.35C>T Transition from C to T in exon 1. 
Missense substitution: Ser12 is changed to Leu. 
This variant is known to ClinVar (July-2020): RCV000232824.1 (Uncertain significance* - Hereditary 
cutaneous melanoma). 
This variant is known to dbSNP (151): rs141798398 (not validated dbSNP entry - Clinical 
significance: CLIN_uncertain_significance).  
 
Additional information 
• Weakly conserved nucleotide (phyloP: 0.29 [-14.1;6.4]) 
• Weakly conserved amino acid (considering 12 species) 
• Large physicochemical difference between Ser and Leu (Grantham dist.: 145 [0-215]) 
• This variant is in protein domain: Ankyrin repeat-containing domain 
• Align GVGD (v2007): C0 (GV: 353.86 - GD: 0.00) 
• SIFT (v6.2.0): Tolerated (score: 0.56, median: 3.43) 
• MutationTaster (v2013): polymorphism (prob: 1) 
 









c.368G>A Transition from G to A in exon 1. 
Missense substitution: Gly123 is changed to Asp. 




• Weakly conserved nucleotide (phyloP: 1.42 [-14.1;6.4]) 
• Weakly conserved amino acid (considering 13 species) 
• Moderate physicochemical difference between Gly and Asp (Grantham dist.: 94 [0-215]) 
• This variant is in protein domain: Methyltransferase, trithorax 
• Align GVGD (v2007): C0 (GV: 353.86 - GD: 0.00) 
• SIFT (v6.2.0): Tolerated (score: 0.67, median: 3.60) 








c.1361G>T Transversion from G to T in exon 12. 
Missense substitution: Ser454 is changed to Ile. 
 
Additional information 
• Highly conserved nucleotide (phyloP: 4.48 [-14.1;6.4]) 
• Highly conserved amino acid, up to Zebrafish (considering 14 species) 
• Large physicochemical difference between Ser and Ile (Grantham dist.: 142 [0-215]) 
• This variant is in protein domains:  
o EGF receptor, L domain 
o Tyrosine protein kinase, EGF/ERB/XmrK receptor 
• Align GVGD (v2007): C65 (GV: 0.00 - GD: 141.80) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32) 









c.183A>C Known Q61H hotspot seen in Lohr supplementary data 
Transversion from A to C in exon 3. 
Missense substitution: Gln61 is changed to His. 
This variant is known to ClinVar (July-2020): RCV000154530.3 (Pathogenic - Non-small cell lung 
cancer), RCV000424748.1 (Likely pathogenic - Acute myeloid leukemia), RCV001004043.1 (Likely 
pathogenic - Juvenile myelomonocytic leukemia), RCV000444370.1 (Pathogenic - Neoplasm of the 
large intestine). 
This variant is known to dbSNP (151): rs17851045 (not validated dbSNP entry - Clinical significance: 
CLIN_likely_pathogenic,CLIN_pathogenic). 
This variant is known to gnomAD (2.1) <Exomes>: ALL:0.00040% - ASJ:0.0099% 
 
Additional information 
• Moderately conserved nucleotide (phyloP: 3.43 [-14.1;6.4]) 
• Highly conserved amino acid, up to Zebrafish (considering 9 species) 
• Small physicochemical difference between Gln and His (Grantham dist.: 24 [0-215]) 
• This variant is in protein domains:  
o Small GTPase superfamily 
o Mitochondrial Rho-like 
o Small GTPase superfamily, ARF/SAR type 
o Elongation factor, GTP-binding domain 
o Small GTP-binding protein domain 
o Small GTPase superfamily, Ras type 
o Small GTPase superfamily, Rab type 
o Small GTPase superfamily, Rho type 
o Ran GTPase 
o P-loop containing nucleoside triphosphate hydrolase 
• Align GVGD (v2007): C15 (GV: 0.00 - GD: 24.08) 




#235 3 ATM stop gained p.Arg1875* c.5623C>T Transition from C to T in exon 38. 
Nonsense substitution. 
The reading frame is interrupted by a premature STOP codon. 
The mRNA produced might be targeted for nonsense mediated decay (NMD). 
This variant is known to ClinVar (July-2020): RCV000236653.4 (Pathogenic* - not provided), 
RCV000493350.5 (Pathogenic** - Hereditary cancer-predisposing syndrome), RCV000540911.5 
(Pathogenic* - Ataxia-telangiectasia syndrome). 
This variant is known to dbSNP (151): rs376603775 (validated dbSNP entry - Clinical significance: 
CLIN_likely_benign,CLIN_pathogenic). 
This variant is known to ESP (ESP6500SIV2): Eur. Am.: T=0.01% - Afr. Am.: T=0.00% 










c.64C>A Transversion from C to A in exon 2. 
Missense substitution: Gln22 is changed to Lys. 
This variant is known to ClinVar (July-2020): RCV000433522.1 (Likely pathogenic - Neoplasm of the 
large intestine), RCV001078206.1 (Likely pathogenic* - Epidermal nevus syndrome). 
This variant is known to dbSNP (151): rs121913236 (not validated dbSNP entry - Clinical 
significance: CLIN_likely_pathogenic,CLIN_pathogenic). 
Additional information 
• Highly conserved nucleotide (phyloP: 5.86 [-14.1;6.4]) 
• Highly conserved amino acid, up to Zebrafish (considering 9 species) 
• Small physicochemical difference between Gln and Lys (Grantham dist.: 53 [0-215]) 
• This variant is in protein domains:  
o Small GTPase superfamily 
o Mitochondrial Rho-like 
o Small GTPase superfamily, ARF/SAR type 
o Small GTP-binding protein domain 
o Small GTPase superfamily, Ras type 
o Small GTPase superfamily, Rab type 
o Small GTPase superfamily, Rho type 
o Ran GTPase 
o P-loop containing nucleoside triphosphate hydrolase 
• Align GVGD (v2007): C45 (GV: 0.00 - GD: 53.23) 










c.57G>C Transversion from G to C in exon 2. 
Missense substitution: Leu19 is changed to Phe. 
This variant is known to ClinVar (July-2020): RCV000441871.1 (Likely pathogenic - Angiosarcoma), 
RCV000201922.3 (Pathogenic - OCULOECTODERMAL SYNDROME). 
This variant is known to dbSNP (151): rs121913538 (validated dbSNP entry - Clinical significance: 
CLIN_uncertain_significance,CLIN_likely_pathogenic). 
This variant is known to gnomAD (2.1) <Exomes>: ALL:0% (Filter: AC0) 
Additional information 
• Moderately conserved nucleotide (phyloP: 2.47 [-14.1;6.4]) 
• Highly conserved amino acid, up to Zebrafish (considering 9 species) 
• Small physicochemical difference between Leu and Phe (Grantham dist.: 22 [0-215]) 
• This variant is in protein domains:  
o Small GTPase superfamily 
o Mitochondrial Rho-like 
o Small GTPase superfamily, ARF/SAR type 
o Small GTP-binding protein domain 
o Small GTPase superfamily, Ras type 
o Small GTPase superfamily, Rab type 
o Small GTPase superfamily, Rho type 
o Ran GTPase 
o P-loop containing nucleoside triphosphate hydrolase 
• Align GVGD (v2007): C15 (GV: 0.00 - GD: 21.82) 











Appendix 6: Table Demonstrating Alamut Evidence for Osteome Variants 




p.Ile256Val c.766A>G Transition from A to G in exon 2. Missense substitution: Ile256 is changed to Val. 
 
This variant is known to ClinVar (July-2020): RCV000005824.2 (Pathogenic - Retinopathy of prematurity). 
This variant is reported as possibly pathogenic by Uniprot 
This variant is known to dbSNP (151): rs104894223 (validated dbSNP entry - Clinical significance: CLIN_pathogenic). 
This variant is known to ESP (ESP6500SIV2): Eur. Am.: C=0.20% - Afr. Am.: C=0.00% 




• Highly conserved nucleotide (phyloP: 5.05 [-14.1;6.4]) 
• Highly conserved amino acid, up to Tetraodon (considering 11 species) 
• Small physicochemical difference between Ile and Val (Grantham dist.: 29 [0-215]) 
• This variant is in protein domains:  
                            Frizzled protein / GPCR, family 2-like 
• Align GVGD (v2007): C25 (GV: 0.00 - GD: 28.68) 
• SIFT (v6.2.0): Deleterious (score: 0, median: 4.32 
• MutationTaster (v2013): disease causing (prob: 1) 
VUS 
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ICAM1   missense 
variant 
p.Lys56Met c.167A>T Transversion from A to T in exon 2. Missense substitution: Lys56 is changed to Met. 
 
This variant is known to ClinVar (July-2020): RCV000015768.3 (Risk factor - Malaria). 
This variant is known to dbSNP (151): rs5491 (MAF/MinorAlleleCount: T=0.084/36 - Clinical significance: CLIN_risk_factor). 
This variant is known to ESP (ESP6500SIV2): Eur. Am.: T=0.30% - Afr. Am.: T=21.20% 
This variant is known to gnomAD (2.1) <Exomes+Genomes>: ALL:3.28% - AFR:22.60% - AMR:1.20% - ASJ:1.37% - EAS:5.36% - SAS:1.61% - NFE:0.31% - 
FIN:3.97% - OTH:1.76% 
 
Additional information 
• Not conserved nucleotide (phyloP: -1.09 [-14.1;6.4]) 
• Weakly conserved amino acid (considering 16 species) 
• Moderate physicochemical difference between Lys and Met (Grantham dist.: 95 [0-215]) 
• This variant is in protein domains: 
                           Intercellular adhesion molecule, N-terminal /  Immunoglobulin subtype 
• Align GVGD (v2007): C0 (GV: 353.86 - GD: 0.00) 
• SIFT (v6.2.0): Tolerated (score: 0.11, median: 3.18) 
• MutationTaster (v2013): polymorphism (prob: 1) 
VUS 
Appendix 7: GenQA Survey Questions 
Genetic Testing in Myeloma Survey 2018 
 
Your laboratory details 
Which category does your laboratory belong too?  
 Diagnostic / Research / Diagnostic and Research / Commercial  
What sector does your laboratory belong too?   
 Public (Hospital, NHS) / Public (University) / Public (other) / Private  
What country is your laboratory based in? 
What is your GenQA laboratory code?       
 
Myeloma testing   
How many Myeloma samples do you analyse per year? 
What is the population covered by the laboratory (geographically & numerically)? 
What is the average turnaround time for your Myeloma service? 
What is the abnormality rate for those patients tested? 
What is the failure rate? 
Do you offer testing for MGUS patients? 
Do you have an age limit for testing Myeloma / MGUS patients? 
 If so, what is this? 
Do you offer genetic testing for follow up samples? 
 
Methodology 
Do you employ a method of plasma cell enrichment? 
 If so, what cell marker is this separation based on? 
 What method is used? 
Do you assess the purity of your samples following plasma cell separation? 
 If so how? 
Do you employ fluorescent cytoplasmic immunoglobulin (cIg) staining?  
Which method do you routinely use for Myeloma analysis? 
                Microarray / SNP array / MLPA / PCR / FISH / Other (specify) 
Describe your testing strategy. 
What regions are tested for? 
If FISH is undertaken, how many cells are scored? 
 What are the cut off values employed for reporting positivity? 
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Please select and complete for all that you use 
Method Manufacturer Version/kit/ FISH probe(s) Comments 
     
     
     
     
     
 
DNA (complete only if applicable) 
What is the minimum amount of DNA you require?   
Do you require control DNA?      
What procedure / methods do you use for extracting DNA  
 
Storage 
Are sample stored once the genetic testing is complete? 
 If so, what samples are stored? 
 And for what period? 
 
Further comments 
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